



Order ID : 123456

Clinical ID : ABC123

Indication : Non-Small Cell Lung Cancer (NSCLC) - NOS

Physician : Dr. Smith

Patient Age : 65

Patient Gender : Male

Patient Status : Newly Diagnosed

Sample Type : Not Available

Genomic Input : NGS Report

---

The Cellworks proprietary workflow solution used to generate this test report from patient's medical records (Test Report), has not been approved by any regulatory or medical authority. Cellworks generated information is adjunctive information to physicians and molecular tumor boards. CELLWORKS DOES NOT ASSURE OR GUARANTEE THE SUCCESS OF ANY THERAPEUTIC OPTION IDENTIFIED IN THIS TEST REPORT. Cellworks reports have not been validated or specifically developed for pregnant women or nursing mothers. The user of this Test Report remains responsible for the conduct of patient care and for evaluating the clinical relevance of information provided by the prediction software. Cellworks is not an entity licensed to practice medicine or clinical activity and the Test Report generated by Cellworks does not amount to, or substitute, qualified professional medical advice.

January 01, 2021

[support@cellworksgroup.zendesk.com](mailto:support@cellworksgroup.zendesk.com)

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS


Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

### 1. Therapy Response Index (TRI) and Patient Predicted Response

The chart below represents all of the NCCN recommended and FDA approved therapies for the patient indication. The horizontal line denotes which therapies are predicted favorable and which are unfavorable. Generally favorable patient response prediction TRI values should be >30 for single agents, >40 for two drug combinations, and >50 for three plus drug combinations.



January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1




## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**



January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1




## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**



January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1




## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**



January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1




## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**





## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

### 2. Master Regulators

The master regulators are uniquely selected for each patient. The Biosimulation process uses the master regulators to identify the targetable pathways for maximum phenotype impact. Up to 10 master regulators are shown her. See [Section 6](#) for detailed illustrations of Specific Master Regulators and their impact on the patient's disease profile.

#### 2.1 Master Regulator Impact Weight



January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

### 2.2 Treatment Impact on Master Regulators

The marks indicate whether each treatment has a meaningful impact on each of the master regulators. It is not required for each responder treatment to impact every master regulator since phenotype response can be driven by more than one pathway. Typically however, treatments that successfully impact several master regulators tend to have the best outcomes.

Therapies of Interest	Master Regulators									
	AURKA	E2F1	FOXM1	GLI1	HK2	ILK	JUN	MTOR	PAK1	PRKCE
Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel-dexamethasone	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Atezolizumab + Carboplatin + Gemcitabine	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Atezolizumab + Carboplatin + Gemcitabine + Radiation	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Atezolizumab + Carboplatin + Nab-paclitaxel	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Atezolizumab + Carboplatin + Paclitaxel-dexamethasone	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Atezolizumab + Carboplatin + Paclitaxel-dexamethasone + Radiation	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Atezolizumab + Carboplatin + Pemetrexed	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Atezolizumab + Carboplatin + Pemetrexed + Radiation	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Atezolizumab + Cisplatin + Docetaxel-dexamethasone	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Atezolizumab + Cisplatin + Docetaxel-dexamethasone + Radiation	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Atezolizumab + Cisplatin + Etoposide	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Atezolizumab + Cisplatin + Etoposide + Radiation	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Atezolizumab + Cisplatin + Gemcitabine	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Atezolizumab + Cisplatin + Gemcitabine + Radiation	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Atezolizumab + Cisplatin + Pemetrexed	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Therapies of Interest	Patient Biomarker Characteristics									
	AURKA	E2F1	FOXM1	GLI1	HK2	ILK	JUN	MTOR	PAK1	PRKCE
Atezolizumab + Cisplatin + Pemetrexed + Radiation	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Atezolizumab + Cisplatin + Radiation + Vinorelbine	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Atezolizumab + Cisplatin + Vinorelbine	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Bevacizumab + Carboplatin + Paclitaxel-dexamethasone	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Bevacizumab + Carboplatin + Pemetrexed	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Bevacizumab + Cisplatin + Pemetrexed	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Bevacizumab + Pemetrexed	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Carboplatin	✓		✓	✓	✓		✓	✓		✓
Carboplatin + Docetaxel-dexamethasone	✓		✓	✓	✓		✓	✓		✓
Carboplatin + Etoposide	✓		✓	✓	✓		✓	✓		✓
Carboplatin + Gemcitabine	✓	✓	✓	✓	✓		✓	✓	✓	✓
Carboplatin + Gemcitabine + Osimertinib	✓	✓	✓	✓	✓		✓	✓	✓	✓
Carboplatin + Gemcitabine + Osimertinib + Radiation	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Carboplatin + Gemcitabine + Radiation	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Carboplatin + Ipilimumab + Nivolumab + Paclitaxel-dexamethasone	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Therapies of Interest	Patient Biomarker Characteristics									
	AURKA	E2F1	FOXM1	GLI1	HK2	ILK	JUN	MTOR	PAK1	PRKCE
Carboplatin + Ipilimumab + Nivolumab + Pemetrexed	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Carboplatin + Nab-paclitaxel	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Carboplatin + Nab-paclitaxel + Pembrolizumab	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Carboplatin + Nivolumab + Paclitaxel-dexamethasone	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Carboplatin + Osimertinib + Paclitaxel-dexamethasone	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Carboplatin + Osimertinib + Paclitaxel-dexamethasone + Radiation	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Carboplatin + Osimertinib + Pemetrexed	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Carboplatin + Osimertinib + Pemetrexed + Radiation	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Carboplatin + Paclitaxel-dexamethasone	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Carboplatin + Paclitaxel-dexamethasone + Pembrolizumab	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Carboplatin + Paclitaxel-dexamethasone + Radiation	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Carboplatin + Pembrolizumab + Pemetrexed	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Carboplatin + Pemetrexed	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Carboplatin + Pemetrexed + Radiation	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Cisplatin	✓		✓	✓	✓		✓	✓		✓



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Therapies of Interest	Patient Biomarker Characteristics									
	AURKA	E2F1	FOXM1	GLI1	HK2	ILK	JUN	MTOR	PAK1	PRKCE
Cisplatin + Docetaxel-dexamethasone	✓	✓	✓	✓	✓		✓	✓	✓	✓
Cisplatin + Docetaxel-dexamethasone + Osimertinib	✓	✓	✓	✓	✓		✓	✓	✓	✓
Cisplatin + Docetaxel-dexamethasone + Osimertinib + Radiation	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Cisplatin + Docetaxel-dexamethasone + Radiation	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Cisplatin + Etoposide	✓	✓	✓	✓	✓		✓	✓	✓	✓
Cisplatin + Etoposide + Osimertinib	✓	✓	✓	✓	✓		✓	✓	✓	✓
Cisplatin + Etoposide + Osimertinib + Radiation	✓	✓	✓	✓	✓		✓	✓	✓	✓
Cisplatin + Etoposide + Radiation	✓	✓	✓	✓	✓		✓	✓	✓	✓
Cisplatin + Gemcitabine	✓	✓	✓	✓	✓		✓	✓	✓	✓
Cisplatin + Gemcitabine + Nectinumab	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Cisplatin + Gemcitabine + Nivolumab	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Cisplatin + Gemcitabine + Osimertinib	✓	✓	✓	✓	✓		✓	✓	✓	✓
Cisplatin + Gemcitabine + Osimertinib + Radiation	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Cisplatin + Gemcitabine + Radiation	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Cisplatin + Ipilimumab + Nivolumab + Pemetrexed	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Therapies of Interest	Patient Biomarker Characteristics									
	AURKA	E2F1	FOXM1	GLI1	HK2	ILK	JUN	MTOR	PAK1	PRKCE
Cisplatin + Nivolumab + Pemetrexed	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Cisplatin + Osimertinib + Pemetrexed	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Cisplatin + Osimertinib + Pemetrexed + Radiation	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Cisplatin + Osimertinib + Radiation + Vinorelbine	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Cisplatin + Osimertinib + Vinorelbine	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Cisplatin + Paclitaxel-dexamethasone	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Cisplatin + Pembrolizumab + Pemetrexed	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Cisplatin + Pemetrexed	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Cisplatin + Pemetrexed + Radiation	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Cisplatin + Radiation + Vinorelbine	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Cisplatin + Vinorelbine	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Crizotinib	✓	✓	✓	✓	✓		✓	✓		✓
Docetaxel-dexamethasone + Gemcitabine	✓		✓	✓	✓		✓	✓		✓
Etoposide			✓	✓				✓		✓
Gemcitabine			✓	✓			✓	✓		✓
Gemcitabine + Vinorelbine	✓		✓	✓	✓		✓	✓	✓	✓
Ipilimumab + Nivolumab	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Pembrolizumab + Pemetrexed	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Therapies of Interest	Patient Biomarker Characteristics									
	AURKA	E2F1	FOXM1	GLI1	HK2	ILK	JUN	MTOR	PAK1	PRKCE
Pemetrexed	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Radiation	✓	✓	✓	✓	✓		✓	✓	✓	✓
Ado-trastuzumab-emtansine										
Afatinib										
Afatinib + Cetuximab										✓
Alectinib			✓	✓			✓	✓		
Atezolizumab										✓
Atezolizumab + Bevacizumab										✓
Bevacizumab										
Bevacizumab + Erlotinib										
Brigatinib	✓		✓	✓	✓		✓	✓		✓
Cabozantinib										
Capmatinib										
Cemiplimab										✓
Ceritinib			✓	✓				✓		
Cetuximab										✓
Dabrafenib										
Dabrafenib + Trametinib				✓						

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Therapies of Interest	Patient Biomarker Characteristics									
	AURKA	E2F1	FOXM1	GLI1	HK2	ILK	JUN	MTOR	PAK1	PRKCE
Dacomitinib										
Docetaxel-dexamethasone										
Docetaxel-dexamethasone + Ramucirumab										
Durvalumab			✓					✓		✓
Entrectinib										
Erlotinib										
Erlotinib + Ramucirumab										
Fam-trastuzumab-deruxtecan-nxki										✓
Gefitinib										
Ipilimumab										
Larotrectinib										
Lorlatinib			✓	✓				✓		
Nab-paclitaxel										✓
Necitumumab										✓
Nivolumab										✓
Osimertinib										
Paclitaxel-dexamethasone			✓							✓
Pembrolizumab										✓



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Therapies of Interest	Patient Biomarker Characteristics									
	AURKA	E2F1	FOXM1	GLI1	HK2	ILK	JUN	MTOR	PAK1	PRKCE
Pralsetinib										
Ramucirumab										
Selpercatinib										
Sotorasib										
Trametinib				✓						
Vemurafenib										
Vinorelbine										



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

### 3. Phenotype Fold Change

The phenotype impact value represents the deviation of the patient's disease from a normal healthy cell model. Cellworks uses index values corresponding to the Hallmarks of Cancer for evaluation. The impact for each drug on the phenotype is used as part of the efficacy score generation.

Phenotype Index	Fold Change
Proliferation	4.5
Evading Growth Suppressors	2.2
Apoptotic Blockade	0.3
Replicative Immortality	1.8
Angiogenesis	1.9
Invasion and Metastasis	2.6
Immune Evasion	2.3



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

### 4. Patient Profile

#### 4.1 Summary of Patient Genomic Profile

The table below includes all of the patient genomic and lab results used as input when generating this report.

Input Data Type	Mutations and CNV
Genetic Mutation(s)	2
Copy Number Variation(s)	1447
MGMT Methylation Status	Not Available
Karyotype Value	Not Available
IHC Value	Not Available

#### 4.2 Detailed Information of Genomic Aberration(s) Modeled

The table below lists all of the gene mutations and copy number variations in chromosomal order.

##### 4.2.1 Gene Mutation(s) with Loss of Function

KDR D1171N

##### 4.2.2 Gene Mutations(s) with Switch of Function

EML4\_ALK FUS

##### 4.2.3 Gene(s) with Increase in Copy Number Variation [CNV]

ABCC1	ABCC11	ABCC6	ACAT1	ACVR1	ACVR2A	AIP	AKIP1
AKTIP	ALDOA	ALG1	ALG8	ALG9	ALKBH3	AMBRA1	AMFR
AMPD3	APOA1	APOC3	ARHGAP17	ARHGAP32	ARHGEF12	ARNTL	ARRB1
ASXL2	ATG13	ATM	B3GAT3	BAD	BCL7C	BDNF	BIRC2
BIRC3	BRD7	CAD	CADM1	CAPN1	CASP1	CASP12	CASP4
CASP5	CAT	CBL	CCL17	CCL22	CCND1	CCS	CD19
CD274	CD3D	CD3E	CD3G	CD44	CD5	CD59	CD81
CDKN1C	CENPA	CES1	CHEK1	CHKA	CPTIA	CRY2	CTNND1
CTSD	CTTN	CUL5	CX3CL1	CXCR5	CYLD	DAGLA	DCHS1

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

DDB1	DDB2	DGKZ	DHCR7	DIXDC1	DKK3	DNMT3A	DRD2
EED	EEF2K	EIF2B4	EIF3C	EIF3F	EIF3M	ESRRA	ETS1
EXT2	F2	FADD	FANCF	FBXO3	FEN1	FGF19	FGF4
FLI1	FOLR1	FOSL1	FOSL2	FTH1	FUS	FZD4	GAB2
GANAB	GAS2	GLIS2	GNAO1	GPD2	GPT2	GSTP1	HBG1
HRAS	HSPA8	IGF2	IL18	IL18BP	IL21R	IL27	IL4R
ILK	INPPL1	INS	IRF7	ITGAD	ITGAL	ITGAM	KAT5
KAT8	KCTD13	KIFC3	KMT2A	KYNU	LAMTOR1	LAT	LDHA
LGR4	LMO1	LMO2	LRP5	LRRC32	MALAT1	MAP3K11	MAP4K2
MAPK3	MAPK8IP1	MDK	ME3	MEN1	MIR125B1	MIR130A	MIR210
MIR365A	MMP1	MMP10	MMP12	MMP13	MMP2	MMP3	MMP7
MMP8	MPG	MS4A1	MT2A	MTA2	MUC2	MUC5AC	MUS81
MVP	MYOD1	NCOA1	NCR3LG1	NLRC5	NOX4	NPRL3	NR1H3
NR4A2	NUP160	NUP93	NUP98	NUPR1	ORC6	P4HA3	PAAFI
PACSIN3	PAGR1	PAK1	PALB2	PANX1	PAX6	PC	PDE2A
PDE3B	PDGFD	PDIA2	PGA3	PGR	PHF21A	PICALM	PLCB3
PLK1	PMM2	POLD3	POLD4	POU2AF1	PPP1CA	PPP1CB	PPP2R1B
PPP4C	PRDX5	PRKCB	PRPF19	PSMA1	PSMC3	PTDSS2	PTGDR2
PTPRJ	PTS	PYCARD	RAB10	RAB1B	RAB6A	RAD9A	RAG1
RAG2	RASGRP2	RBBP6	RBL2	RCE1	RELA	RHOG	RIF1
RINI	RND3	ROBO3	ROBO4	RPRM	RPS3	RPS6KA4	RPS6KB2
RRAS2	RRM1	RSF1	SAA1	SAA2	SALL1	SART1	SDHD
SERPINH1	SESN3	SETD1A	SF1	SH2B1	SIAH1	SIK2	SIRT3
SLC22A6	SLC22A8	SLC29A2	SLC3A2	SLC6A2	SLC6A5	SLCO2B1	SMG1
SMPD1	SOCS1	SPA17	SPDYA	SPI1	ST3GAL4	STT3A	SULT1A1
SULT1A3	SYVN1	TALDO1	TCIRG1	TEAD1	TFAP4	TGFB111	TH
THRSP	TIRAP	TNFAIP6	TOLLIP	TP53AIP1	TP53I3	TPH1	TRAF6
UBE2L6	UPP2	USP28	USP7	UVRAG	VASN	VEGFB	VIPR1

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

VWA5A	WEE1	WT1	XYLT1	YAP1	ZBTB16	ZEB2	ZNF143
ZNF668							

### 4.2.4 Gene(s) with Decrease in Copy Number Variation [CNV]

ABCA1	ABCC2	ABCC4	ABCC5	ABHD17B	ABHD6	ABL1	ABL2
ACAA2	ACACB	ACAT2	ACO2	ACTL6A	ACVR1B	ADAM10	ADAM17
ADCYAP1	ADK	ADORA1	ADORA2A	ADORA2B	ADORA3	AGPAT2	AGT
AK1	AKT1	AKT3	ALDH18A1	ALDH1A1	ALDH1A2	ALDH1L1	ALDH2
ALDH3A1	ALDH9A1	ALDOB	ALG12	ALG14	ALG2	ALG3	ALK
ALKBH2	ALOX12	ALOX12B	ALOX15	AMPD1	AMPD2	ANAPC2	ANAPC5
ANGPT2	ANKRD11	ANKRD54	ANO6	ANP32B	ANXA1	ANXA11	ANXA2
AOX1	AP2M1	APCDD1	APH1A	APPL1	APRT	APTX	ARG1
ARG2	ARHGAP8	ARHGEF11	ARHGEF15	ARHGEF3	ARHGEF7	ARID1B	ARID2
ARNT	ARRB2	ASAH1	ASB2	ASB6	ASH2L	ASS1	ATF1
ATF2	ATF3	ATF6	ATG2B	ATG5	ATP10A	ATP2A2	ATP2A3
ATRIP	AURKB	B2M	B4GALT6	BACH2	BAG1	BAG2	BAG4
BAP1	BCAN	BCAS2	BCL11B	BCL2	BCL2L10	BCL6	BCL7A
BCL9	BCR	BDH1	BGLAP	BID	BIK	BLK	BLNK
BMPRI1A	BRAP	BRD3	BTG2	BTRC	BUB1B	C4BPA	C5
CA9	CABLES1	CAMK2G	CAMKK1	CAMKK2	CAPN2	CARD9	CASP10
CASP8	CBFA2T3	CCL19	CCL21	CCNB2	CCNC	CCNDBP1	CCNK
CCNT1	CD160	CD1A	CD1B	CD1C	CD1D	CD1E	CD2
CD247	CD34	CD46	CD48	CD55	CD58	CD72	CD80
CD86	CDC14A	CDC14B	CDC16	CDC25A	CDC25B	CDC26	CDC42BPA
CDC45	CDC7	CDC73	CDCA7	CDH2	CDK20	CDK9	CDKN2A
CDKN2B	CDT1	CEP192	CEP70	CERK	CERS2	CERS5	CFH
CFHR1	CFLAR	CGN	CHD3	CHDH	CHEK2	CHFR	CHKB
CHMP1A	CHST3	CHUK	CISH	CITED2	CKB	CKS1B	CLDN1

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

CLDN5	CLIP1	CLK1	CLTA	CLU	CNBP	CNDP2	CNOT7
COL15A1	COL2A1	COL3A1	COL4A1	COL4A2	COL5A1	COPS2	COPS3
COPS4	COX4I1	CRI	CR2	CRABP2	CREB3	CRK	CRKL
CRP	CRTC2	CSF1	CSF2RB	CSGALNACT1	CSNK2A1	CTDP1	CTSB
CTSK	CTSL	CTSS	CUL4A	CXCL16	CYBA	CYP26A1	CYP2C8
CYP2C9	DAB2IP	DAPK1	DAPK2	DCC	DCUNID1	DDIT4	DDR2
DDX20	DDX23	DEDD	DEGS1	DEGS2	DEPDC5	DERL2	DGKG
DHH	DIABLO	DICER1	DKK4	DLC1	DLG1	DLL1	DLL4
DNAJA1	DNAJC3	DNM1	DNTT	DOCK3	DOLK	DPEP1	DPY30
DPYD	DTL	DTX1	DUOX1	DUOX2	DUOXA1	DUOXA2	DUSP23
DUT	DVL2	DVL3	DYNLT1	E2F6	EA2F2	ECT2	EDF1
EEF1A1	EFNA1	EFNA3	EFNA4	EFNB2	EFNB3	EGLN1	EGR3
EHMT1	EIF2AK2	EIF2AK4	EIF2S1	EIF3D	EIF3J	EIF3L	EIF4EBP1
EIF4G1	ELF3	ELK4	ELL3	ELP3	ENDOG	ENPP1	ENTPD1
EP300	EPHA7	EPHB3	EPHX2	ERC2	ERCC5	ERP44	ESR1
ETV5	EVI5	EWSR1	EXO1	EXTL2	EZR	F3	F7
FABP7	FAM20B	FANCA	FANCC	FANCG	FAS	FASLG	FBP1
FBP2	FBXO15	FBXO31	FBXO40	FBXO5	FBXW5	FBXW8	FCER1G
FCGR1A	FCGR2B	FCGR3A	FDFT1	FDPS	FEZF2	FGF5	FGF7
FGF8	FGFR1	FH	FHIT	FKBP1A	FLCN	FLNB	FNTB
FOS	FOXA2	FOXC2	FOXF1	FOXL1	FOXL2	FOXO3	FOXP1
FPGS	FRAT1	FRK	FSIP1	FUT8	FYN	FZD10	GABPB1
GALNT12	GALNT14	GAS6	GATA2	GATA4	GATA6	GCHFR	GCLC
GCNT1	GDA	GFI1	GFI1B	GFRA2	GFRA4	GFRAL	GGPS1
GJA1	GLDC	GLS	GLUD1	GLUL	GMPPB	GNAI3	GNAQ
GNE	GNL3	GOT1	GPD1	GPS2	GPSM1	GPX1	GRIN1
GRIN3A	GRK1	GSK3B	GSKIP	GSR	GSTA1	GSTA2	GSTA4
GSTA5	GSTM1	GTSE1	GUCY2D	GUK1	GZFI	HCAR3	HCLS1

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

HDAC10	HDAC2	HDAC7	HES1	HHAT	HHEX	HIC1	HIF1AN
HMOX1	HNFA	HNRNPK	HOXD13	HPSE	HR	HRK	HSP90AA1
HSPA5	HSPD1	HSPE1	HTRIB	HTRIE	HTR7	HYAL1	HYAL2
IBTK	ID2	IDH3B	IDO1	IDO2	IFI16	IFIT1	IFNGR1
IGF2R	IGHD	IGHE	IGHM	IGSF11	IKBKB	IKBKE	IL10
IL11RA	IL17A	IL17F	IL17RA	IL17RB	IL1RAP	IL20	IL20RA
IL20RB	IL22RA2	IL2RB	IL6R	IMPDH2	INPP5E	IRAK4	IRF2BP2
IRF8	IRS2	ITGA4	ITGA6	ITGAE	ITGAV	ITGB5	JAG2
JAK2	KALRN	KAT6A	KAT6B	KDM2B	KDM4C	KDM5B	KDM6B
KDSR	KIDINS220	KIF12	KIF14	KISS1	KLF3	KLF5	KLF4
KLF9	KLHL18	KLHL20	KLHL22	KLHL6	KLLN	KMO	KMT2D
KNTC1	KPNA1	L3MBTL2	LAMA1	LAMA3	LAMA4	LAMB3	LAMC1
LAMC2	LAMTOR2	LATS1	LBX1	LCN2	LDB1	LGALS1	LIF
LIG4	LIN9	LMAN1	LOXL2	LPA	LPAR1	LPIN1	LPL
LRRK2	LTBP1	LTK	LZTR1	MAF	MAG11	MALT1	MAN1B1
MAP1LC3B	MAP2K1	MAP2K3	MAP2K4	MAP3K13	MAP3K4	MAP3K5	MAP3K7
MAP4	MAPK1	MAPK11	MAPK12	MAPK4	MAPK6	MAPK7	MAPKAP1
MAPKAPK2	MAPKAPK5	MARK3	MAT1A	MAVS	MAX	MBD1	MBD2
MBD4	MBTPS1	MCL1	MCM2	MCM3	MCM5	MDM4	ME1
ME2	MECOM	MED13L	MEF2D	MELK	MEX3A	MGA	MGLL
MIB1	MIF	MINK1	MIR130B	MIR132	MIR134	MIR181B1	MIR199A2
MIR199B	MIR23B	MIR29C	MIR320A	MIR33A	MIR33B	MIR370	MIR410
MIR488	MIR648	MIR92B	MIRLET7A1	MIS12	MITF	MLH3	MLLT11
MLLT3	MLXIP	MLYCD	MN1	MNT	MOAP1	MSI1	MSMP
MST1	MST1R	MTA1	MTAP	MTHFD1L	MTR	MTUS1	MUC1
MUC4	MVD	MVK	MYB	MYBBP1A	MYCN	MYLK	MYO1C
MYO5A	MYOG	NCF2	NCF4	NCK1	NCKAP1	NCKIPSD	NCOR1
NCOR2	NCSTN	NDC80	NDN	NEDD4	NEDD4L	NEIL2	NEK2

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

NEK6	NELFB	NEUROD1	NF2	NFATC1	NFE2L2	NFKB2	NGF
NID1	NLRP1	NLRP3	NOPI0	NOTCH1	NOTCH2	NOX3	NOXA1
NPC1	NPR1	NPR2	NPRL2	NR1I2	NR2E1	NR4A3	NR5A2
NRARP	NRAS	NRG1	NRG3	NRON	NSFL1C	NSL1	NT5C2
NT5E	NTNI	NTPCR	NTRK1	NTRK2	NUDT18	NUF2	NUP214
NUP50	NUS1	ONECUT1	ONECUT2	OSM	P2RX1	P2RX7	P4HA1
PAK2	PARP1	PARP3	PARP9	PATZ1	PAX2	PAX5	PBK
PBRM1	PBX1	PCYT1A	PDCD1LG2	PDCD2	PDIA3	PDIA6	PDK1
PDLIM2	PDZK1	PEA15	PEBP1	PEMT	PER1	PFAS	PFKM
PGAM1	PGF	PGM3	PHGDH	PHLPP1	PIAS2	PIAS3	PIK3AP1
PIK3C2B	PIK3C3	PIK3CA	PIK3CB	PIK3IP1	PIM3	PISD	PITPNA
PKLR	PKN3	PLA2G4A	PLAT	PLAU	PLCE1	PLCG2	PLD1
PLD2	PLG	PLXNB1	PLXNB2	PLXND1	PMAIP1	PMS1	PMVK
POLB	POLE	POLL	POLQ	POLR2A	POLR3A	POU2F1	POU3F2
PPARA	PPP1CC	PPP1R2	PPP2R2A	PPP2R5A	PPP2R5C	PPP6C	PRDMI
PRDX6	PRF1	PRICKLE1	PRKAB1	PRKAR2A	PRKCD	PRKCI	PRKG2
PRKRA	PRNP	PRODH	PRPF8	PRPSAP2	PRR5	PRRX1	PSAT1
PSEN2	PSMA5	PSMB1	PSMB4	PSMB6	PSMB7	PSMD2	PSMD4
PSMD5	PSMD6	PSMD9	PSMG2	PTCH1	PTEN	PTGDS	PTGES
PTGS1	PTGS2	PTK2B	PTPN11	PTPN14	PTPN2	PTPN3	PTPRA
PTPRC	PTPRD	PTPRG	PTPRK	PXN	PYCR2	PYGO1	RAB14
RAB31	RAB35	RAB4A	RAB7A	RAB8B	RAC2	RAD23B	RAD51
RAD51B	RALBP1	RALGAPA2	RALGDS	RAN	RANBP1	RANGAP1	RAPIA
RAPGEF1	RAPGEF3	RAPGEF4	RASA3	RASAL1	RASD1	RASGRP1	RASGRP3
RASSF1	RASSF5	RBBP5	RBBP8	RBCK1	RBFOX2	RBM15	RBP4
RCOR1	RDH11	RDH12	REN	REV3L	RFC4	RFC5	RFT1
RFX5	RGS2	RGS4	RGS5	RHOA	RHOB	RIOK3	RIT1
RMRP	RNF111	RNF146	RNF168	RNF187	RNF2	RNF20	ROCK1

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

ROR2	RORC	ROS1	RPA1	RPL26	RPL5	RPS6	RPS6KA2
RPS6KC1	RRAGA	RRAGD	RRM2	RSPO3	RXRA	RYR2	S100A10
S100A4	S100A6	S100A7	S1PR1	S1PR3	SALL3	SARDH	SCAP
SCD	SCO2	SDC1	SDHC	SEC31A	SEC61A1	SEC61B	SEH1L
SEMA3B	SEMA4A	SEMA4D	SENP1	SENP2	SENP3	SENP6	SERPINA1
SERPINB2	SERPINF1	SERPINF2	SESNI	SET	SETBP1	SETD1B	SETD2
SETDB1	SF3B1	SFRP1	SFTPC	SGK1	SH2B3	SHC1	SHMT1
SHPRH	SIRPA	SIRT4	SIVA1	SLAMF6	SLAMF7	SLC14A2	SLC15A1
SLC16A1	SLC16A10	SLC22A1	SLC22A16	SLC22A2	SLC25A11	SLC25A20	SLC27A2
SLC27A4	SLC28A2	SLC28A3	SLC29A3	SLC2A2	SLC2A4	SLC31A1	SLC38A1
SLC38A2	SLC43A2	SLC44A1	SLC7A5	SMAD2	SMAD3	SMAD4	SMAD6
SMAD7	SMARCA2	SMARCB1	SMARCC1	SMARCD1	SMC1B	SMPD2	SMYD2
SMYD3	SNCG	SOCS6	SOD2	SOX10	SOX2	SP3	SPTLC1
SREBF1	SREBF2	SRSF9	SRXN1	SS18	ST6GALNAC4	STARD9	STAT1
STAT4	STK24	STOM	STRN	SUFU	SYK	TAB2	TAF5L
TAL2	TAOK3	TBCID13	TBL1XR1	TBX3	TBX5	TCF12	TCL1A
TEK	TERC	TERF2IP	TFDP1	TFRC	TGFB2	TGFB3	TGFBR1
TGFBR3	THBS1	THBS2	THPO	TIMP3	TJP1	TJP2	TKT
TLE1	TLE4	TLN1	TLR4	TLR9	TLX1	TMEM30A	TNC
TNFAIP3	TNFRSF10A	TNFRSF10B	TNFRSF10C	TNFRSF10D	TNFRSF11A	TNFRSF13B	TNFRSF13C
TNFSF10	TNFSF12	TNFSF13	TNFSF13B	TNFSF15	TNFSF18	TNFSF4	TNFSF8
TNIK	TNK2	TNKS	TNKS2	TP53	TP53BP1	TP63	TPR
TRAF1	TRAF2	TRAF3	TRAF3IP2	TRAF3IP3	TRAF5	TREX1	TRIB2
TRIB3	TRIM33	TSC1	TTF1	TTK	TTR	TUBA1A	TUBB3
TUBB4B	TXN	TXN2	TXNIP	TXNRD2	TYMP	TYMS	TYRO3
UAP1	UBA3	UBA7	UBC	UBE2G1	UBE2L3	UBE2R2	UBE2T
UBE3A	UBQLN1	UBXN7	UCK1	UCK2	UGCG	UGGT2	UHMK1
ULBP1	ULBP2	ULBP3	ULK1	ULK2	UMPS	UNG	UPB1

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

USF1	USP10	USP13	USP18	USP21	USP6	USP8	UTRN
VAMP2	VAV2	VAV3	VCAM1	VCL	VCP	VDR	VIP
VRK1	VSNL1	WASF1	WDR5	WDR77	WNT1	WNT3A	WNT5A
WNT7B	WRAP53	WRN	WSB2	WWOX	XAF1	XBP1	XDH
XPA	XRCC3	XRCC6	YES1	YWHAE	YWHAQ	YY1	YY1API
ZBTB2	ZBTB7C	ZDHHC14	ZDHHC16	ZDHHC19	ZDHHC2	ZDHHC21	ZDHHC7
ZDHHC8	ZFPM1	ZNF140	ZNF24	ZNF521	ZNF692		



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

### 5. Therapy Rationales

Rationales provided in this section highlight the pathways connected to drug sensitivity and resistance and include references to supporting published literature.

Species in **red** denote drug impact points. Species highlighted in **blue** are the Master Regulators.

Ado-trastuzumab-emtansine				
Mechanism of Action: <b>ADO-TRASTUZUMAB-EMTANSINE</b> —  <b>ERBB2</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
HRAS	CNV Amplification	Resistant	HRAS → RAF1 → MAP2K1/2 → MAPK1/3 —  ERBB2	<a href="#">24659374</a> <a href="#">18356021</a> <a href="#">12077341</a> <a href="#">20562913</a> <a href="#">25367036</a> <a href="#">27531070</a> <a href="#">28843257</a>

Ado-trastuzumab-emtansine				
Mechanism of Action: <b>ADO-TRASTUZUMAB-EMTANSINE</b> —  <b>ERBB2</b> → <b>EGFR_ERBB2</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
PTEN	CNV Deletion	Resistant	PTEN —  PI345P3 → PDPK1 → AKT → PIKFYVE —  EGFR → EGFR_ERBB2	<a href="#">24682654</a> <a href="#">30206164</a> <a href="#">29695635</a> <a href="#">15324695</a> <a href="#">25295225</a> <a href="#">23757022</a>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Afatinib				
Mechanism of Action: <b>AFATINIB</b> —  <b>EGFR</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
HRAS	CNV Amplification	Resistant	HRAS → RAF1 → MAP2K1/2 → MAPK1/3 —  EGFR	<a href="#">32567494</a> <a href="#">18356021</a> <a href="#">12077341</a> <a href="#">20562913</a>
PTEN	CNV Deletion	Resistant	PTEN —  PI345P3 → PDPK1 → AKT → PIKFYVE —  EGFR	<a href="#">24086949</a> <a href="#">25295225</a> <a href="#">23757022</a> <a href="#">27073576</a> <a href="#">9094314</a> <a href="#">22952397</a>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Atezolizumab				
Mechanism of Action: <b>ATEZOLIZUMAB</b> —  <b>CD274</b> —> <b>PD-1</b> —  <b>CTL_Activation</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
CCND1	CNV Amplification	Resistant	CCND1 —> CDK4_CCND1 —> BRCA1 —> DNA REPAIR (HR) —  APM_Machinery —> CTL_Activation —> GZMB —> CASP3 —> APOPTOSIS	<a href="#">27398650</a> <a href="#">25685857</a> <a href="#">32903763</a> <a href="#">28492290</a>
B2M	CNV Deletion	Resistant	B2M —> MHC1_COMPLEX —> APM_Machinery —> CTL_Activation —> GZMB —> CASP3 —> APOPTOSIS	<a href="#">29070816</a> <a href="#">28717238</a> <a href="#">29423109</a>
CDH2	CNV Deletion	Resistant	CDH2 —  CTNNB1 —> ATF3 —  CCL4 —> CTL_Activation —> GZMB —> CASP3 —> APOPTOSIS	<a href="#">28717238</a> <a href="#">12604612</a> <a href="#">25970248</a> <a href="#">31078045</a> <a href="#">8707857</a>
FAS	CNV Deletion	Resistant	FAS —> CTL_Activation —> GZMB —> CASP3 —> APOPTOSIS	<a href="#">28492290</a> <a href="#">30429213</a>
GSK3B	CNV Deletion	Resistant	GSK3B —  CTNNB1 —> ATF3 —  CCL4 —> CTL_Activation —> GZMB —> CASP3 —> APOPTOSIS	<a href="#">28717238</a> <a href="#">25970248</a> <a href="#">31078045</a> <a href="#">17621269</a>
PTEN	CNV Deletion	Resistant	PTEN —  PDPK1 —> AKT —  TSC1_TSC2 —  RHEB —> MTOR —> HIF1A —> VEGFA —  CTL_Activation —> GZMB —> CASP3 —> APOPTOSIS	<a href="#">28492290</a> <a href="#">26645196</a>
TP53	CNV Deletion	Resistant	TP53 —> TAP1 —> APM_Machinery —> CTL_Activation —> GZMB —> CASP3 —> APOPTOSIS	<a href="#">32266087</a> <a href="#">31097096</a> <a href="#">32694238</a> <a href="#">32927274</a> <a href="#">32997907</a>

Atezolizumab				
Mechanism of Action: <b>ATEZOLIZUMAB</b> —  <b>CD274</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
JAK2	CNV Deletion	Resistant	JAK2 —> STAT3 —> CD274 —> PD-1 —  CTL_Activation —> GZMB —> CASP3 —> APOPTOSIS	<a href="#">28492290</a> <a href="#">31428520</a> <a href="#">32461348</a> <a href="#">27903500</a>

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

### Atezolizumab

Mechanism of Action: **ATEZOLIZUMAB** —| **CD274**

Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
CD274	CNV Amplification	Sensitive	CD274 → PD-1 —  CTL_Activation → GZMB → CASP3 → APOPTOSIS	<a href="#">28492290</a> <a href="#">31428520</a> <a href="#">32461348</a>
PTPN2	CNV Deletion	Sensitive	PTPN2 —  STAT1 → CD274 → PD-1 —  CTL_Activation → GZMB → CASP3 → APOPTOSIS	<a href="#">28717238</a> <a href="#">28723893</a>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Bevacizumab				
Mechanism of Action: <b>BEVACIZUMAB</b> —  <b>para_VEGFA</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
DNMT3A	CNV Amplification	Resistant	DNMT3A → CPGMET —  VEGFA → para_VEGFA → KDR → ANGIOGENESIS → CANCER PROGRESSION	<a href="#">15961063</a> <a href="#">17145519</a> <a href="#">28252641</a> <a href="#">26850336</a> <a href="#">27619687</a>
TP53	CNV Deletion	Sensitive	TP53 —  HIF1A → VEGFA → para_VEGFA → KDR → ANGIOGENESIS → CANCER PROGRESSION	<a href="#">15961063</a> <a href="#">17145519</a> <a href="#">31564192</a> <a href="#">23449391</a> <a href="#">27619687</a>

Bevacizumab				
Mechanism of Action: <b>BEVACIZUMAB</b> —  <b>para_VEGFA</b> → <b>KDR</b> → <b>SRC</b> —  <b>HRAS</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
HRAS	CNV Amplification	Resistant	HRAS → RAF1 → MAP2K1/2 → MAPK1/3 → MYC → E2F1 → CANCER PROGRESSION	<a href="#">22302382</a> <a href="#">25157176</a> <a href="#">22461507</a> <a href="#">15944709</a> <a href="#">12509223</a> <a href="#">33139506</a>

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Brigatinib				
Mechanism of Action: <b>BRIGATINIB</b> — <b>ROS1</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
ROS1	CNV Deletion	Resistant	<p>ROS1 → SOS1 → RAS → RAF1 → MAP2K1/2 → MAPK1/3 → MYC → E2F1 → CANCER PROGRESSION</p> <p>(Direct drug target loss is reported in the profile)</p>	<a href="#">32462394</a> <a href="#">22915320</a> <a href="#">22461507</a> <a href="#">23415111</a> <a href="#">23589333</a> <a href="#">18345030</a>

Brigatinib				
Mechanism of Action: <b>BRIGATINIB</b> — <b>EML4_ALK</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
EML4_ALK	Switch of Function	Sensitive	<p>EML4_ALK → GRB2 → SOS1 → RAS → RAF1 → MAP2K1/2 → MAPK1/3 → MYC → GLI1 → CANCER PROGRESSION</p>	<a href="#">21415216</a> <a href="#">22461507</a> <a href="#">30804663</a> <a href="#">26901483</a> <a href="#">33848463</a> <a href="#">33209633</a> <a href="#">23525267</a> <a href="#">21245935</a>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Cabozantinib				
Mechanism of Action: <b>CABOZANTINIB</b> —  <b>MET</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
HRAS	CNV Amplification	Resistant	HRAS → RAF1 → MAP2K1/2 → MAPK1/3 → ADAM17 —  MET	<a href="#">26536165</a> <a href="#">24931611</a> <a href="#">30352902</a> <a href="#">32034073</a>

Cabozantinib				
Mechanism of Action: <b>CABOZANTINIB</b> —  <b>ROS1</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
ROS1	CNV Deletion	Resistant	ROS1 → SOS1 → RAS → RAF1 → MAP2K1/2 → MAPK1/3 → MYC → E2F1 → CANCER PROGRESSION (Direct drug target deletion is reported in the profile)	<a href="#">25351743</a> <a href="#">22915320</a> <a href="#">22461507</a> <a href="#">23415111</a> <a href="#">23589333</a> <a href="#">18345030</a>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Carboplatin				
Mechanism of Action: <b>CARBOPLATIN</b> → <b>ICL</b> → <b>DSB</b> → <b>DNA DAMAGE</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
CCND1	CNV Amplification	Resistant	CCND1 → CDK4_CCND1 → BRCA1 → DNA REPAIR (HR) DNA DAMAGE	<a href="#">20395447</a> <a href="#">12570712</a> <a href="#">3512077</a> <a href="#">16696564</a>
FEN1	CNV Amplification	Resistant	FEN1 → DNA REPAIR (BER) → DNA DAMAGE	<a href="#">26718738</a> <a href="#">24880630</a> <a href="#">12570712</a> <a href="#">3512077</a> <a href="#">16696564</a>
GSTP1	CNV Amplification	Resistant	GSTP1 → CARBOPLATIN	<a href="#">3512077</a> <a href="#">16696564</a> <a href="#">25010864</a>
HRAS	CNV Amplification	Resistant	HRAS → RAF1 → MAP2K1/2 → MAPK1/3 → MYC → BRCA1 → DNA REPAIR (HR) → DNA DAMAGE	<a href="#">3512077</a> <a href="#">18356021</a> <a href="#">12077341</a> <a href="#">22461507</a> <a href="#">21668996</a> <a href="#">23388117</a>
KAT5	CNV Amplification	Resistant	KAT5 → MRE11A-NBN-RAD50 → DNA REPAIR (HR) → DNA DAMAGE	<a href="#">28634400</a> <a href="#">26915295</a> <a href="#">18458078</a> <a href="#">12570712</a> <a href="#">3512077</a> <a href="#">16696564</a>
PAK1	CNV Amplification	Resistant	PAK1 → AURKA → BRCA1 → DNA REPAIR (HR) → DNA DAMAGE	<a href="#">27713506</a> <a href="#">28535002</a> <a href="#">10531298</a> <a href="#">12570712</a> <a href="#">3512077</a> <a href="#">16696564</a>
PLK1	CNV Amplification	Resistant	PLK1 → BRCA1 → DNA REPAIR (HR) → DNA DAMAGE	<a href="#">27748936</a> <a href="#">29663364</a> <a href="#">30876762</a> <a href="#">30488440</a> <a href="#">12570712</a> <a href="#">3512077</a> <a href="#">16696564</a>
SIRT3	CNV Amplification	Resistant	SIRT3 → SOD2 → ROS → DNA DAMAGE	<a href="#">3512077</a> <a href="#">27420645</a> <a href="#">33655712</a>
CDKN2A	CNV Deletion	Resistant	CDKN2A → CDK4_CCND1 → RB1 → E2F1 → BRCA1/2 → DNA REPAIR (HR) → DNA DAMAGE	<a href="#">3512077</a> <a href="#">16696564</a> <a href="#">18438954</a> <a href="#">12947386</a> <a href="#">10660629</a>

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Carboplatin				
Mechanism of Action: <b>CARBOPLATIN</b> → <b>ICL</b> → <b>DSB</b> → <b>DNA DAMAGE</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
CDKN2B	CNV Deletion	Resistant	CDKN2B —  CDK4_CCND1 —  RB1 —  E2F1 → BRCA1/2 → DNA REPAIR (HR) —  DNA DAMAGE	<a href="#">3512077</a> <a href="#">16696564</a> <a href="#">18438954</a> <a href="#">12947386</a> <a href="#">10660629</a>
LIG4	CNV Deletion	Resistant	LIG4 → DNA REPAIR (NHEJ) —  DNA REPAIR (HR) —  DNA DAMAGE	<a href="#">3512077</a> <a href="#">20538911</a> <a href="#">20598602</a> <a href="#">28930678</a>
PPP2R2A	CNV Deletion	Resistant	PPP2R2A —  ATM → BRCA1 → DNA REPAIR (HR) → DNA DAMAGE	<a href="#">23087057</a> <a href="#">26800397</a> <a href="#">31221814</a> <a href="#">12570712</a> <a href="#">3512077</a> <a href="#">16696564</a>
PTEN	CNV Deletion	Resistant	PTEN —  AKT → RAD51 → DNA REPAIR (HR) —  DNA DAMAGE	<a href="#">2649354</a> <a href="#">18657898</a> <a href="#">23663432</a> <a href="#">29156644</a>
RASSF1	CNV Deletion	Resistant	RASSF1 —  CCND1 → CDK4_CCND1 → BRCA1 → DNA REPAIR (HR) —  DNA DAMAGE	<a href="#">23147544</a> <a href="#">29368096</a> <a href="#">25368379</a> <a href="#">12570712</a> <a href="#">3512077</a> <a href="#">16696564</a>
SLC31A1	CNV Deletion	Resistant	SLC31A1 → CARBOPLATIN	<a href="#">22725681</a> <a href="#">3512077</a> <a href="#">23010323</a> <a href="#">16847145</a>
SMAD4	CNV Deletion	Resistant	SMAD4 —  BRCA1 → DNA REPAIR (HR) → DNA DAMAGE	<a href="#">19686080</a> <a href="#">20807115</a> <a href="#">24773018</a> <a href="#">30506138</a> <a href="#">12570712</a> <a href="#">3512077</a> <a href="#">16696564</a>
SUFU	CNV Deletion	Resistant	SUFU —  GLI1 → FOXM1 → RAD51 → DNA REPAIR (HR) —  DNA DAMAGE SUFU —  GLI1 → FOXM1 → BRCA2 → DNA REPAIR (HR) —  DNA DAMAGE	<a href="#">23162656</a> <a href="#">28405019</a> <a href="#">25373737</a> <a href="#">22977194</a> <a href="#">12183437</a>
TP53	CNV Deletion	Resistant	TP53 —  BRCA2 → DNA REPAIR (HR) —  DNA DAMAGE	<a href="#">3512077</a> <a href="#">11595686</a> <a href="#">25263447</a> <a href="#">12591928</a>

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Carboplatin				
Mechanism of Action: <b>CARBOPLATIN</b> → <b>ICL</b> → <b>DSB</b> → <b>DNA DAMAGE</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
TP53BP1	CNV Deletion	Resistant	TP53BP1 → DNA REPAIR (NHEJ) → DNA REPAIR (HR) → DNA DAMAGE	<a href="#">3512077</a> <a href="#">20538911</a> <a href="#">20598602</a> <a href="#">24326623</a>
XRCC6	CNV Deletion	Resistant	XRCC6 → DNA REPAIR (NHEJ) → DNA REPAIR (HR) → DNA DAMAGE	<a href="#">20598602</a> <a href="#">20538911</a> <a href="#">3512077</a>
PRKCB	CNV Amplification	Sensitive	PRKCB → AKT → AKT1S1 → MTOR → ULK1 → AUTOPHAGY → SQSTM1 → RAD51 → DNA REPAIR (HR) → DNA DAMAGE	<a href="#">28246354</a> <a href="#">12570712</a> <a href="#">3512077</a> <a href="#">16696564</a>
CHEK2	CNV Deletion	Sensitive	CHEK2 → BRCA1/2 → DNA REPAIR (HR) → DNA DAMAGE	<a href="#">3512077</a> <a href="#">16696564</a> <a href="#">14701743</a> <a href="#">26957554</a> <a href="#">10843985</a>
ERCC5	CNV Deletion	Sensitive	ERCC5 → DNA REPAIR (NER) → DNA DAMAGE	<a href="#">3512077</a> <a href="#">12208738</a>
FANCA	CNV Deletion	Sensitive	FANCA → FA COMPLEX → DNA REPAIR (ICL) → DNA DAMAGE	<a href="#">3512077</a> <a href="#">25891850</a> <a href="#">26385482</a> <a href="#">20509860</a> <a href="#">26238431</a> <a href="#">30882047</a>
FANCC	CNV Deletion	Sensitive	FANCC → FA COMPLEX → DNA REPAIR (ICL) → DNA DAMAGE	<a href="#">26238431</a> <a href="#">20509860</a> <a href="#">3512077</a>
FANCG	CNV Deletion	Sensitive	FANCG → FA COMPLEX → DNA REPAIR (ICL) → DNA DAMAGE	<a href="#">26385482</a> <a href="#">25891850</a> <a href="#">26238431</a> <a href="#">20509860</a> <a href="#">3512077</a> <a href="#">12861027</a>
HSP90AA1	CNV Deletion	Sensitive	HSP90AA1 → RAD51 → DNA REPAIR (HR) → DNA DAMAGE	<a href="#">3512077</a> <a href="#">30153855</a> <a href="#">23069143</a> <a href="#">10843985</a> <a href="#">24971740</a>
MAPILC3B	CNV Deletion	Sensitive	MAPILC3B → AUTOPHAGY → SQSTM1 → RAD51 → DNA REPAIR (HR) → DNA DAMAGE	<a href="#">3512077</a> <a href="#">20807115</a> <a href="#">26553068</a>

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Carboplatin				
Mechanism of Action: <b>CARBOPLATIN</b> → <b>ICL</b> → <b>DSB</b> → <b>DNA DAMAGE</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
MBD1	CNV Deletion	Sensitive	MBD1 → MRE11A-NBN-RAD50 → DNA REPAIR(HR) → <b>DNA DAMAGE</b>	<a href="#">3512077</a> <a href="#">23588667</a>
RAD51	CNV Deletion	Sensitive	RAD51 → DNA REPAIR (HR) → <b>DNA DAMAGE</b>	<a href="#">10843985</a> <a href="#">3512077</a> <a href="#">18544565</a> <a href="#">24971740</a>
RAD51B	CNV Deletion	Sensitive	RAD51B → RAD51 → DNA REPAIR (HR) → <b>DNA DAMAGE</b>	<a href="#">3512077</a> <a href="#">25368520</a>
RBBP8	CNV Deletion	Sensitive	RBBP8 → DNA REPAIR (HR) → <b>DNA DAMAGE</b>	<a href="#">16696564</a> <a href="#">3512077</a> <a href="#">17965729</a>
REV3L	CNV Deletion	Sensitive	REV3L → DNA REPAIR (TLS) → <b>DNA DAMAGE</b>	<a href="#">21068376</a> <a href="#">3512077</a>
WRN	CNV Deletion	Sensitive	WRN → RAD52 → ERCC1-ERCC4 → DNA REPAIR (NER) → <b>DNA DAMAGE</b>	<a href="#">25801465</a> <a href="#">3512077</a>
XPA	CNV Deletion	Sensitive	XPA → DNA REPAIR (NER) → <b>DNA DAMAGE</b>	<a href="#">12208738</a> <a href="#">8512813</a>
XRCC3	CNV Deletion	Sensitive	XRCC3 → DNA REPAIR (HR) → <b>DNA DAMAGE</b>	<a href="#">15843498</a> <a href="#">3512077</a> <a href="#">16696564</a>

Carboplatin				
Mechanism of Action: <b>CARBOPLATIN</b> → <b>AP</b> → <b>MMR</b> → <b>FUTILE REPAIR</b> → <b>DNA DAMAGE</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
EP300	CNV Deletion	Resistant	EP300 → CREBBP_EP300 → MSH2 → MMR	<a href="#">26004186</a> <a href="#">23229133</a> <a href="#">9721864</a> <a href="#">3512077</a>
EXO1	CNV Deletion	Resistant	EXO1 → MMR	<a href="#">2649354</a> <a href="#">24829455</a> <a href="#">25956862</a> <a href="#">32167078</a>

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Carboplatin				
Mechanism of Action: <b>CARBOPLATIN</b> → <b>AP</b> → <b>MMR</b> → <b>FUTILE REPAIR</b> → <b>DNA DAMAGE</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
KMT2D	CNV Deletion	Resistant	KMT2D → H3K4 METHYLATION → MLH1 → MMR	<a href="#">19038057</a> <a href="#">8895738</a> <a href="#">19286655</a> <a href="#">28669924</a> <a href="#">25043185</a>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Cemiplimab				
Mechanism of Action: <b>CEMIPLIMAB</b> —  <b>CD274</b> —> <b>PD-1</b> —  <b>CTL_Activation</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
B2M	CNV Deletion	Resistant	B2M —> MHC1_COMPLEX —> APM_Machinery —> CTL_Activation —> GZMB —> CASP3 —> APOPTOSIS	<a href="#">30775025</a> <a href="#">29070816</a> <a href="#">30456447</a> <a href="#">30021886</a>
CDH2	CNV Deletion	Resistant	CDH2 —  CTNNB1 —> ATF3 —  CCL4 —> CTL_Activation —> GZMB —> CASP3 —> APOPTOSIS	<a href="#">29863979</a> <a href="#">12604612</a> <a href="#">25970248</a> <a href="#">31078045</a> <a href="#">8707857</a>
FAS	CNV Deletion	Resistant	FAS —> CTL_Activation —> GZMB —> CASP3 —> APOPTOSIS	<a href="#">30456447</a> <a href="#">32461348</a> <a href="#">30429213</a>
GSK3B	CNV Deletion	Resistant	GSK3B —  CTNNB1 —> ATF3 —  CCL4 —> CTL_Activation —> GZMB —> CASP3 —> APOPTOSIS	<a href="#">29863979</a> <a href="#">25970248</a> <a href="#">31078045</a> <a href="#">17621269</a>
PTEN	CNV Deletion	Resistant	PTEN —  PDPK1 —> AKT —  TSC1_TSC2 —  RHEB —> MTOR —> HIF1A —> VEGFA —  CTL_Activation —> GZMB —> CASP3 —> APOPTOSIS	<a href="#">26645196</a> <a href="#">29863979</a> <a href="#">30456447</a>
TP53	CNV Deletion	Resistant	TP53 —> TAP1 —> APM_Machinery —> CTL_Activation —> GZMB —> CASP3 —> APOPTOSIS	<a href="#">30456447</a> <a href="#">31097096</a> <a href="#">32694238</a> <a href="#">32927274</a>
PTPN2	CNV Deletion	Sensitive	PTPN2 —  STAT1 —> CD274 —> PD-1 —  CTL_Activation —> GZMB —> CASP3 —> APOPTOSIS	<a href="#">30456447</a> <a href="#">28723893</a> <a href="#">29764444</a> <a href="#">35059117</a> <a href="#">29360728</a>

Cemiplimab				
Mechanism of Action: <b>CEMIPLIMAB</b> —  <b>CD274</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
JAK2	CNV Deletion	Resistant	JAK2 —> STAT3 —> CD274 —> PD-1 —  CTL_Activation —> GZMB —> CASP3 —> APOPTOSIS	<a href="#">27903500</a> <a href="#">29863979</a> <a href="#">30456447</a>

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

### Cemiplimab

Mechanism of Action: **CEMIPLIMAB** —| **CD274**

Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
CD274	CNV Amplification	Sensitive	CD274 → PD-1 —  CTL_Activation → GZMB → CASP3 → APOPTOSIS	<a href="#">29863979</a> <a href="#">30456447</a> <a href="#">18064039</a>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Cetuximab				
Mechanism of Action: <b>CETUXIMAB</b> —  <b>EGFR</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
HRAS	CNV Amplification	Resistant	HRAS → RAF1 → MAP2K1/2 → MAPK1/3 —  EGFR	<a href="#">16117976</a> <a href="#">18356021</a> <a href="#">12077341</a> <a href="#">20562913</a>
PTEN	CNV Deletion	Resistant	PTEN —  PI345P3 → PDPK1 → AKT → PIKFYVE —  EGFR	<a href="#">23757022</a> <a href="#">30926065</a> <a href="#">30478503</a> <a href="#">25295225</a> <a href="#">17607921</a>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Cisplatin				
Mechanism of Action: <b>CISPLATIN</b> → <b>ICL</b> → <b>DSB</b> → <b>DNA DAMAGE</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
CCND1	CNV Amplification	Resistant	CCND1 → CDK4_CCND1 → BRCA1 → DNA REPAIR (HR) — DNA DAMAGE	<a href="#">20395447</a> <a href="#">12570712</a> <a href="#">25058905</a>
FEN1	CNV Amplification	Resistant	FEN1 → DNA REPAIR (BER) — DNA DAMAGE	<a href="#">26718738</a> <a href="#">24880630</a> <a href="#">12570712</a> <a href="#">25058905</a>
GSTP1	CNV Amplification	Resistant	GSTP1 — CISPLATIN	<a href="#">25058905</a> <a href="#">27688757</a> <a href="#">20807115</a> <a href="#">18701490</a> <a href="#">18852128</a> <a href="#">31221747</a> <a href="#">25010864</a> <a href="#">30431119</a>
HRAS	CNV Amplification	Resistant	HRAS → RAF1 → MAP2K1/2 → MAPK1/3 → MYC → BRCA1 → DNA REPAIR (HR) — DNA DAMAGE	<a href="#">25058905</a> <a href="#">18356021</a> <a href="#">12077341</a> <a href="#">22461507</a> <a href="#">21668996</a> <a href="#">23388117</a>
KAT5	CNV Amplification	Resistant	KAT5 → MRE11A-NBN-RAD50 → DNA REPAIR (HR) — DNA DAMAGE	<a href="#">28634400</a> <a href="#">26915295</a> <a href="#">18458078</a> <a href="#">12570712</a> <a href="#">25058905</a>
PAK1	CNV Amplification	Resistant	PAK1 → AURKA → BRCA1 → DNA REPAIR (HR) — DNA DAMAGE	<a href="#">27713506</a> <a href="#">28535002</a> <a href="#">10531298</a> <a href="#">12570712</a> <a href="#">25058905</a>
PLK1	CNV Amplification	Resistant	PLK1 → BRCA1 → DNA REPAIR (HR) — DNA DAMAGE	<a href="#">27748936</a> <a href="#">29663364</a> <a href="#">30876762</a> <a href="#">30488440</a> <a href="#">12570712</a> <a href="#">25058905</a>
SIRT3	CNV Amplification	Resistant	SIRT3 — SOD2 → ROS → DNA DAMAGE	<a href="#">25058905</a> <a href="#">19403702</a> <a href="#">27420645</a> <a href="#">33655712</a>
CDKN2A	CNV Deletion	Resistant	CDKN2A — CDK4_CCND1 — RB1 — E2F1 → BRCA1/2 → DNA REPAIR (HR) — DNA DAMAGE	<a href="#">29394020</a> <a href="#">18438954</a> <a href="#">12947386</a> <a href="#">10660629</a>

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Cisplatin				
Mechanism of Action: <b>CISPLATIN</b> → <b>ICL</b> → <b>DSB</b> → <b>DNA DAMAGE</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
CDKN2B	CNV Deletion	Resistant	CDKN2B —  CDK4_CCND1 —  RB1 —  E2F1 → BRCA1/2 → DNA REPAIR (HR) —  DNA DAMAGE	<a href="#">29394020</a> <a href="#">18438954</a> <a href="#">12947386</a> <a href="#">10660629</a>
LIG4	CNV Deletion	Resistant	LIG4 → DNA REPAIR (NHEJ) —  DNA REPAIR (HR) —  DNA DAMAGE	<a href="#">20538911</a> <a href="#">20598602</a> <a href="#">28930678</a> <a href="#">25058905</a>
PPP2R2A	CNV Deletion	Resistant	PPP2R2A —  ATM → BRCA1 → DNA REPAIR (HR) → DNA DAMAGE	<a href="#">23087057</a> <a href="#">26800397</a> <a href="#">31221814</a> <a href="#">12570712</a> <a href="#">25058905</a>
PTEN	CNV Deletion	Resistant	PTEN —  AKT → RAD51 → DNA REPAIR (HR) —  DNA DAMAGE	<a href="#">18657898</a> <a href="#">23663432</a> <a href="#">3512077</a> <a href="#">29156644</a>
RASSF1	CNV Deletion	Resistant	RASSF1 —  CCND1 → CDK4_CCND1 → BRCA1 → DNA REPAIR (HR) —  DNA DAMAGE	<a href="#">23147544</a> <a href="#">29368096</a> <a href="#">25368379</a> <a href="#">12570712</a> <a href="#">25058905</a>
SLC31A1	CNV Deletion	Resistant	SLC31A1 → CISPLATIN	<a href="#">22725681</a> <a href="#">23010323</a> <a href="#">16847145</a> <a href="#">25058905</a>
SMAD4	CNV Deletion	Resistant	SMAD4 —  BRCA1 → DNA REPAIR (HR) → DNA DAMAGE	<a href="#">19686080</a> <a href="#">20807115</a> <a href="#">24773018</a> <a href="#">30506138</a> <a href="#">12570712</a> <a href="#">25058905</a>
SUFU	CNV Deletion	Resistant	SUFU —  GLI1 → FOXM1 → RAD51 → DNA REPAIR (HR) —  DNA DAMAGE	<a href="#">23162656</a> <a href="#">28405019</a> <a href="#">25373737</a> <a href="#">22977194</a> <a href="#">12183437</a>
TP53	CNV Deletion	Resistant	TP53 —  BRCA2 → DNA REPAIR (HR) —  DNA DAMAGE	<a href="#">12591928</a> <a href="#">25058905</a> <a href="#">11595686</a> <a href="#">25263447</a>
TP53BP1	CNV Deletion	Resistant	TP53BP1 → DNA REPAIR (NHEJ) —  DNA REPAIR (HR) —  DNA DAMAGE	<a href="#">20598602</a> <a href="#">20538911</a> <a href="#">24326623</a> <a href="#">25058905</a>

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Cisplatin				
Mechanism of Action: <b>CISPLATIN</b> → <b>ICL</b> → <b>DSB</b> → <b>DNA DAMAGE</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
XRCC6	CNV Deletion	Resistant	XRCC6 → DNA REPAIR (NHEJ) → DNA REPAIR (HR) → DNA DAMAGE	<a href="#">20598602</a> <a href="#">20538911</a> <a href="#">25058905</a>
PRKCB	CNV Amplification	Sensitive	PRKCB → AKT → AKT1S1 → MTOR → ULK1 → AUTOPHAGY → SQSTM1 → RAD51 → DNA REPAIR (HR) → DNA DAMAGE	<a href="#">28246354</a> <a href="#">12570712</a> <a href="#">25058905</a>
CHEK2	CNV Deletion	Sensitive	CHEK2 → BRCA1/2 → DNA REPAIR (HR) → DNA DAMAGE	<a href="#">26957554</a> <a href="#">10843985</a> <a href="#">23229133</a> <a href="#">25847936</a> <a href="#">14701743</a> <a href="#">18797466</a>
ERCC5	CNV Deletion	Sensitive	ERCC5 → DNA REPAIR (NER) → DNA DAMAGE	<a href="#">25058905</a> <a href="#">27688757</a> <a href="#">20807115</a> <a href="#">33469680</a> <a href="#">21452186</a> <a href="#">7799936</a> <a href="#">21385444</a>
FANCA	CNV Deletion	Sensitive	FANCA → FA COMPLEX → DNA REPAIR (ICL) → DNA DAMAGE	<a href="#">25058905</a> <a href="#">27688757</a> <a href="#">20807115</a> <a href="#">28864460</a> <a href="#">12692539</a>
FANCC	CNV Deletion	Sensitive	FANCC → FA COMPLEX → DNA REPAIR (ICL) → DNA DAMAGE	<a href="#">25058905</a> <a href="#">27688757</a> <a href="#">20807115</a> <a href="#">20034732</a> <a href="#">32165095</a> <a href="#">12692539</a>
FANCG	CNV Deletion	Sensitive	FANCG → FA COMPLEX → DNA REPAIR (ICL) → DNA DAMAGE	<a href="#">25058905</a> <a href="#">27688757</a> <a href="#">20807115</a> <a href="#">12692539</a> <a href="#">12861027</a>
HSP90AA1	CNV Deletion	Sensitive	HSP90AA1 → RAD51 → DNA REPAIR (HR) → DNA DAMAGE	<a href="#">3512077</a> <a href="#">30153855</a> <a href="#">23069143</a> <a href="#">10843985</a> <a href="#">24971740</a>
MAP1LC3B	CNV Deletion	Sensitive	MAP1LC3B → AUTOPHAGY → SQSTM1 → RAD51 → DNA REPAIR (HR) → DNA DAMAGE	<a href="#">25058905</a> <a href="#">27688757</a> <a href="#">20807115</a> <a href="#">26553068</a>

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Cisplatin				
Mechanism of Action: <b>CISPLATIN</b> → <b>ICL</b> → <b>DSB</b> → <b>DNA DAMAGE</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
MBD1	CNV Deletion	Sensitive	MBD1 → MRE11A-NBN-RAD50 → DNA REPAIR(HR) → <b>DNA DAMAGE</b>	<a href="#">23588667</a> <a href="#">25058905</a>
RAD51	CNV Deletion	Sensitive	RAD51 → DNA REPAIR (HR) → <b>DNA DAMAGE</b>	<a href="#">25058905</a> <a href="#">10843985</a> <a href="#">24971740</a> <a href="#">18544565</a>
RAD51B	CNV Deletion	Sensitive	RAD51B → RAD51 → DNA REPAIR (HR) → <b>DNA DAMAGE</b>	<a href="#">25058905</a> <a href="#">25368520</a>
RBBP8	CNV Deletion	Sensitive	RBBP8 → DNA REPAIR (HR) → <b>DNA DAMAGE</b>	<a href="#">27688757</a> <a href="#">17965729</a> <a href="#">30956230</a> <a href="#">21087997</a>
REV3L	CNV Deletion	Sensitive	REV3L → DNA REPAIR (TLS) → <b>DNA DAMAGE</b>	<a href="#">25058905</a> <a href="#">26165320</a> <a href="#">19289490</a> <a href="#">21068376</a>
WRN	CNV Deletion	Sensitive	WRN → RAD52 → ERCC1-ERCC4 → DNA REPAIR (NER) → <b>DNA DAMAGE</b>	<a href="#">25801465</a> <a href="#">25058905</a>
XPA	CNV Deletion	Sensitive	XPA → DNA REPAIR (NER) → <b>DNA DAMAGE</b>	<a href="#">12208738</a> <a href="#">8512813</a>
XRCC3	CNV Deletion	Sensitive	XRCC3 → DNA REPAIR (HR) → <b>DNA DAMAGE</b>	<a href="#">10725659</a> <a href="#">25058905</a> <a href="#">15843498</a>

Cisplatin				
Mechanism of Action: <b>CISPLATIN</b> → <b>AP</b> → <b>MMR</b> → <b>FUTILE REPAIR</b> → <b>DNA DAMAGE</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
EP300	CNV Deletion	Resistant	EP300 → CREBBP_EP300 → MSH2 → MMR	<a href="#">26004186</a> <a href="#">23229133</a> <a href="#">9721864</a> <a href="#">25058905</a>
EXO1	CNV Deletion	Resistant	EXO1 → MMR	<a href="#">24829455</a> <a href="#">27688757</a> <a href="#">25956862</a>

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Cisplatin				
Mechanism of Action: <b>CISPLATIN</b> → <b>AP</b> → <b>MMR</b> → <b>FUTILE REPAIR</b> → <b>DNA DAMAGE</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
KMT2D	CNV Deletion	Resistant	KMT2D → H3K4 METHYLATION → MLH1 → MMR	<a href="#">12570712</a> <a href="#">8895738</a> <a href="#">19286655</a> <a href="#">28669924</a> <a href="#">25043185</a>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Crizotinib				
Mechanism of Action: <b>CRIZOTINIB</b> — <b>ROS1</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
ROS1	CNV Deletion	Resistant	<p>ROS1 → SOS1 → RAS → RAF1 → MAP2K1/2                      → MAPK1/3 → MYC → E2F → CANCER                      PROGRESSION                      (Direct drug target deletion is reported in the profile)</p>	<p><a href="#">21154129</a> <a href="#">29596029</a>  <a href="#">22915320</a> <a href="#">22461507</a>  <a href="#">23415111</a> <a href="#">23589333</a>  <a href="#">18345030</a></p>

Crizotinib				
Mechanism of Action: <b>CRIZOTINIB</b> — <b>EML4_ALK</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
EML4_ALK	Switch of Function	Sensitive	<p>EML4_ALK → GRB2 → SOS1 → RAS → RAF1                      → MAP2K1/2 → MAPK1/3 → MYC → GLI →                      CANCER PROGRESSION</p>	<p><a href="#">21415216</a> <a href="#">25170012</a>  <a href="#">29650534</a> <a href="#">22461507</a>  <a href="#">26901483</a> <a href="#">33848463</a>  <a href="#">23525267</a> <a href="#">21245935</a></p>

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Dabrafenib				
Mechanism of Action: <b>DABRAFENIB</b> — <b>BRAF-V600E</b> — <b>RAF1</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
HRAS	CNV Amplification	Resistant	HRAS → RAF1 → MAP2K1/2 → MAPK1/3 → MYC → GLI1 → CANCER PROGRESSION	<a href="#">23844038</a> <a href="#">24265153</a> <a href="#">27124486</a> <a href="#">34496925</a> <a href="#">20179705</a> <a href="#">27239960</a>

Dabrafenib				
Mechanism of Action: <b>DABRAFENIB</b> — <b>BRAF-V600E</b> — <b>AKT</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
PTEN	CNV Deletion	Resistant	PTEN — PI345P3 → PDPK1 → AKT — GSK3B — MYC → E2F1 → CANCER PROGRESSION	<a href="#">28220839</a> <a href="#">32076493</a> <a href="#">33340965</a> <a href="#">10576742</a> <a href="#">15671063</a>
TP53	CNV Deletion	Resistant	TP53 — PIK3CA → PI345P3 → PDPK1 → AKT — GSK3B — MYC → E2F1 → CANCER PROGRESSION	<a href="#">24971404</a> <a href="#">22552284</a> <a href="#">32365809</a> <a href="#">30514931</a> <a href="#">20361045</a> <a href="#">10698680</a> <a href="#">15023437</a> <a href="#">15944709</a> <a href="#">11959846</a>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

### Dacomitinib

Mechanism of Action: **DACOMITINIB** —| **EGFR**

Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
PTEN	CNV Deletion	Resistant	<p>PTEN —  PI345P3 → PDPK1 → AKT → PIKFYVE —  EGFR</p>	<a href="#">31050691</a> <a href="#">29163853</a> <a href="#">25295225</a> <a href="#">23757022</a>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Docetaxel-dexamethasone				
Mechanism of Action: <b>DOCETAXEL-DEXAMETHASONE</b> → <b>SPINDLE POISON</b> → <b>ANAPC1_CDC26_CDC20</b> → <b>CCNB1_CDK1</b> → <b>MITOTIC_CATASTROPHE</b> → <b>MITOTIC_SLIPPAGE</b> → <b>APOPTOSIS</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
MUC5AC	CNV Amplification	Resistant	MUC5AC → CD44 → STAT3 → ABCB1 → DOCETAXEL-DEXAMETHASONE	<a href="#">20447949</a> <a href="#">16012521</a> <a href="#">25410489</a> <a href="#">32098629</a> <a href="#">33920736</a> <a href="#">25995342</a>
BUB1B	CNV Deletion	Resistant	BUB1B → CCNB1_CDK1 → MITOTIC_CATASTROPHE → MITOTIC_SLIPPAGE → APOPTOSIS	<a href="#">18728853</a> <a href="#">15975912</a> <a href="#">20855838</a> <a href="#">25519703</a> <a href="#">17099726</a> <a href="#">25698537</a> <a href="#">27143916</a> <a href="#">26491220</a> <a href="#">31199987</a> <a href="#">24096242</a>
PTEN	CNV Deletion	Resistant	PTEN → PI345P3 → PDPK1 → AKT → AKT1S1 → MTOR → HIF1A → TUBB3 → DOCETAXEL- DEXAMETHASONE → APOPTOSIS	<a href="#">20361045</a> <a href="#">18466115</a> <a href="#">19143635</a> <a href="#">15094766</a> <a href="#">14673156</a> <a href="#">21779440</a> <a href="#">22354785</a> <a href="#">19143636</a> <a href="#">17386266</a> <a href="#">18515545</a> <a href="#">17502379</a> <a href="#">23364970</a> <a href="#">18178340</a> <a href="#">12533264</a> <a href="#">15140405</a> <a href="#">1808657</a>
STARD9	CNV Deletion	Sensitive	STARD9 → SPINDLE POISON	<a href="#">12533264</a> <a href="#">15140405</a> <a href="#">18086570</a> <a href="#">22153075</a>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

### Docetaxel-dexamethasone

Mechanism of Action: **DOCETAXEL-DEXAMETHASONE** → **SPINDLE\_POISON** → **ANAPC1\_CDC26\_CDC20** → **CCNB1\_CDK1**  
 → **MITOTIC\_CATASTROPHE** → **MITOTIC\_SLIPPAGE** → **APOPTOSIS**

Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
PAK1	CNV Amplification	Resistant	PAK1 → AURKA → PLK1 → MITOTIC_CATASTROPHE	<a href="#">31055879</a> <a href="#">23634246</a> <a href="#">21041660</a> <a href="#">23661607</a> <a href="#">15140405</a> <a href="#">33451333</a>

### Docetaxel-dexamethasone

Mechanism of Action: **DOCETAXEL-DEXAMETHASONE** → **NR3C1** → **TSC22D3** → **TP53** → **PMAIPI**

Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
PMAIPI	CNV Deletion	Resistant	PMAIPI → CANCER PROGRESSION	<a href="#">10551779</a> <a href="#">25168242</a> <a href="#">22719835</a> <a href="#">32150332</a>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Durvalumab				
Mechanism of Action: <b>DURVALUMAB</b> —  <b>CD274</b> —> <b>PD-1</b> —  <b>CTL_Activation</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
CCND1	CNV Amplification	Resistant	CCND1 —> CDK4_CCND1 —> BRCA1 —> DNA REPAIR (HR) —  APM_Machinery —> CTL_Activation —> GZMB —> CASP3 —> APOPTOSIS	<a href="#">29416316</a> <a href="#">32903763</a>
B2M	CNV Deletion	Resistant	B2M —> MHC1_COMPLEX —> APM_Machinery —> CTL_Activation —> GZMB —> CASP3 —> APOPTOSIS	<a href="#">30775025</a> <a href="#">29070816</a> <a href="#">28717238</a> <a href="#">30021886</a> <a href="#">29423109</a> <a href="#">29416316</a>
CDH2	CNV Deletion	Resistant	CDH2 —  CTNNB1 —> ATF3 —  CCL4 —> CTL_Activation —> GZMB —> CASP3 —> APOPTOSIS	<a href="#">25970248</a> <a href="#">12604612</a> <a href="#">29416316</a> <a href="#">31078045</a> <a href="#">8707857</a>
FAS	CNV Deletion	Resistant	FAS —> CTL_Activation —> GZMB —> CASP3 —> APOPTOSIS	<a href="#">30429213</a> <a href="#">29416316</a>
GSK3B	CNV Deletion	Resistant	GSK3B —  CTNNB1 —> ATF3 —  CCL4 —> CTL_Activation —> GZMB —> CASP3 —> APOPTOSIS	<a href="#">25970248</a> <a href="#">29416316</a> <a href="#">31078045</a> <a href="#">17621269</a>
PTEN	CNV Deletion	Resistant	PTEN —  PDPK1 —> AKT —  TSC1_TSC2 —  RHEB —> MTOR —> HIF1A —> VEGFA —  CTL_Activation —> GZMB —> CASP3 —> APOPTOSIS	<a href="#">26645196</a> <a href="#">29416316</a>
TP53	CNV Deletion	Resistant	TP53 —> TAP1 —> APM_Machinery —> CTL_Activation —> GZMB —> CASP3 —> APOPTOSIS	<a href="#">31097096</a> <a href="#">32694238</a> <a href="#">32927274</a> <a href="#">29416316</a>

Durvalumab				
Mechanism of Action: <b>DURVALUMAB</b> —  <b>CD274</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
JAK2	CNV Deletion	Resistant	JAK2 —> STAT3 —> CD274 —> PD-1 —  CTL_Activation —> GZMB —> CASP3 —> APOPTOSIS	<a href="#">29416316</a> <a href="#">27903500</a>
CD274	CNV Amplification	Sensitive	CD274 —> PD-1 —  CTL_Activation —> GZMB —> CASP3 —> APOPTOSIS	<a href="#">29416316</a> <a href="#">32209338</a>

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

### Durvalumab

Mechanism of Action: **DURVALUMAB** —| **CD274**

Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
PTPN2	CNV Deletion	Sensitive	<p>PTPN2 —  STAT1 —&gt; CD274 —&gt; PD-1 — </p> <p>CTL_Activation —&gt; GZMB —&gt; CASP3 —&gt; APOPTOSIS</p>	<a href="#">29416316</a> <a href="#">28723893</a> <a href="#">28717238</a>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Entrectinib				
Mechanism of Action: <b>ENTRECTINIB</b> — <b>NTRK1</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
HRAS	CNV Amplification	Resistant	HRAS → RAF1 → MAP2K1/2 → MAPK1/3 → MYC → E2F1 → CANCER PROGRESSION (Alternative activation of ERK signaling causes resistance to drug)	<a href="#">30050303</a> <a href="#">18356021</a> <a href="#">12077341</a> <a href="#">22461507</a> <a href="#">15944709</a>
PTEN	CNV Deletion	Resistant	PTEN — PI345P3 → PDPK1 → AKT — TSC1_TSC2 — MTOR → EIF4E → TRANSLATION → MYC → CANCER PROGRESSION (Parallel pathway activation causes resistance to drug)	<a href="#">26939704</a> <a href="#">31871269</a> <a href="#">32133433</a>
TP53	CNV Deletion	Resistant	TP53 — PIK3CA → PI345P3 → PDPK1 → AKT — GSK3B — MYC → FOXM1 → CANCER PROGRESSION (Parallel pathway activation causes resistance to drug)	<a href="#">30050303</a> <a href="#">24520092</a> <a href="#">30898150</a> <a href="#">32365809</a> <a href="#">31871269</a> <a href="#">1638116</a> <a href="#">29554906</a> <a href="#">11959846</a>

Entrectinib				
Mechanism of Action: <b>ENTRECTINIB</b> — <b>NTRK2</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
NTRK2	CNV Deletion	Resistant	NTRK2 → SHC1 → PIK3CA → PI345P3 → PDPK1 → AKT → CHUK_IKBKB → NFKB1 → CANCER PROGRESSION (Direct drug target deletion is reported in the profile)	<a href="#">30050303</a> <a href="#">26565381</a> <a href="#">10985347</a> <a href="#">19609947</a>

Entrectinib				
Mechanism of Action: <b>ENTRECTINIB</b> — <b>ROS1</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Entrectinib				
Mechanism of Action: <b>ENTRECTINIB</b> — <b>ROS1</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
ROS1	CNV Deletion	Resistant	<p>                     ROS1 → SOS1 → RAS → RAF1 → MAP2K1/2                      → MAPK1/3 → MYC → E2F1 → CANCER                      PROGRESSION                      (Direct drug target deletion is reported in the profile)                 </p>	<p> <a href="#">30050303</a> <a href="#">22461507</a>  <a href="#">33290717</a> <a href="#">23415111</a>  <a href="#">23589333</a> <a href="#">18345030</a> </p>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Erlotinib				
Mechanism of Action: <b>ERLOTINIB</b> —  <b>EGFR</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
HRAS	CNV Amplification	Resistant	HRAS → RAF1 → MAP2K1/2 → MAPK1/3 —  EGFR	<a href="#">17591829</a> <a href="#">18356021</a> <a href="#">12077341</a> <a href="#">20562913</a>
PTEN	CNV Deletion	Resistant	PTEN —  PI345P3 → PDPK1 → AKT → PIKFYVE —  EGFR	<a href="#">20477246</a> <a href="#">25295225</a> <a href="#">23757022</a> <a href="#">25934712</a>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Etoposide				
Mechanism of Action: <b>ETOPOSIDE</b> → <b>TOP2CC</b> → <b>DSB</b> → <b>DNA DAMAGE</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
ABCC1	CNV Amplification	Resistant	ABCC1 —  ETOPOSIDE	<a href="#">8910583</a> <a href="#">31671674</a> <a href="#">15999103</a> <a href="#">19214144</a> <a href="#">17187268</a>
CCND1	CNV Amplification	Resistant	CCND1 → CDK4_CCND1 → BRCA1 → DNA REPAIR (HR) —  DNA DAMAGE	<a href="#">24766193</a> <a href="#">18171670</a> <a href="#">15546503</a> <a href="#">23388117</a>
GSTP1	CNV Amplification	Resistant	GSTP1 —  ETOPOSIDE	<a href="#">12112003</a> <a href="#">15999103</a> <a href="#">24766193</a> <a href="#">19377506</a>
PAK1	CNV Amplification	Resistant	PAK1 → AURKA → BRCA1 → DNA REPAIR (HR) —  DNA DAMAGE	<a href="#">24766193</a> <a href="#">31429028</a> <a href="#">18171670</a> <a href="#">16246726</a> <a href="#">34632941</a>
BCL11B	CNV Deletion	Resistant	BCL11B → BRG_ARID1A_BAF_COMPLEX → TOP2A → TOP2CC → DSB → DNA DAMAGE	<a href="#">25827435</a> <a href="#">25544751</a> <a href="#">19377506</a>
CDKN2A	CNV Deletion	Resistant	CDKN2A —  CDK4_CCND1 —  RB1 —  E2F1 → BRCA1/2 → DNA REPAIR (HR) —  DNA DAMAGE	<a href="#">18438954</a> <a href="#">12947386</a> <a href="#">10660629</a> <a href="#">19377506</a>
CDKN2B	CNV Deletion	Resistant	CDKN2B —  CDK4_CCND1 —  RB1 —  E2F1 → BRCA1/2 → DNA REPAIR (HR) —  DNA DAMAGE	<a href="#">18438954</a> <a href="#">12947386</a> <a href="#">10660629</a> <a href="#">19377506</a>
PTEN	CNV Deletion	Resistant	PTEN —  AKT → PRKDC_XRCC6_XRCC5 → DNA REPAIR (NHEJ) —  DNA DAMAGE	<a href="#">8910583</a> <a href="#">31671674</a> <a href="#">21784088</a> <a href="#">23796964</a> <a href="#">26986476</a> <a href="#">24811392</a>
RNF168	CNV Deletion	Resistant	RNF168 → TOP2A → TOP2CC → DSB → DNA DAMAGE	<a href="#">8910583</a> <a href="#">31671674</a> <a href="#">24461734</a> <a href="#">27558965</a>
SMAD4	CNV Deletion	Resistant	SMAD4 —  BRCA1 → DNA REPAIR (HR) → DNA DAMAGE	<a href="#">26600742</a> <a href="#">16696564</a> <a href="#">15735739</a> <a href="#">23388117</a> <a href="#">26957554</a>

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Etoposide				
Mechanism of Action: <b>ETOPOSIDE</b> → <b>TOP2CC</b> → <b>DSB</b> → <b>DNA DAMAGE</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
SUFU	CNV Deletion	Resistant	SUFU —  GLI1 → FOXM1 → BRCA2 → DNA REPAIR (HR) —  DNA DAMAGE	<a href="#">8910583</a> <a href="#">25287128</a> <a href="#">27863385</a> <a href="#">12947386</a> <a href="#">20956384</a>
CHEK2	CNV Deletion	Sensitive	CHEK2 → BRCA1/2 → DNA REPAIR (HR) —  DNA DAMAGE	<a href="#">8910583</a> <a href="#">31671674</a> <a href="#">14701743</a> <a href="#">15546503</a> <a href="#">18797466</a>
LIG4	CNV Deletion	Sensitive	LIG4 → DNA REPAIR (NHEJ) —  DNA DAMAGE	<a href="#">28695890</a> <a href="#">12853643</a> <a href="#">24766193</a> <a href="#">19377506</a>
MBD1	CNV Deletion	Sensitive	MBD1 → MRE11A-NBN-RAD50 → DNA REPAIR(HR) —  DNA DAMAGE	<a href="#">16818498</a> <a href="#">21087997</a> <a href="#">27814490</a> <a href="#">23588667</a>
RAD51	CNV Deletion	Sensitive	RAD51 → DNA REPAIR (HR) —  DNA DAMAGE	<a href="#">8910583</a> <a href="#">31671674</a> <a href="#">12712436</a>
RAD51B	CNV Deletion	Sensitive	RAD51B → RAD51 → DNA REPAIR (HR) —  DNA DAMAGE	<a href="#">16101488</a> <a href="#">12712436</a> <a href="#">10938124</a>
RBBP8	CNV Deletion	Sensitive	RBBP8 → DNA REPAIR (HR) —  DNA DAMAGE	<a href="#">8910583</a> <a href="#">31671674</a> <a href="#">21087997</a>
REV3L	CNV Deletion	Sensitive	REV3L → DNA REPAIR (TLS) —  DNA DAMAGE	<a href="#">24766193</a> <a href="#">21926160</a> <a href="#">21068376</a>
TP53BP1	CNV Deletion	Sensitive	TP53BP1 → DNA REPAIR (NHEJ) —  DNA DAMAGE	<a href="#">8910583</a> <a href="#">31671674</a> <a href="#">24000320</a> <a href="#">30352856</a>
XRCC3	CNV Deletion	Sensitive	XRCC3 → RAD51 → DNA REPAIR (HR) —  DNA DAMAGE	<a href="#">15372620</a> <a href="#">19377506</a> <a href="#">9705276</a>

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Etoposide				
Mechanism of Action: <b>ETOPOSIDE</b> → <b>TOP2CC</b> → <b>DSB</b> → <b>DNA DAMAGE</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
XRCC6	CNV Deletion	Sensitive	XRCC6 → PRKDC_XRCC6_XRCC5 → DNA REPAIR (NHEJ) — DNA DAMAGE	<a href="#">8910583</a> <a href="#">31671674</a> <a href="#">24000320</a> <a href="#">18674614</a> <a href="#">15827325</a> <a href="#">24130054</a>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Fam-trastuzumab-deruxtecan-nxki				
Mechanism of Action: <b>FAM-TRASTUZUMAB-DERUXTECAN-NXKI</b> — <b>ERBB2</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
HRAS	CNV Amplification	Resistant	HRAS → RAF1 → MAP2K1/2 → MAPK1/3 — <b>ERBB2</b>	<a href="#">33629601</a> <a href="#">18356021</a> <a href="#">12077341</a> <a href="#">20562913</a> <a href="#">25367036</a> <a href="#">27531070</a> <a href="#">28843257</a>

Fam-trastuzumab-deruxtecan-nxki				
Mechanism of Action: <b>FAM-TRASTUZUMAB-DERUXTECAN-NXKI</b> → <b>TOP1CC</b> → <b>DSB</b> → <b>DNA DAMAGE</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
PAK1	CNV Amplification	Resistant	<b>PAK1</b> → <b>AURKA</b> → BRCA1 → DNA REPAIR (HR) — <b>DNA DAMAGE</b>	<a href="#">33629601</a> <a href="#">33451333</a> <a href="#">18056443</a> <a href="#">15546503</a> <a href="#">11879553</a>
CHEK2	CNV Deletion	Sensitive	CHEK2 → BRCA1/2 → DNA REPAIR (HR) — <b>DNA DAMAGE</b>	<a href="#">33629601</a> <a href="#">22114986</a> <a href="#">23388117</a>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Gefitinib				
Mechanism of Action: <b>GEFITINIB</b> — <b>EGFR</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
PTEN	CNV Deletion	Resistant	<pre> graph LR     PTEN --  PI345P3     PTEN --  EGFR     PI345P3 --&gt; PDPK1     PDPK1 --&gt; AKT     AKT --&gt; PIKFYVE                     </pre>	<a href="#">26980062</a> <a href="#">20959484</a> <a href="#">14555504</a> <a href="#">25295225</a> <a href="#">23757022</a>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Gemcitabine				
Mechanism of Action: <b>GEMCITABINE</b> → <b>dFdCTP</b> → <b>DNA DAMAGE</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
ABCC1	CNV Amplification	Resistant	ABCC1 —  GEMCITABINE	<a href="#">31514451</a> <a href="#">7481842</a> <a href="#">30195264</a> <a href="#">21804948</a>
SMAD4	CNV Deletion	Resistant	SMAD4 → CDH1 —  CTNNB1 → ABCB1 —  GEMCITABINE	<a href="#">10340887</a> <a href="#">28534865</a> <a href="#">27708512</a> <a href="#">24625091</a>
CHEK2	CNV Deletion	Sensitive	CHEK2 → BRCA1/2 → DNA REPAIR (HR) —  DNA DAMAGE	<a href="#">31514451</a> <a href="#">7481842</a> <a href="#">14701743</a> <a href="#">18797466</a>
EP300	CNV Deletion	Sensitive	EP300 → CREBBP_EP300 → MSH2 → DNA REPAIR (MMR) —  DNA DAMAGE	<a href="#">33445797</a> <a href="#">10340887</a> <a href="#">25558828</a> <a href="#">27322077</a>
EXO1	CNV Deletion	Sensitive	EXO1 → DNA REPAIR (MMR) —  DNA DAMAGE	<a href="#">33445797</a> <a href="#">10340887</a> <a href="#">19237629</a> <a href="#">26743341</a> <a href="#">25956862</a>
KMT2D	CNV Deletion	Sensitive	KMT2D → H3K4 METHYLATION → MLH1 → DNA REPAIR (MMR) —  DNA DAMAGE	<a href="#">33445797</a> <a href="#">10340887</a> <a href="#">14583494</a> <a href="#">29498679</a> <a href="#">25043185</a>

Gemcitabine				
Mechanism of Action: <b>GEMCITABINE</b> → <b>dFdCDP</b> —  <b>RRM1/2</b> → <b>dCTP</b> —  <b>REPLICATION STRESS</b> → <b>APOPTOSIS</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
HRAS	CNV Amplification	Resistant	HRAS → RAF1 → MAP2K1/2 → MAPK1/3 → MYC → dCTP —  REPLICATION STRESS → APOPTOSIS	<a href="#">7481842</a> <a href="#">18356021</a> <a href="#">12077341</a> <a href="#">22461507</a> <a href="#">10340887</a> <a href="#">29170413</a>
TP53	CNV Deletion	Sensitive	TP53 → POLH —  REPLICATION STRESS → APOPTOSIS	<a href="#">10340887</a> <a href="#">19010910</a> <a href="#">16449651</a>

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Gemcitabine				
Mechanism of Action: <b>GEMCITABINE</b> → <b>dFdCDP</b> → <b>RRM1/2</b> → <b>dCTP</b> → <b>REPLICATION STRESS</b> → <b>APOPTOSIS</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
WDR5	CNV Deletion	Sensitive	WDR5 → MYC → dCTP → REPLICATION STRESS → APOPTOSIS	<a href="#">10340887</a> <a href="#">27320920</a> <a href="#">24504118</a> <a href="#">27517489</a>

Gemcitabine				
Mechanism of Action: <b>GEMCITABINE</b> → <b>dFdCDP</b> → <b>RRM1-RRM2</b> → <b>dCTP</b> → <b>REPLICATION STRESS</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
RRM1	CNV Amplification	Resistant	RRM1 → RRM1-RRM2 → dCTP → REPLICATION STRESS → APOPTOSIS	<a href="#">31514451</a> <a href="#">7481842</a> <a href="#">29853661</a> <a href="#">18414411</a> <a href="#">25837929</a>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Ipilimumab				
Mechanism of Action: <b>IPILIMUMAB</b> —  <b>CTLA4</b> —  <b>CTL_Activation</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
B2M	CNV Deletion	Resistant	B2M → MHC1_COMPLEX → APM_Machinery → CTL_Activation → GZMB → CASP3 → APOPTOSIS	<a href="#">21900389</a> <a href="#">18064039</a> <a href="#">29070816</a> <a href="#">30021886</a>
CDH2	CNV Deletion	Resistant	CDH2 —  CTNNB1 → ATF3 —  CCL4 → CTL_Activation → GZMB → CASP3 → APOPTOSIS	<a href="#">21900389</a> <a href="#">12604612</a> <a href="#">25970248</a> <a href="#">31078045</a> <a href="#">8707857</a>
FAS	CNV Deletion	Resistant	FAS → CTL_Activation → GZMB → CASP3 → APOPTOSIS	<a href="#">21900389</a> <a href="#">18064039</a> <a href="#">29724044</a> <a href="#">12140383</a>
GSK3B	CNV Deletion	Resistant	GSK3B —  CTNNB1 → ATF3 —  CCL4 → CTL_Activation → GZMB → CASP3 → APOPTOSIS	<a href="#">21900389</a> <a href="#">25970248</a> <a href="#">31078045</a> <a href="#">17621269</a>
PTEN	CNV Deletion	Resistant	PTEN —  PDPK1 → AKT —  TSC1_TSC2 —  RHEB → MTOR → HIF1A → VEGFA —  CTL_Activation → GZMB → CASP3 → APOPTOSIS	<a href="#">21900389</a> <a href="#">18064039</a> <a href="#">26645196</a> <a href="#">31703593</a>
CDKN2A	CNV Deletion	Sensitive	CDKN2A → CHEK2 → BRCA1/2 → DNA REPAIR (HR) —  APM_Machinery → CTL_Activation → GZMB → CASP3 → APOPTOSIS	<a href="#">21900389</a> <a href="#">18064039</a> <a href="#">30291219</a> <a href="#">31703593</a>

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Larotrectinib				
Mechanism of Action: <b>LAROTRECTINIB</b> —  <b>NTRK1</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
HRAS	CNV Amplification	Resistant	HRAS → RAFI → MAP2K1/2 → MAPK1/3 → MYC → E2F1 → CANCER PROGRESSION (Alternative activation of ERK signaling causes resistance to drug)	<a href="#">31469968</a> <a href="#">18356021</a> <a href="#">12077341</a> <a href="#">22461507</a> <a href="#">15944709</a>
PTEN	CNV Deletion	Resistant	PTEN —  PI345P3 → PDPK1 → AKT —  TSC1_TSC2 —  MTOR → EIF4E → TRANSLATION → MYC → CANCER PROGRESSION (Parallel pathway activation causes resistance to drug)	<a href="#">28578312</a> <a href="#">31871269</a> <a href="#">32133433</a>
TP53	CNV Deletion	Resistant	TP53 —  PIK3CA → PI345P3 → PDPK1 → AKT —  GSK3B —  MYC → FOXM1 → CANCER PROGRESSION (Parallel pathway activation causes resistance to drug)	<a href="#">29466156</a> <a href="#">11959846</a> <a href="#">30050303</a> <a href="#">24520092</a> <a href="#">30898150</a> <a href="#">32365809</a> <a href="#">31871269</a> <a href="#">1638116</a> <a href="#">29554906</a>

Larotrectinib				
Mechanism of Action: <b>LAROTRECTINIB</b> —  <b>NTRK2</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
NTRK2	CNV Deletion	Resistant	NTRK2 → SHC1 → PIK3CA → PI345P3 → PDPK1 → AKT → CHUK_IKBKB → NFKB1 → CANCER PROGRESSION (Direct drug target deletion is reported in the profile)	<a href="#">11147812</a> <a href="#">30328953</a> <a href="#">1960</a> <a href="#">10985347</a> <a href="#">19609947</a>

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Lorlatinib				
Mechanism of Action: <b>LORLATINIB</b> — <b>ROS1</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
ROS1	CNV Deletion	Resistant	<p>ROS1 → SOS1 → RAS → RAF1 → MAP2K1/2                      → MAPK1/3 → MYC → E2F → CANCER                      PROGRESSION                      (Direct drug target deletion is reported in the profile)</p>	<p><a href="#">32122926</a> <a href="#">31669155</a>  <a href="#">27401242</a> <a href="#">22461507</a>  <a href="#">33290717</a> <a href="#">23415111</a>  <a href="#">23589333</a> <a href="#">18345030</a></p>

Lorlatinib				
Mechanism of Action: <b>LORLATINIB</b> — <b>EML4_ALK</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
EML4_ALK	Switch of Function	Sensitive	<p>EML4_ALK → GRB2 → SOS1 → RAS → RAF1                      → MAP2K1/2 → MAPK1/3 → MYC → GLI →                      CANCER PROGRESSION</p>	<p><a href="#">21415216</a> <a href="#">29650534</a>  <a href="#">22461507</a> <a href="#">26901483</a>  <a href="#">33848463</a> <a href="#">23525267</a>  <a href="#">33352844</a> <a href="#">21245935</a></p>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Nab-paclitaxel				
Mechanism of Action: <b>NAB-PACLITAXEL</b> → <b>SPINDLE POISON</b> → <b>ANAPC1_CDC26_CDC20</b> → <b>CCNB1_CDK1</b> → <b>MITOTIC_CATASTROPHE</b> → <b>MITOTIC_SLIPPAGE</b> → <b>APOPTOSIS</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
HRAS	CNV Amplification	Resistant	HRAS → RAF1 → MAP2K1/2 → MAPK1/3 → CHUK_IKBKB → NFKB1 → BIRC5 → MITOTIC_SLIPPAGE → APOPTOSIS	<a href="#">27177222</a> <a href="#">15729715</a> <a href="#">31096466</a> <a href="#">26035434</a> <a href="#">24168763</a> <a href="#">20498641</a> <a href="#">27484466</a> <a href="#">10962577</a> <a href="#">12077341</a>
PAK1	CNV Amplification	Resistant	PAK1 → AURKA → PLK1 → MITOTIC_CATASTROPHE	<a href="#">31055879</a> <a href="#">23634246</a> <a href="#">21041660</a> <a href="#">23661607</a> <a href="#">15140405</a> <a href="#">33451333</a>
BUB1B	CNV Deletion	Resistant	BUB1B → CCNB1_CDK1 → MITOTIC_CATASTROPHE → MITOTIC_SLIPPAGE → APOPTOSIS	<a href="#">23154965</a> <a href="#">26491220</a> <a href="#">26137480</a> <a href="#">24096242</a> <a href="#">30674582</a> <a href="#">31199987</a> <a href="#">25698537</a>
RASSF1	CNV Deletion	Resistant	RASSF1 → SPINDLE POISON	<a href="#">16722814</a> <a href="#">26491220</a> <a href="#">22548172</a> <a href="#">22438769</a> <a href="#">31804463</a>
STARD9	CNV Deletion	Sensitive	STARD9 → SPINDLE POISON	<a href="#">26491220</a> <a href="#">26137480</a> <a href="#">30160609</a> <a href="#">22153075</a> <a href="#">24096242</a> <a href="#">30674582</a> <a href="#">31199987</a>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Nab-paclitaxel				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
Mechanism of Action: <b>NAB-PACLITAXEL</b> → <b>SPINDLE POISON</b> → <b>ANAPC1_CDC26_CDC20</b> → <b>CCNB1_CDK1</b> → <b>MITOTIC_CATASTROPHE</b> → <b>MITOTIC_SLIPPAGE</b> → <b>APOPTOSIS</b> <b>NAB-PACLITAXEL</b> → <b>SPINDLE POISON</b> → <b>ANAPC1_CDC26_P_CDC20</b> → <b>CCNB1_CDK1</b> → <b>MITOTIC_CATASTROPHE</b> → <b>MITOTIC_SLIPPAGE</b> → <b>APOPTOSIS</b>				
PTEN	CNV Deletion	Resistant	PTEN → PI345P3 → PDPK1 → AKT → AKT1S1 → MTOR → HIF1A → TUBB3 → NAB-PACLITAXEL → APOPTOSIS PTEN → PI345P3 → PDPK1 → AKT → AKT1S1 → MTOR → HIF1A → TUBB3 → NAB-PACLITAXEL	<a href="#">20361045</a> <a href="#">18466115</a> <a href="#">19143635</a> <a href="#">15094766</a> <a href="#">14673156</a> <a href="#">21779440</a> <a href="#">22354785</a> <a href="#">19143636</a> <a href="#">17386266</a> <a href="#">18515545</a> <a href="#">17502379</a> <a href="#">23364970</a> <a href="#">18178340</a>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Nivolumab				
Mechanism of Action: <b>NIVOLUMAB</b> —  <b>CD274</b> —> <b>PD-1</b> —  <b>CTL_Activation</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
CCND1	CNV Amplification	Resistant	CCND1 —> CDK4_CCND1 —> BRCA1 —> DNA REPAIR (HR) —  APM_Machinery —> CTL_Activation —> GZMB —> CASP3 —> APOPTOSIS	<a href="#">28261342</a> <a href="#">32903763</a>
B2M	CNV Deletion	Resistant	B2M —> MHC1_COMPLEX —> APM_Machinery —> CTL_Activation —> GZMB —> CASP3 —> APOPTOSIS	<a href="#">30775025</a> <a href="#">29070816</a> <a href="#">28261342</a> <a href="#">30021886</a>
CDH2	CNV Deletion	Resistant	CDH2 —  CTNNB1 —> ATF3 —  CCL4 —> CTL_Activation —> GZMB —> CASP3 —> APOPTOSIS	<a href="#">24872026</a> <a href="#">12604612</a> <a href="#">25970248</a> <a href="#">31078045</a> <a href="#">8707857</a>
FAS	CNV Deletion	Resistant	FAS —> CTL_Activation —> GZMB —> CASP3 —> APOPTOSIS	<a href="#">28261342</a> <a href="#">32461348</a> <a href="#">30429213</a> <a href="#">30259383</a>
GSK3B	CNV Deletion	Resistant	GSK3B —  CTNNB1 —> ATF3 —  CCL4 —> CTL_Activation —> GZMB —> CASP3 —> APOPTOSIS	<a href="#">24872026</a> <a href="#">25970248</a> <a href="#">31078045</a> <a href="#">17621269</a>
PTEN	CNV Deletion	Resistant	PTEN —  PDPK1 —> AKT —  TSC1_TSC2 —  RHEB —> MTOR —> HIF1A —> VEGFA —  CTL_Activation —> GZMB —> CASP3 —> APOPTOSIS	<a href="#">26645196</a> <a href="#">28261342</a>
TP53	CNV Deletion	Resistant	TP53 —> TAP1 —> APM_Machinery —> CTL_Activation —> GZMB —> CASP3 —> APOPTOSIS	<a href="#">31097096</a> <a href="#">32694238</a> <a href="#">32927274</a> <a href="#">28261342</a>
PTPN2	CNV Deletion	Sensitive	PTPN2 —  STAT1 —> CD274 —> PD-1 —  CTL_Activation —> GZMB —> CASP3 —> APOPTOSIS	<a href="#">28261342</a> <a href="#">28723893</a> <a href="#">29764444</a> <a href="#">35059117</a> <a href="#">29360728</a>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Nivolumab				
Mechanism of Action: <b>NIVOLUMAB</b> —  <b>CD274</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
JAK2	CNV Deletion	Resistant	JAK2 → STAT3 → CD274 → PD-1 —  CTL_Activation → GZMB → CASP3 → APOPTOSIS	<a href="#">27903500</a> <a href="#">28261342</a>
CD274	CNV Amplification	Sensitive	CD274 → PD-1 —  CTL_Activation → GZMB → CASP3 → APOPTOSIS	<a href="#">30304963</a> <a href="#">24872026</a> <a href="#">28261342</a>

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Paclitaxel-dexamethasone				
Mechanism of Action: <b>PACLITAXEL-DEXAMETHASONE</b> → <b>SPINDLE POISON</b> → <b>ANAPC1_CDC26_CDC20</b> → <b>CCNB1_CDK1</b> → <b>MITOTIC_CATASTROPHE</b> → <b>MITOTIC_SLIPPAGE</b> → <b>APOPTOSIS</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
GSTP1	CNV Amplification	Resistant	GSTP1 → <b>PACLITAXEL-DEXAMETHASONE</b>	<a href="#">26491220</a> <a href="#">26137480</a> <a href="#">24096242</a> <a href="#">17764884</a> <a href="#">30674582</a> <a href="#">31199987</a> <a href="#">32535103</a>
MUC5AC	CNV Amplification	Resistant	MUC5AC → CD44 → STAT3 → ABCB1 → <b>PACLITAXEL-DEXAMETHASONE</b>	<a href="#">20447949</a> <a href="#">27415012</a> <a href="#">22179563</a> <a href="#">32098629</a> <a href="#">33920736</a> <a href="#">25995342</a>
BUB1B	CNV Deletion	Resistant	BUB1B → CCNB1_CDK1 → MITOTIC_CATASTROPHE → <b>MITOTIC_SLIPPAGE</b> → <b>APOPTOSIS</b>	<a href="#">23154965</a> <a href="#">26491220</a> <a href="#">26137480</a> <a href="#">24096242</a> <a href="#">30674582</a> <a href="#">31199987</a> <a href="#">25698537</a>
RASSF1	CNV Deletion	Resistant	RASSF1 → SPINDLE POISON	<a href="#">23907557</a> <a href="#">26491220</a> <a href="#">22548172</a> <a href="#">22438769</a> <a href="#">31804463</a>
STARD9	CNV Deletion	Sensitive	STARD9 → <b>SPINDLE POISON</b>	<a href="#">26491220</a> <a href="#">26137480</a> <a href="#">30160609</a> <a href="#">22153075</a> <a href="#">24096242</a> <a href="#">30674582</a> <a href="#">31199987</a>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Paclitaxel-dexamethasone				
Mechanism of Action: <b>PACLITAXEL-DEXAMETHASONE</b> → <b>SPINDLE_POISON</b> → <b>ANAPC1_CDC26_CDC20</b> → <b>CCNB1_CDK1</b> → <b>MITOTIC_CATASTROPHE</b> → <b>MITOTIC_SLIPPAGE</b> → <b>APOPTOSIS</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
PAK1	CNV Amplification	Resistant	<b>PAK1</b> → <b>AURKA</b> → <b>PLK1</b> → <b>MITOTIC_CATASTROPHE</b>	<a href="#">29654797</a> <a href="#">23634246</a> <a href="#">21041660</a> <a href="#">23661607</a> <a href="#">15140405</a> <a href="#">33451333</a>
CHFR	CNV Deletion	Sensitive	<b>CHFR</b> → <b>SPINDLE_POISON</b>	<a href="#">26491220</a> <a href="#">26137480</a> <a href="#">24096242</a> <a href="#">30674582</a> <a href="#">31199987</a> <a href="#">21792009</a>

Paclitaxel-dexamethasone				
Mechanism of Action: <b>PACLITAXEL-DEXAMETHASONE</b> → <b>NR3C1</b> → <b>TSC22D3</b> → <b>TP53</b> → <b>PMAIP1</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
PMAIP1	CNV Deletion	Resistant	<b>PMAIP1</b> → <b>CANCER PROGRESSION</b>	<a href="#">11455223</a> <a href="#">10551779</a> <a href="#">25168242</a> <a href="#">22719835</a> <a href="#">32150332</a>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

### Paclitaxel-dexamethasone

Mechanism of Action: **PACLITAXEL-DEXAMETHASONE** → **SPINDLE POISON** → **ANAPC1\_CDC26\_P\_CDC20** → **CCNB1\_CDK1**  
 → **MITOTIC\_CATASTROPHE** → **MITOTIC\_SLIPPAGE** → **APOPTOSIS**

Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
PTEN	CNV Deletion	Resistant	PTEN → PI345P3 → PDK1 → AKT → AKT1S1 → MTOR → HIF1A → TUBB3 → PACLITAXEL-DEXAMETHASONE	<a href="#">20361045</a> <a href="#">18466115</a> <a href="#">19143635</a> <a href="#">15094766</a> <a href="#">14673156</a> <a href="#">21779440</a> <a href="#">22354785</a> <a href="#">19143636</a> <a href="#">17386266</a> <a href="#">18515545</a> <a href="#">17502379</a> <a href="#">23364970</a> <a href="#">18178340</a>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Pembrolizumab				
Mechanism of Action: <b>PEMBROLIZUMAB</b> —  <b>CD274</b> —> <b>PD-1</b> —  <b>CTL_Activation</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
CCND1	CNV Amplification	Resistant	CCND1 —> CDK4_CCND1 —> BRCA1 —> DNA REPAIR (HR) —  APM_Machinery —> CTL_Activation —> GZMB —> CASP3 —> APOPTOSIS	<a href="#">27398650</a> <a href="#">25685857</a> <a href="#">32903763</a>
B2M	CNV Deletion	Resistant	B2M —> MHC1_COMPLEX —> APM_Machinery —> CTL_Activation —> GZMB —> CASP3 —> APOPTOSIS	<a href="#">30775025</a> <a href="#">29070816</a> <a href="#">25685857</a> <a href="#">30021886</a>
CDH2	CNV Deletion	Resistant	CDH2 —  CTNNB1 —> ATF3 —  CCL4 —> CTL_Activation —> GZMB —> CASP3 —> APOPTOSIS	<a href="#">25685857</a> <a href="#">12604612</a> <a href="#">25970248</a> <a href="#">31078045</a> <a href="#">8707857</a>
FAS	CNV Deletion	Resistant	FAS —> CTL_Activation —> GZMB —> CASP3 —> APOPTOSIS	<a href="#">25685857</a> <a href="#">32461348</a> <a href="#">30429213</a>
GSK3B	CNV Deletion	Resistant	GSK3B —  CTNNB1 —> ATF3 —  CCL4 —> CTL_Activation —> GZMB —> CASP3 —> APOPTOSIS	<a href="#">25685857</a> <a href="#">25970248</a> <a href="#">31078045</a> <a href="#">17621269</a>
PTEN	CNV Deletion	Resistant	PTEN —  PDPK1 —> AKT —  TSC1_TSC2 —  RHEB —> MTOR —> HIF1A —> VEGFA —  CTL_Activation —> GZMB —> CASP3 —> APOPTOSIS	<a href="#">25685857</a> <a href="#">27398650</a> <a href="#">26645196</a>
TP53	CNV Deletion	Resistant	TP53 —> TAP1 —> APM_Machinery —> CTL_Activation —> GZMB —> CASP3 —> APOPTOSIS	<a href="#">31097096</a> <a href="#">27398650</a> <a href="#">25685857</a> <a href="#">32694238</a> <a href="#">32927274</a>
PTPN2	CNV Deletion	Sensitive	PTPN2 —  STAT1 —> CD274 —> PD-1 —  CTL_Activation —> GZMB —> CASP3 —> APOPTOSIS	<a href="#">27398650</a> <a href="#">28723893</a> <a href="#">29764444</a> <a href="#">35059117</a> <a href="#">29360728</a>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Pembrolizumab				
Mechanism of Action: <b>PEMBROLIZUMAB</b> —  <b>CD274</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
JAK2	CNV Deletion	Resistant	JAK2 → STAT3 → CD274 → PD-1 —  CTL_Activation → GZMB → CASP3 → APOPTOSIS	<a href="#">25685857</a> <a href="#">27903500</a>
CD274	CNV Amplification	Sensitive	CD274 → PD-1 —  CTL_Activation → GZMB → CASP3 → APOPTOSIS	<a href="#">25685857</a> <a href="#">27398650</a>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Pemetrexed				
Mechanism of Action: <b>PEMETREXED</b> —  <b>TYMS</b> —> <b>dTTP</b> —  <b>REPLICATION STRESS</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
ATRIP	CNV Deletion	Sensitive	ATRIP —> ATR-ATRIP —> CHEK1 —  REPLICATION STRESS —> APOPTOSIS	<a href="#">15117425</a> <a href="#">24040222</a> <a href="#">22203733</a> <a href="#">24113549</a> <a href="#">15743907</a>
TYMS	CNV Deletion	Sensitive	TYMS —> dTTP —  REPLICATION STRESS —> APOPTOSIS (Low/negative TYMS expression is significantly associated with higher response rate of PEMETREXED)	<a href="#">15117425</a> <a href="#">24040222</a> <a href="#">30127925</a> <a href="#">26502926</a>
UNG	CNV Deletion	Sensitive	UNG —  REPLICATION STRESS —> APOPTOSIS	<a href="#">24040222</a> <a href="#">15117425</a> <a href="#">24503537</a> <a href="#">23873851</a>
WRN	CNV Deletion	Sensitive	WRN —  REPLICATION STRESS —> APOPTOSIS	<a href="#">15117425</a> <a href="#">24040222</a> <a href="#">20802463</a>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Radiation				
Mechanism of Action: <b>RADIATION</b> → <b>DSB</b> → <b>DNA DAMAGE</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
CCND1	CNV Amplification	Resistant	CCND1 → CDK4_CCND1 → BRCA1 → DNA REPAIR (HR) DNA DAMAGE	<a href="#">25988165</a> <a href="#">29416789</a> <a href="#">27338091</a> <a href="#">30414739</a> <a href="#">17334399</a>
HRAS	CNV Amplification	Resistant	HRAS → PIK3CA → PI345P3 → PDPK1 → AKT → PRKDC_XRCC6_XRCC5 → DNA REPAIR (NHEJ) DNA DAMAGE	<a href="#">18644989</a> <a href="#">15713897</a> <a href="#">12947393</a>
PAK1	CNV Amplification	Resistant	PAK1 → AKT → PRKDC_XRCC6_XRCC5 → DNA REPAIR (NHEJ) DNA DAMAGE	<a href="#">26333361</a> <a href="#">23849504</a>
CDKN2A	CNV Deletion	Resistant	CDKN2A → CDK4_CCND1 → FOXM1 → BRCA2 → DNA REPAIR (HR) DNA DAMAGE CDKN2A → CDK4_CCND1 → FOXM1 → RAD51 → DNA REPAIR (HR) DNA DAMAGE	<a href="#">25988165</a> <a href="#">21910158</a> <a href="#">29789556</a> <a href="#">22094256</a> <a href="#">23849504</a>
CDKN2B	CNV Deletion	Resistant	CDKN2B → CDK4_CCND1 → FOXM1 → BRCA2 → DNA REPAIR (HR) DNA DAMAGE CDKN2B → CDK4_CCND1 → FOXM1 → RAD51 → DNA REPAIR (HR) DNA DAMAGE	<a href="#">29281054</a> <a href="#">15892297</a> <a href="#">22094256</a> <a href="#">25287128</a> <a href="#">31160965</a>
PTCH1	CNV Deletion	Resistant	PTCH1 → SMO → SUFU → GLI1 → FOXM1 → RAD51 → DNA REPAIR (HR) DNA DAMAGE PTCH1 → SMO → SUFU → GLI1 → FOXM1 → BRCA2 → DNA REPAIR (HR) DNA DAMAGE	<a href="#">25988165</a> <a href="#">30191873</a> <a href="#">29274272</a> <a href="#">12183437</a> <a href="#">29789556</a>
PTEN	CNV Deletion	Resistant	PTEN → AKT → PRKDC_XRCC6_XRCC5 → DNA REPAIR (NHEJ) DNA DAMAGE	<a href="#">25988165</a> <a href="#">18644989</a> <a href="#">29088815</a> <a href="#">22724027</a>
SMAD4	CNV Deletion	Resistant	SMAD4 → BRCA1 → DNA REPAIR (HR) → DNA DAMAGE	<a href="#">25988165</a> <a href="#">16696564</a> <a href="#">15735739</a> <a href="#">23388117</a> <a href="#">26957554</a> <a href="#">10843985</a>
SUFU	CNV Deletion	Resistant	SUFU → GLI1 → FOXM1 → RAD51 → DNA REPAIR (HR) DNA DAMAGE SUFU → GLI1 → FOXM1 → BRCA2 → DNA REPAIR (HR) DNA DAMAGE	<a href="#">25988165</a> <a href="#">29274272</a> <a href="#">12183437</a> <a href="#">29789556</a>

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Radiation				
Mechanism of Action: <b>RADIATION</b> → <b>DSB</b> → <b>DNA DAMAGE</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
TP53	CNV Deletion	Resistant	TP53  BRCA2  DNA REPAIR (HR)  DNA DAMAGE	<a href="#">8516323</a> <a href="#">25988165</a> <a href="#">12591928</a> <a href="#">25201193</a>
ATG2B	CNV Deletion	Sensitive	ATG2B  ATG5_ATG10_ATG7  AUTOPHAGY SQSTM1  RAD51  DNA REPAIR (HR)  DNA DAMAGE	<a href="#">23849504</a> <a href="#">18509530</a> <a href="#">28391715</a> <a href="#">27391408</a>
CHEK2	CNV Deletion	Sensitive	CHEK2  BRCA1/2  DNA REPAIR (HR)  DNA DAMAGE	<a href="#">25988165</a> <a href="#">14701743</a> <a href="#">15546503</a> <a href="#">18797466</a> <a href="#">26573794</a>
EXO1	CNV Deletion	Sensitive	EXO1  DNA REPAIR (HR)  DNA DAMAGE	<a href="#">23849504</a> <a href="#">20019063</a>
LIG4	CNV Deletion	Sensitive	LIG4  DNA REPAIR (NHEJ)  DNA DAMAGE	<a href="#">25988165</a> <a href="#">11593023</a> <a href="#">27009971</a> <a href="#">23849504</a>
MBD1	CNV Deletion	Sensitive	MBD1  MRE11A-NBN-RAD50  DNA REPAIR(HR)  DNA DAMAGE	<a href="#">25988165</a> <a href="#">23588667</a> <a href="#">10523656</a>
PARP1	CNV Deletion	Sensitive	PARP1  DNA REPAIR (BER)  DNA DAMAGE	<a href="#">25988165</a> <a href="#">1702304</a> <a href="#">24970148</a>
POLB	CNV Deletion	Sensitive	POLB  DNA REPAIR (BER)  DNA DAMAGE	<a href="#">25988165</a> <a href="#">12087186</a> <a href="#">17126614</a>
RAD51	CNV Deletion	Sensitive	RAD51  DNA REPAIR (HR)  DNA DAMAGE	<a href="#">25988165</a> <a href="#">18618591</a> <a href="#">15785736</a>
RAD51B	CNV Deletion	Sensitive	RAD51B  RAD51  DNA REPAIR (HR)  DNA DAMAGE	<a href="#">25988165</a> <a href="#">10938124</a> <a href="#">23849504</a>
RBBP8	CNV Deletion	Sensitive	RBBP8  DNA REPAIR (HR)  DNA DAMAGE	<a href="#">25988165</a> <a href="#">18171670</a> <a href="#">19357644</a> <a href="#">24403251</a>

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Radiation				
Mechanism of Action: <b>RADIATION</b> → <b>DSB</b> → <b>DNA DAMAGE</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
SETD2	CNV Deletion	Sensitive	SETD2 → H3K36 METHYLATION → TP53BP1 → DNA REPAIR (NHEJ) → <b>DNA DAMAGE</b>	<a href="#">25988165</a> <a href="#">24843002</a> <a href="#">2169821</a>
TP53BP1	CNV Deletion	Sensitive	TP53BP1 → DNA REPAIR (NHEJ) → <b>DNA DAMAGE</b>	<a href="#">25988165</a> <a href="#">12640136</a> <a href="#">16866876</a> <a href="#">22915756</a>
WRN	CNV Deletion	Sensitive	WRN → RAD52 → DNA REPAIR (HR) → <b>DNA DAMAGE</b>	<a href="#">25988165</a> <a href="#">17611195</a> <a href="#">16394631</a> <a href="#">12242278</a> <a href="#">9774658</a> <a href="#">12750383</a>
XRCC3	CNV Deletion	Sensitive	XRCC3 → DNA REPAIR (HR) → <b>DNA DAMAGE</b>	<a href="#">25988165</a> <a href="#">26034131</a> <a href="#">26383967</a> <a href="#">23849504</a>
XRCC6	CNV Deletion	Sensitive	XRCC6 → PRKDC_XRCC6_XRCC5 → DNA REPAIR (NHEJ) → <b>DNA DAMAGE</b>	<a href="#">25988165</a> <a href="#">9223317</a> <a href="#">17630212</a>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

### Ramucirumab

Mechanism of Action: **RAMUCIRUMAB** —| **KDR**

Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
DNMT3A	CNV Amplification	Resistant	DNMT3A → CPGMET —  VEGFA → KDR → ANGIOGENESIS → CANCER PROGRESSION	<a href="#">27217518</a> <a href="#">22395469</a> <a href="#">32636303</a>
TP53	CNV Deletion	Sensitive	TP53 —  HIF1A → KDR → ANGIOGENESIS → CANCER PROGRESSION	<a href="#">25672981</a> <a href="#">32722340</a>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Trametinib				
Mechanism of Action: <b>TRAMETINIB</b> —  <b>MAP2K1</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
MAP2K1	CNV Deletion	Resistant	MAP2K1 → MAPK1/3 → MYC → GLI1 → CANCER PROGRESSION (Direct drug target deletion is reported in the profile)	<a href="#">26347206</a> <a href="#">30410366</a> <a href="#">16899113</a> <a href="#">23525267</a>

Trametinib				
Mechanism of Action: <b>TRAMETINIB</b> —  <b>MAP2K1/2</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
PTEN	CNV Deletion	Resistant	PTEN —  PI345P3 → PDK1 → AKT —  RAF1 → MAP2K1/2	<a href="#">23846731</a> <a href="#">33340965</a> <a href="#">10576742</a> <a href="#">28220839</a> <a href="#">25295225</a>
HRAS	CNV Amplification	Sensitive	HRAS → RAF1 → MAP2K1/2 → MAPK1/3 → MYC → GLI1 → CANCER PROGRESSION	<a href="#">18356021</a> <a href="#">12077341</a> <a href="#">22461507</a> <a href="#">21523318</a> <a href="#">10969079</a> <a href="#">25199829</a> <a href="#">25722381</a> <a href="#">23525267</a>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Vemurafenib				
Mechanism of Action: <b>VEMURAFENIB</b> —  <b>BRAF-V600E</b> —  <b>RAFI</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
HRAS	CNV Amplification	Resistant	HRAS → RAFI → MAP2K1/2 → MAPK1/3 → MYC → GLI1 → CANCER PROGRESSION	<a href="#">30488019</a> <a href="#">24265153</a> <a href="#">27124486</a> <a href="#">34496925</a> <a href="#">20179705</a> <a href="#">27239960</a>

Vemurafenib				
Mechanism of Action: <b>VEMURAFENIB</b> —  <b>BRAF-V600E</b> —  <b>AKT</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
PTEN	CNV Deletion	Resistant	PTEN —  PI345P3 → PDPK1 → AKT —  GSK3B —  MYC → E2F1 → CANCER PROGRESSION	<a href="#">28220839</a> <a href="#">32076493</a> <a href="#">33340965</a> <a href="#">10576742</a> <a href="#">15671063</a>
TP53	CNV Deletion	Resistant	TP53 —  PIK3CA → PI345P3 → PDPK1 → AKT —  GSK3B —  MYC → E2F1 → CANCER PROGRESSION	<a href="#">30488019</a> <a href="#">22552284</a> <a href="#">32365809</a> <a href="#">30514931</a> <a href="#">20361045</a> <a href="#">10698680</a> <a href="#">15023437</a> <a href="#">15944709</a> <a href="#">11959846</a>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Vinorelbine				
Mechanism of Action: <b>VINORELBINE</b> → <b>SPINDLE_POISON</b> → <b>ANAPC1_CDC26_CDC20</b> → <b>CCNB1_CDK1</b> → <b>MITOTIC_CATASTROPHE</b> → <b>MITOTIC_SLIPPAGE</b> → <b>APOPTOSIS</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
PAK1	CNV Amplification	Resistant	<b>PAK1</b> → <b>AURKA</b> → <b>PLK1</b> → <b>MITOTIC_CATASTROPHE</b>	<a href="#">27889644</a> <a href="#">11016627</a> <a href="#">8639632</a> <a href="#">9484953</a> <a href="#">26779436</a> <a href="#">33451333</a> <a href="#">12244051</a>

Vinorelbine				
Mechanism of Action: <b>VINORELBINE</b> → <b>SPINDLE_POISON</b> → <b>ANAPC1_CDC26_CDC20</b> → <b>CCNB1_CDK1</b> → <b>MITOTIC_CATASTROPHE</b> → <b>MITOTIC_SLIPPAGE</b> → <b>APOPTOSIS</b>				
Gene	Status	Drug Effect	Gene Status Drug Action Pathways	Supporting PMIDs
BUB1B	CNV Deletion	Resistant	<b>BUB1B</b> → <b>CCNB1_CDK1</b> → <b>MITOTIC_CATASTROPHE</b> → <b>MITOTIC_SLIPPAGE</b> → <b>APOPTOSIS</b>	<a href="#">30126203</a> <a href="#">11016627</a> <a href="#">8639632</a> <a href="#">21887332</a>
PTEN	CNV Deletion	Resistant	<b>PTEN</b> → <b>PDPK1</b> → <b>AKT</b> → <b>CHUK_IKBKB</b> → <b>NFKB1</b> → <b>GLI1</b> → <b>ABCB1</b> → <b>VINORELBINE</b>	<a href="#">26809587</a> <a href="#">20350282</a> <a href="#">24427333</a> <a href="#">23743572</a> <a href="#">17363506</a> <a href="#">24352480</a> <a href="#">19609947</a> <a href="#">25252859</a> <a href="#">32814794</a> <a href="#">20442307</a>
RASSF1	CNV Deletion	Resistant	<b>RASSF1</b> → <b>SPINDLE_POISON</b>	<a href="#">30126203</a> <a href="#">11016627</a> <a href="#">8639632</a> <a href="#">19156899</a>
TUBB4B	CNV Deletion	Sensitive	<b>TUBB4B</b> → <b>SPINDLE_POISON</b>	<a href="#">9484953</a> <a href="#">34157583</a> <a href="#">23634282</a> <a href="#">27889644</a> <a href="#">11016627</a> <a href="#">8639632</a>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

### 6. Genomic Aberration to Master Regulator Pathway(s)

This section provides a snapshot of paths connecting the most significant gene aberrations with patient master regulators and references to published research supporting these pathways.

**RED:** Gain of Function/Switch of Function Mutation(s) or Amplified Gene(s)

**BLUE:** Loss of Function Mutation(s) or Deleted Gene(s)

#### TRANSCRIPTION FACTORS:

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
JUN	PPP2R2A <b>RED</b> MAPK8 <b>BLUE</b> HNRNPJ <b>BLUE</b> JUN	
	PSMB6 <b>BLUE</b> PSMB5 <b>RED</b> MAPK8 <b>BLUE</b> HNRNPJ <b>BLUE</b> JUN	
	TP53 <b>BLUE</b> DUSP1 <b>RED</b> MAPK8 <b>BLUE</b> HNRNPJ <b>BLUE</b> JUN	
	FANCA <b>RED</b> CAPN1_CAPNS1 <b>BLUE</b> PTK2 <b>BLUE</b> PLCG1 <b>BLUE</b> PRKCA <b>BLUE</b> JUN	<a href="#">10430888</a> <a href="#">20518497</a>
	ARHGEF12 <b>BLUE</b> RHOA <b>BLUE</b> PTK2 <b>BLUE</b> PLCG1 <b>BLUE</b> PRKCA <b>BLUE</b> JUN	<a href="#">10430888</a> <a href="#">18854312</a> <a href="#">19805522</a>
	ATRIP <b>BLUE</b> FANCA <b>RED</b> CAPN1_CAPNS1 <b>BLUE</b> PTK2 <b>BLUE</b> PLCG1 <b>BLUE</b> PRKCA <b>BLUE</b> JUN	<a href="#">10430888</a> <a href="#">20518497</a>
JUN	PRKCB <b>BLUE</b> CARD11 <b>BLUE</b> BCL10 <b>BLUE</b> MALTI <b>BLUE</b> MAPK8 <b>BLUE</b> HNRNPJ <b>BLUE</b> JUN	<a href="#">12228228</a> <a href="#">15125833</a> <a href="#">16356855</a> <a href="#">19815501</a> <a href="#">20516126</a> <a href="#">23690623</a>
FOXM1	PPP2R2A <b>RED</b> PKN1 <b>BLUE</b> CDC25B <b>BLUE</b> CCNA2_CDK2 <b>BLUE</b> FOXM1	
	RCE1 <b>BLUE</b> RALB <b>BLUE</b> TBK1 <b>BLUE</b> PLK1 <b>BLUE</b> FOXM1	<a href="#">17018283</a> <a href="#">19737929</a> <a href="#">23404835</a>
	PEBP1 <b>RED</b> IKBKB <b>BLUE</b> MAP3K8 <b>BLUE</b> PIN1 <b>BLUE</b> CCNA2_CDK2 <b>BLUE</b> FOXM1	<a href="#">11585904</a>
	TNFAIP3 <b>RED</b> MAP3K14 <b>BLUE</b> IKBKB <b>BLUE</b> MAP3K8 <b>BLUE</b> PIN1 <b>BLUE</b> CCNA2_CDK2 <b>BLUE</b> FOXM1	<a href="#">10094049</a> <a href="#">10887201</a> <a href="#">11784851</a> <a href="#">15024054</a> <a href="#">15208311</a> <a href="#">9275204</a>
	RASSF1 <b>BLUE</b> SAV1 <b>BLUE</b> STK4 <b>BLUE</b> LATS2 <b>RED</b> IKBKB <b>BLUE</b> MAP3K8 <b>BLUE</b> PIN1 <b>BLUE</b> CCNA2_CDK2 <b>BLUE</b> FOXM1	<a href="#">21489991</a> <a href="#">25946971</a> <a href="#">26898830</a>

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
FOXM1	<p>CD81 → CD19 → PIK3CB → PDPK1 → RPS6KA3 → PIN1 → CCNA2_CDK2 → FOXM1</p>	<a href="#">9445476</a>
	<p>DDIT4 → TSC1_TSC2 → RHEB → ULK1 → FBPI → NPM1 → AURKA → PLK1 → FOXM1</p>	<a href="#">12869586</a> <a href="#">19737929</a> <a href="#">21258367</a> <a href="#">23404835</a>
	<p>PMAIP1 → MCL1 → BAK1 → HTRA2 → UCHL1 → CDK5 → CDC25A → CCNA2_CDK2 → FOXM1</p>	<a href="#">10837489</a> <a href="#">15077116</a> <a href="#">15574336</a> <a href="#">15637055</a> <a href="#">15694340</a> <a href="#">15721256</a> <a href="#">15901672</a> <a href="#">16697956</a> <a href="#">22001920</a> <a href="#">22361683</a> <a href="#">22899714</a> <a href="#">23543736</a>
	<p>FBPI → NPM1 → AURKA → PLK1 → FOXM1</p>	<a href="#">19737929</a> <a href="#">23404835</a>
	<p>EIF3C → EIF3E → EIF4E → CCNA2 → CCNA2_CDK2 → FOXM1</p>	
	<p>RELA → NPM1 → FOXM1</p>	
FOXM1	<p>TP53 → CDKN1A → CCNA2_CDK2 → FOXM1</p>	<a href="#">17101782</a> <a href="#">18585004</a> <a href="#">19011621</a> <a href="#">20673369</a> <a href="#">23431171</a>
	<p>YAPI → SLC7A5 → ITGA4_ITGB1 → SRC → AURKA → PLK1 → FOXM1</p>	<a href="#">19737929</a> <a href="#">23404835</a> <a href="#">25501815</a>
	<p>CHEK2 → BRCA1 → CDKN1A → CCNA2_CDK2 → FOXM1</p>	<a href="#">10373534</a> <a href="#">14701743</a> <a href="#">17101782</a>
	<p>TP63 → CDKN1A → CCNA2_CDK2 → FOXM1</p>	
	<p>RELN → NPM1 → FOXM1</p>	

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
FOXM1	<p>ULK1 → FBPI —  NPM1 → AURKA → PLK1 → FOXM1</p>	<p><a href="#">19737929</a> <a href="#">23404835</a></p>
	<p>IL4R → JAK3 → PIK3CA → SLC9A1 → PTK2 → SRC → AURKA → PLK1 → FOXM1</p>	<p><a href="#">16129412</a> <a href="#">16684964</a> <a href="#">18281483</a> <a href="#">19737929</a> <a href="#">20378826</a> <a href="#">20671117</a> <a href="#">23404835</a> <a href="#">25501815</a> <a href="#">8266076</a> <a href="#">8962143</a></p>
	<p>FLI1 → EZH2 —  CDKN1B —  CCNA2_CDK2 → FOXM1</p>	
	<p>CD19 → PIK3CB → PDPK1 → RPS6KA3 → PIN1 → CCNA2_CDK2 → FOXM1</p>	<p><a href="#">9445476</a></p>
	<p>MAP4K2 → MAP3K1 → MAP2K3 → MAPK12 → PLK1 → FOXM1</p>	<p><a href="#">11062067</a> <a href="#">11784851</a> <a href="#">19737929</a> <a href="#">23404835</a></p>
FOXM1	<p>MMP7 → SPP1 → ITGA4_ITGB1 → SRC → AURKA → PLK1 → FOXM1</p>	<p><a href="#">11375993</a> <a href="#">19737929</a> <a href="#">23404835</a> <a href="#">25501815</a></p>
	<p>FAS → DAXX → RASSF1 → SAV1 → STK4 → LATS2 —  IKKBK → MAP3K8 → PIN1 → CCNA2_CDK2 → FOXM1</p>	<p><a href="#">11003656</a> <a href="#">11483955</a> <a href="#">21199877</a> <a href="#">21489991</a> <a href="#">25946971</a> <a href="#">26898830</a></p>
	<p>TSC1 → TSC1_TSC2 —  RHEB —  ULK1 → FBPI —  NPM1 → AURKA → PLK1 → FOXM1</p>	<p><a href="#">12869586</a> <a href="#">19737929</a> <a href="#">21258367</a> <a href="#">23404835</a></p>
	<p>PMS1 → CHEK1 —  CDC25A → CCNA2_CDK2 → FOXM1</p>	
	<p>DNMT3A —  CDKN1A —  CCNA2_CDK2 → FOXM1</p>	



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
FOXMI	<p>FANCA —  CAPN1_CAPNS1 → PTK2 → SRC → AURKA → PLK1                      → FOXMI</p>	<p><a href="#">11927607</a> <a href="#">19737929</a>  <a href="#">20378826</a> <a href="#">20518497</a>  <a href="#">23404835</a> <a href="#">25501815</a></p>
	<p>KLF4 → CDKN1B —  CCNA2_CDK2 → FOXMI</p>	
	<p>SETD2 → CDKN1A —  CCNA2_CDK2 → FOXMI</p>	<p><a href="#">18585004</a></p>
	<p>MAP3K5 → MAP2K7 → MAPK9 → BCL2L1 —  BCL2L1 —  BAK1                      → HTRA2 —  UCHL1 → CDK5 → CDC25A → CCNA2_CDK2 → FOXMI</p>	<p><a href="#">11062067</a> <a href="#">12169272</a>  <a href="#">12566458</a> <a href="#">12818176</a>  <a href="#">15574336</a> <a href="#">15694340</a>  <a href="#">15901672</a> <a href="#">16478725</a>  <a href="#">20679476</a> <a href="#">22001920</a>  <a href="#">22899714</a> <a href="#">23543736</a></p>
	<p>ETS1 → HPSE → FGFR3 → RPS6KA3 → PIN1 → CCNA2_CDK2                      → FOXMI</p>	
FOXMI	<p>BID —  BCL2L1 —  BAK1 → HTRA2 —  UCHL1 → CDK5 → CDC25A → CCNA2_CDK2 → FOXMI</p>	<p><a href="#">15353804</a> <a href="#">15574336</a>  <a href="#">15694340</a> <a href="#">15901672</a>  <a href="#">18469004</a> <a href="#">22001920</a>  <a href="#">22899714</a> <a href="#">23543736</a></p>
	<p>XRCC6 → XRCC5_XRCC6 → CHEK2 → BRCA1 → CDKN1A —  CCNA2_CDK2 → FOXMI</p>	<p><a href="#">10373534</a> <a href="#">14701743</a>  <a href="#">15668230</a> <a href="#">17101782</a></p>
	<p>PLK1 → FOXMI</p>	<p><a href="#">19737929</a> <a href="#">23404835</a></p>
	<p>ARHGEF2 → RHOA → ROCK1 → PKN1 → CDC25B → CCNA2_CDK2 → FOXMI</p>	
	<p>MMP2 → MMP3 → SPP1 → ITGA4_ITGB1 → SRC → AURKA → PLK1 → FOXMI</p>	<p><a href="#">11120741</a> <a href="#">11375993</a>  <a href="#">19737929</a> <a href="#">22275356</a>  <a href="#">23404835</a> <a href="#">25501815</a>  <a href="#">8663255</a> <a href="#">9665471</a></p>

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
FOXM1	CCNK → CDK12 → BRCA1 → CDKN1A —  CCNA2_CDK2 → FOXM1	
	IL21R → IL21_IL21R → PIK3CA → SLC9A1 → PTK2 → SRC → AURKA → PLK1 → FOXM1	<a href="#">11438544</a> <a href="#">18281483</a> <a href="#">19230867</a> <a href="#">19737929</a> <a href="#">20378826</a> <a href="#">23404835</a> <a href="#">25501815</a> <a href="#">9178903</a>
	BAP1 → BAP1_L3MBTL2 —  EZH2 —  CDKN1B —  CCNA2_CDK2 → FOXM1	
	ATRIP → CHEK1 —  CDC25A → CCNA2_CDK2 → FOXM1	
	FOXO3 → CDKN1B —  CCNA2_CDK2 → FOXM1	<a href="#">11994454</a> <a href="#">14976264</a> <a href="#">15100294</a> <a href="#">18393360</a>
FOXM1	STAT1 → CDKN1B —  CCNA2_CDK2 → FOXM1	
	MMP10 → MMP7 → SPP1 → ITGA4_ITGB1 → SRC → AURKA → PLK1 → FOXM1	<a href="#">11375993</a> <a href="#">19737929</a> <a href="#">23404835</a> <a href="#">25501815</a> <a href="#">9578462</a>
	MS4A1 → FYN → CDK5 → CDC25A → CCNA2_CDK2 → FOXM1	<a href="#">12372285</a> <a href="#">22899714</a> <a href="#">7545683</a>
	ZEB2 → CTBP1_ZEB2 → VIM → ITGA5_ITGB1 → FYN → CDK5 → CDC25A → CCNA2_CDK2 → FOXM1	<a href="#">12372285</a> <a href="#">22899714</a>
	PRKCB → MS4A1 → FYN → CDK5 → CDC25A → CCNA2_CDK2 → FOXM1	<a href="#">12372285</a> <a href="#">22899714</a> <a href="#">7545683</a>
FOXM1	BIK → BAK1 → HTRA2 —  UCHL1 → CDK5 → CDC25A → CCNA2_CDK2 → FOXM1	<a href="#">15574336</a> <a href="#">22001920</a> <a href="#">22899714</a> <a href="#">23543736</a>
	TP53BP1 → BRCA1 → CDKN1A —  CCNA2_CDK2 → FOXM1	<a href="#">10373534</a> <a href="#">12364621</a>
	EED —  CDKN1B —  CCNA2_CDK2 → FOXM1	
	PAK1 → AURKA → PLK1 → FOXM1	<a href="#">19737929</a> <a href="#">23404835</a>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
GLI1	PPP2R2A —  RPS6KA3 —> NEK2 —> GLI1	<a href="#">11923207</a>
	RCE1 —> RALB —> TBK1 —> PLK1 —> NEK2 —> GLI1	<a href="#">17018283</a>
	PEBP1 —  IKKBK —> MAP3K8 —> PIN1 —  GSK3B —  AURKA —> GLI1 PLK1 —> NEK2 —> GLI1	<a href="#">11585904</a> <a href="#">22513362</a>
	TNFAIP3 —  MAP3K14 —> IKKBK —> MAP3K8 —> PIN1 —  GSK3B —  AURKA —> PLK1 —> NEK2 —> GLI1	<a href="#">10094049</a> <a href="#">10887201</a> <a href="#">11784851</a> <a href="#">15024054</a> <a href="#">15208311</a> <a href="#">22513362</a> <a href="#">9275204</a>
	CD81 —> CD19 —> PIK3CB —> PDPK1 —> RPS6KA3 —> NEK2 —> GLI1	<a href="#">11923207</a> <a href="#">9445476</a>
GLI1	DDIT4 —> TSC1_TSC2 —  RHEB —  ULK1 —> FBPI —  NPM1 —> GLI1 AURKA —> PLK1 —> NEK2 —> GLI1	<a href="#">12869586</a> <a href="#">21258367</a>
	PMAIP1 —  MCL1 —  BAK1 —> HTRA2 —  UCHL1 —> CCNB1_CDK1 —> MAPK12 —> PLK1 —> NEK2 —> GLI1	<a href="#">10837489</a> <a href="#">15077116</a> <a href="#">15574336</a> <a href="#">15637055</a> <a href="#">15694340</a> <a href="#">15721256</a> <a href="#">15901672</a> <a href="#">16697956</a> <a href="#">22001920</a> <a href="#">22361683</a>
	FBPI —  NPM1 —> AURKA —> PLK1 —> NEK2 —> GLI1	
	TP53 —  PTK2 —> SRC —> AURKA —> PLK1 —> NEK2 —> GLI1	<a href="#">15157737</a> <a href="#">17725966</a> <a href="#">20378826</a> <a href="#">25501815</a>
	YAPI —> SLC7A5 —> ITGA1_ITGB1 —> FYN —> RPS6KA3 —> NEK2 —> GLI1	<a href="#">11923207</a>
GLI1	LMO1 —> LDB1_LMO1 —> LYL1_TALI —> EPOR —> PIK3CB —> PDPK1 —> RPS6KA3 —> NEK2 —> GLI1	<a href="#">11923207</a> <a href="#">9445476</a>
	CHEK2 —> BRCA1 —> CDKN1A —  CCNB1_CDK1 —> MAPK12 —> PLK1 —> NEK2 —> GLI1	<a href="#">14701743</a> <a href="#">24067368</a>
	TP63 —> CDKN1A —  CCNB1_CDK1 —> MAPK12 —> PLK1 —> NEK2 —> GLI1	
	ULK1 —> FBPI —  NPM1 —> AURKA —> PLK1 —> NEK2 —> GLI1	
	ITGAM —> ITGAM_ITGB2 —> ILK —> PDGFRA —> FYN —> RPS6KA3 —> NEK2 —> GLI1	<a href="#">11923207</a> <a href="#">9736715</a>

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
GLI1	<p>ITGAL → ITGAL_ITGB2 → ILK → PDGFRA → FYN → RPS6KA3                      → NEK2 → GLI1</p>	<p><a href="#">11923207</a> <a href="#">9736715</a></p>
	<p>IL4R → JAK3 → PIK3CB → PDPK1 → RPS6KA3 → NEK2 → GLI1</p>	<p><a href="#">11035047</a> <a href="#">11923207</a>  <a href="#">15010462</a> <a href="#">16129412</a>  <a href="#">16873377</a> <a href="#">8266076</a>  <a href="#">9445476</a></p>
	<p>ILK → PDGFRA → FYN → RPS6KA3 → NEK2 → GLI1</p>	<p><a href="#">11923207</a></p>
	<p>GSTP1 → GAPDH → AKT → GSK3B → AURKA → PLK1 →                      NEK2 → GLI1</p>	<p><a href="#">11035810</a> <a href="#">12172554</a>  <a href="#">15678105</a> <a href="#">22513362</a>  <a href="#">27563096</a></p>
	<p>CD19 → PIK3CB → PDPK1 → RPS6KA3 → NEK2 → GLI1</p>	<p><a href="#">11923207</a> <a href="#">9445476</a></p>
GLI1	<p>MAP4K2 → MAP3K1 → MAP2K3 → MAPK12 → PLK1 → NEK2                      → GLI1</p>	<p><a href="#">11062067</a> <a href="#">11784851</a></p>
	<p>MMP7 → SPP1 → ITGAV_ITGB3 → FGFR3 → RPS6KA3 → NEK2                      → GLI1</p>	<p><a href="#">10835423</a> <a href="#">11375993</a>  <a href="#">11923207</a> <a href="#">7592829</a></p>
	<p>TSC1 → TSC1_TSC2 → RHEB → ULK1 → FBPI → NPM1 →                      AURKA → PLK1 → NEK2 → GLI1</p>	<p><a href="#">12869586</a> <a href="#">21258367</a></p>
	<p>PMS1 → CHEK1 → WEE1 → CCNB1_CDK1 → MAPK12 → PLK1                      → NEK2 → GLI1</p>	<p><a href="#">8428596</a></p>
	<p>DNMT3A → CDKN1A → CCNB1_CDK1 → MAPK12 → PLK1 → NEK2                      → GLI1</p>	



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
GLI1	<p>FANCA —  CAPN1_CAPNS1 —&gt; PTK2 —&gt; SRC —&gt; AURKA —&gt; PLK1                      —&gt; NEK2 —&gt; GLI1</p>	<p><a href="#">11927607</a> <a href="#">20378826</a>  <a href="#">20518497</a> <a href="#">25501815</a></p>
	<p>SETD2 —&gt; CDKN1A —  CCNB1_CDK1 —&gt; MAPK12 —&gt; PLK1 —&gt; NEK2                      —&gt; GLI1</p>	<p><a href="#">18585004</a></p>
	<p>MAP3K5 —&gt; MAP2K7 —&gt; MAPK9 —&gt; BCL2L1 —  BCL2L1 —  BAK1                      —&gt; HTRA2 —  UCHL1 —&gt; CCNB1_CDK1 —&gt; MAPK12 —&gt; PLK1 —&gt; NEK2 —&gt; GLI1                      NEK2 —&gt; GLI1</p>	<p><a href="#">11062067</a> <a href="#">11923207</a>  <a href="#">12169272</a> <a href="#">12566458</a>  <a href="#">12818176</a> <a href="#">15574336</a>  <a href="#">15694340</a> <a href="#">15901672</a>  <a href="#">16478725</a> <a href="#">20679476</a>  <a href="#">22001920</a> <a href="#">9430630</a></p>
	<p>ETS1 —&gt; HPSE —&gt; FGFR3 —&gt; RPS6KA3 —&gt; NEK2 —&gt; GLI1</p>	<p><a href="#">11923207</a></p>
	<p>BID —  BCL2L1 —  BAK1 —&gt; HTRA2 —  UCHL1 —&gt; CCNB1_CDK1                      —&gt; MAPK12 —&gt; PLK1 —&gt; NEK2 —&gt; GLI1</p>	<p><a href="#">15353804</a> <a href="#">15574336</a>  <a href="#">15694340</a> <a href="#">15901672</a>  <a href="#">18469004</a> <a href="#">22001920</a></p>
	GLI1	<p>PLK1 —&gt; NEK2 —&gt; GLI1</p>
<p>LMO2 —&gt; LDB1_LMO2 —&gt; LYL1_TAL1 —&gt; EPOR —&gt; PIK3CB —&gt; PDPK1                      —&gt; RPS6KA3 —&gt; NEK2 —&gt; GLI1</p>		<p><a href="#">11923207</a> <a href="#">9445476</a></p>
<p>ARHGEF12 —&gt; RHOA —&gt; ROCK1 —&gt; PKN1 —&gt; MAPK12 —&gt; PLK1 —&gt; NEK2 —&gt; GLI1</p>		<p><a href="#">12761180</a></p>
<p>RPS6KB2 —&gt; XIAP —&gt; AKT —  GSK3B —  AURKA —&gt; PLK1 —&gt; NEK2 —&gt; GLI1</p>		<p><a href="#">11035810</a> <a href="#">12172554</a>  <a href="#">15678105</a> <a href="#">22513362</a>  <a href="#">23640046</a></p>
<p>MMP2 —&gt; MMP9 —&gt; IGFBP2 —&gt; ITGA5_ITGB1 —&gt; FYN —&gt; RPS6KA3                      —&gt; NEK2 —&gt; GLI1</p>		<p><a href="#">11923207</a> <a href="#">12879005</a>  <a href="#">16569642</a> <a href="#">20514406</a></p>

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
GLI1	CCNK → CDK12 → BRCA1 → CDKN1A —  CCNB1_CDK1 → MAPK12 → PLK1 → NEK2 → GLI1	<a href="#">24067368</a>
	IL21R → IL21_IL21R → PIK3CB → PDPK1 → RPS6KA3 → NEK2 → GLI1	<a href="#">11923207</a> <a href="#">9178903</a> <a href="#">9445476</a>
	GSK3B —  AURKA → PLK1 → NEK2 → GLI1	<a href="#">22513362</a>
	BAP1 → BAP1_L3MBTL2 —  EZH2 → CPGMET —  CDKN1A —  CCNB1_CDK1 → MAPK12 → PLK1 → NEK2 → GLI1	<a href="#">16357870</a>
	ATRIP → CHEK1 → WEE1 —  CCNB1_CDK1 → MAPK12 → PLK1 → NEK2 → GLI1	<a href="#">8428596</a>
GLI1	FOXO3 → GADD45A —  CCNB1_CDK1 → MAPK12 → PLK1 → NEK2 → GLI1	<a href="#">12124778</a> <a href="#">14976264</a>
	STAT1 → CDKN1A —  CCNB1_CDK1 → MAPK12 → PLK1 → NEK2 → GLI1	
	MMP10 → MMP7 → SPPI → ITGAV_ITGB3 → FGFR3 → RPS6KA3 → NEK2 → GLI1	<a href="#">10835423</a> <a href="#">11375993</a> <a href="#">11923207</a> <a href="#">7592829</a> <a href="#">9578462</a>
	MS4A1 → FYN → RPS6KA3 → NEK2 → GLI1	<a href="#">11923207</a> <a href="#">7545683</a>
	ZEB2 → CTBP1_ZEB2 → VIM → ITGA5_ITGB1 → FYN → RPS6KA3 → NEK2 → GLI1	<a href="#">11923207</a>
GLI1	PRKCB → MS4A1 → FYN → RPS6KA3 → NEK2 → GLI1	<a href="#">11923207</a> <a href="#">7545683</a>
	BIK → BAK1 → HTRA2 —  UCHL1 → CCNB1_CDK1 → MAPK12 → PLK1 → NEK2 → GLI1	<a href="#">15574336</a> <a href="#">22001920</a>
	TP53BP1 → BRCA1 → CDKN1A —  CCNB1_CDK1 → MAPK12 → PLK1 → NEK2 → GLI1	<a href="#">12364621</a> <a href="#">24067368</a>
	EED → CPGMET —  CDKN1A —  CCNB1_CDK1 → MAPK12 → PLK1 → NEK2 → GLI1	<a href="#">16357870</a>
	PAK1 → AURKA → PLK1 → NEK2 → GLI1	

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
E2F1	PPP2R2A —  SRC —> AURKA —> E2F1	<a href="#">20300951</a> <a href="#">25501815</a>
	RCE1 —> RAC1 —> PAK1 —> AURKA —> E2F1	<a href="#">20300951</a>
	PEBP1 —  IKKBK —> MAP3K8 —> PIN1 —  GSK3B —  AURKA —> E2F1	<a href="#">11585904</a> <a href="#">20300951</a> <a href="#">22513362</a>
	TNFAIP3 —  MAP3K14 —> IKKBK —> MAP3K8 —> PIN1 —  GSK3B —  AURKA —> E2F1	<a href="#">10094049</a> <a href="#">10887201</a> <a href="#">11784851</a> <a href="#">15024054</a> <a href="#">15208311</a> <a href="#">20300951</a> <a href="#">22513362</a> <a href="#">9275204</a>
	RASSF1 —> SAV1 —> STK4 —> LATS2 —  IKKBK —> MAP3K8 —> PIN1 —  GSK3B —  AURKA —> E2F1	<a href="#">20300951</a> <a href="#">21489991</a> <a href="#">22513362</a> <a href="#">25946971</a> <a href="#">26898830</a>
E2F1	CD81 —> CD19 —> PIK3CB —> PRKCZ —  GSK3B —  AURKA —> E2F1	<a href="#">11481324</a> <a href="#">16510873</a> <a href="#">17606986</a> <a href="#">20300951</a> <a href="#">22513362</a>
	DDIT4 —> TSC1_TSC2 —  RHEB —  ULK1 —> FBPI —  NPM1 —> AURKA —> E2F1	<a href="#">12869586</a> <a href="#">20300951</a> <a href="#">21258367</a>
	PMAIP1 —  MCL1 —  BAK1 —> HTRA2 —  XIAP —> AKT —  GSK3B —  AURKA —> E2F1	<a href="#">10837489</a> <a href="#">11035810</a> <a href="#">11583623</a> <a href="#">11602612</a> <a href="#">11606597</a> <a href="#">11803371</a> <a href="#">12172554</a> <a href="#">15077116</a> <a href="#">15574336</a> <a href="#">15637055</a> <a href="#">15678105</a> <a href="#">15694340</a>
	FBPI —  NPM1 —> AURKA —> E2F1	<a href="#">20300951</a>
	EIF3C —> EIF3E —> EIF4E —> XIAP —> AKT —  GSK3B —  AURKA —> E2F1	<a href="#">11035810</a> <a href="#">12172554</a> <a href="#">15678105</a> <a href="#">20300951</a> <a href="#">22513362</a> <a href="#">23518498</a> <a href="#">23640046</a>

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
E2F1	<p>TP53  PTK2  SRC  AURKA  E2F1</p>	<p><a href="#">14627987</a> <a href="#">15157737</a>  <a href="#">17725966</a> <a href="#">19610065</a>  <a href="#">20300951</a> <a href="#">20378826</a>  <a href="#">25501815</a></p>
	<p>YAP1  SLC7A5  ITGA4_ITGB1  SRC  AURKA  E2F1</p>	<p><a href="#">20300951</a> <a href="#">25501815</a></p>
	<p>LMO1  LDB1_LMO1  LYL1_TALI  EPOR  PIK3CA  SLC9A1   PTK2  SRC  AURKA  E2F1</p>	<p><a href="#">20300951</a> <a href="#">20378826</a>  <a href="#">25501815</a></p>
	<p>CHEK2  BRCA1  FANCA  CAPN1_CAPNS1  PTK2  SRC   AURKA  E2F1</p>	<p><a href="#">11927607</a> <a href="#">14701743</a>  <a href="#">20300951</a> <a href="#">20378826</a>  <a href="#">20518497</a> <a href="#">25501815</a></p>
	<p>TP63  STK11  PRKAA1  ULK1  FBP1  NPM1  AURKA   E2F1</p>	<p><a href="#">14985505</a> <a href="#">15231735</a>  <a href="#">20300951</a> <a href="#">21159649</a></p>
E2F1	<p>ULK1  FBP1  NPM1  AURKA  E2F1</p>	<p><a href="#">20300951</a></p>
	<p>ITGAM  ITGAM_ITGB2  ILK  GSK3B  AURKA  E2F1</p>	<p><a href="#">20300951</a> <a href="#">22513362</a>  <a href="#">9736715</a></p>
	<p>ITGAL  ITGAL_ITGB2  ILK  GSK3B  AURKA  E2F1</p>	<p><a href="#">20300951</a> <a href="#">22513362</a>  <a href="#">9736715</a></p>
	<p>IL4R  JAK3  PIK3CA  SLC9A1  PTK2  SRC  AURKA   E2F1</p>	<p><a href="#">16129412</a> <a href="#">16684964</a>  <a href="#">18281483</a> <a href="#">20300951</a>  <a href="#">20378826</a> <a href="#">20671117</a>  <a href="#">25501815</a> <a href="#">8266076</a>  <a href="#">8962143</a></p>
	<p>ILK  GSK3B  AURKA  E2F1</p>	<p><a href="#">20300951</a> <a href="#">22513362</a>  <a href="#">9736715</a></p>

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
E2F1	<p><b>GSTP1</b> → GAPDH → AKT → GSK3B → AURKA → E2F1</p>	<p><a href="#">11035810</a> <a href="#">12172554</a>  <a href="#">15678105</a> <a href="#">20300951</a>  <a href="#">22513362</a> <a href="#">23518498</a>  <a href="#">27563096</a></p>
	<p><b>CD19</b> → PIK3CB → PRKCZ → GSK3B → AURKA → E2F1</p>	<p><a href="#">11481324</a> <a href="#">16510873</a>  <a href="#">17606986</a> <a href="#">20300951</a>  <a href="#">22513362</a></p>
	<p><b>MAP4K2</b> → MAP3K1 → MAP2K3 → MAPK12 → PLK1 → TPX2            → AURKA → E2F1</p>	<p><a href="#">11062067</a> <a href="#">11784851</a>  <a href="#">14580337</a> <a href="#">15173575</a>  <a href="#">20300951</a></p>
	<p><b>MMP7</b> → SPP1 → ITGA4_ITGB1 → SRC → AURKA → E2F1</p>	<p><a href="#">11375993</a> <a href="#">20300951</a>  <a href="#">25501815</a></p>
	<p><b>NDN</b> → E2F1</p>	<p><a href="#">9422723</a></p>
E2F1	<p><b>FAS</b> → DAXX → RASSF1 → SAV1 → STK4 → LATS2 → IKKBK            → MAP3K8 → PIN1 → GSK3B → AURKA → E2F1</p>	<p><a href="#">11003656</a> <a href="#">11483955</a>  <a href="#">20300951</a> <a href="#">21199877</a>  <a href="#">21489991</a> <a href="#">22513362</a>  <a href="#">25946971</a> <a href="#">26898830</a></p>
	<p><b>TSC1</b> → TSC1_TSC2 → RHEB → ULK1 → FBPI → NPM1 →            AURKA → E2F1</p>	<p><a href="#">12869586</a> <a href="#">20300951</a>  <a href="#">21258367</a></p>
	<p><b>PMS1</b> → CHEK1 → WEE1 → CCNB1_CDK1 → MAPK12 → PLK1            → TPX2 → AURKA → E2F1</p>	<p><a href="#">14580337</a> <a href="#">15173575</a>  <a href="#">20300951</a> <a href="#">8428596</a></p>
	<p><b>DNMT3A</b> → CDKN1A → CCNB1_CDK1 → MAPK12 → PLK1 → TPX2            → AURKA → E2F1</p>	<p><a href="#">14580337</a> <a href="#">15173575</a>  <a href="#">20300951</a></p>
	<p><b>FANCA</b> → CAPN1_CAPNS1 → PTK2 → SRC → AURKA → E2F1</p>	<p><a href="#">11927607</a> <a href="#">20300951</a>  <a href="#">20378826</a> <a href="#">20518497</a>  <a href="#">25501815</a></p>

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
E2F1	<p>SETD2 → CDKN1A → CCNB1_CDK1 → MAPK12 → PLK1 → TPX2                      → AURKA → E2F1</p>	<p><a href="#">14580337</a> <a href="#">15173575</a>  <a href="#">18585004</a> <a href="#">20300951</a></p>
	<p>MITF → HIF1A → DNMT2 → RAC1 → PAK1 → AURKA → E2F1</p>	<p><a href="#">12086670</a> <a href="#">15983061</a>  <a href="#">20300951</a></p>
	<p>MAP3K5 → MAP2K7 → MAPK9 → BCL2L1 → BCL2L1 → BAK1                      → HTRA2 → XIAP → AKT → GSK3B → AURKA → E2F1</p>	<p><a href="#">11035810</a> <a href="#">11062067</a>  <a href="#">11583623</a> <a href="#">11602612</a>  <a href="#">11606597</a> <a href="#">11803371</a>  <a href="#">12169272</a> <a href="#">12172554</a>  <a href="#">12566458</a> <a href="#">12818176</a>  <a href="#">15574336</a> <a href="#">15678105</a></p>
	<p>ETS1 → KIF4 → AKT → GSK3B → AURKA → E2F1</p>	<p><a href="#">11035810</a> <a href="#">12172554</a>  <a href="#">15678105</a> <a href="#">20300951</a>  <a href="#">22513362</a> <a href="#">23518498</a></p>
	<p>BID → BCL2L1 → BAK1 → HTRA2 → XIAP → AKT → GSK3B                      → AURKA → E2F1</p>	<p><a href="#">11035810</a> <a href="#">11583623</a>  <a href="#">11602612</a> <a href="#">11606597</a>  <a href="#">11803371</a> <a href="#">12172554</a>  <a href="#">15353804</a> <a href="#">15574336</a>  <a href="#">15678105</a> <a href="#">15694340</a>  <a href="#">15901672</a> <a href="#">18469004</a></p>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
E2F1	<p><b>FANCG</b> → <b>FANCA</b> —  <b>CAPN1_CAPNS1</b> → <b>PTK2</b> → <b>SRC</b> → <b>AURKA</b>                      → <b>E2F1</b></p>	<p><a href="#">11927607</a> <a href="#">15138265</a>  <a href="#">20300951</a> <a href="#">20378826</a>  <a href="#">20518497</a> <a href="#">25501815</a></p>
	<p><b>PLK1</b> → <b>TPX2</b> → <b>AURKA</b> → <b>E2F1</b></p>	<p><a href="#">14580337</a> <a href="#">15173575</a>  <a href="#">20300951</a></p>
	<p><b>LMO2</b> → <b>LDB1_LMO2</b> → <b>LYL1_TAL1</b> → <b>EPOR</b> → <b>PIK3CA</b> → <b>SLC9A1</b>                      → <b>PTK2</b> → <b>SRC</b> → <b>AURKA</b> → <b>E2F1</b></p>	<p><a href="#">20300951</a> <a href="#">20378826</a>  <a href="#">25501815</a></p>
	<p><b>ARHGEF12</b> → <b>RHOA</b> → <b>PTK2</b> → <b>SRC</b> → <b>AURKA</b> → <b>E2F1</b></p>	<p><a href="#">18854312</a> <a href="#">20300951</a>  <a href="#">20378826</a> <a href="#">25501815</a></p>
	<p><b>RPS6KB2</b> → <b>XIAP</b> → <b>AKT</b> —  <b>GSK3B</b> —  <b>AURKA</b> → <b>E2F1</b></p>	<p><a href="#">11035810</a> <a href="#">12172554</a>  <a href="#">15678105</a> <a href="#">20300951</a>  <a href="#">22513362</a> <a href="#">23518498</a>  <a href="#">23640046</a></p>
E2F1	<p><b>MMP2</b> → <b>MMP3</b> → <b>SPP1</b> → <b>ITGA4_ITGB1</b> → <b>SRC</b> → <b>AURKA</b>                      → <b>E2F1</b></p>	<p><a href="#">11120741</a> <a href="#">11375993</a>  <a href="#">20300951</a> <a href="#">25501815</a>  <a href="#">8663255</a> <a href="#">9665471</a></p>
	<p><b>CCNK</b> → <b>CDK12</b> → <b>BRCA1</b> → <b>FANCA</b> —  <b>CAPN1_CAPNS1</b> → <b>PTK2</b>                      → <b>SRC</b> → <b>AURKA</b> → <b>E2F1</b></p>	<p><a href="#">11927607</a> <a href="#">20300951</a>  <a href="#">20378826</a> <a href="#">20518497</a>  <a href="#">25501815</a></p>
	<p><b>IL21R</b> → <b>IL21_IL21R</b> → <b>PIK3CA</b> → <b>SLC9A1</b> → <b>PTK2</b> → <b>SRC</b> →  <b>AURKA</b> → <b>E2F1</b></p>	<p><a href="#">11438544</a> <a href="#">18281483</a>  <a href="#">19230867</a> <a href="#">20300951</a>  <a href="#">20378826</a> <a href="#">25501815</a>  <a href="#">9178903</a></p>
	<p><b>GSK3B</b> —  <b>AURKA</b> → <b>E2F1</b></p>	<p><a href="#">20300951</a> <a href="#">22513362</a></p>
	<p><b>BAP1</b> → <b>BAP1_L3MBTL2</b> —  <b>EZH2</b> → <b>CPGMET</b> —  <b>BRCA1</b> → <b>FANCA</b>                      —  <b>CAPN1_CAPNS1</b> → <b>PTK2</b> → <b>SRC</b> → <b>AURKA</b> → <b>E2F1</b></p>	<p><a href="#">11927607</a> <a href="#">16357870</a>  <a href="#">19079346</a> <a href="#">20300951</a>  <a href="#">20378826</a> <a href="#">20518497</a>  <a href="#">22211105</a> <a href="#">25501815</a></p>

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
E2F1	<p> <a href="#">ATRIP</a> → <a href="#">FANCA</a> —  <a href="#">CAPN1_CAPNS1</a> → <a href="#">PTK2</a> → <a href="#">SRC</a> → <a href="#">AURKA</a>            → <a href="#">E2F1</a> </p>	<p> <a href="#">11927607</a> <a href="#">20300951</a>  <a href="#">20378826</a> <a href="#">20518497</a>  <a href="#">25501815</a> </p>
	<p> <a href="#">FOXO3</a> → <a href="#">BBC3</a> —  <a href="#">MCL1</a> —  <a href="#">BAK1</a> → <a href="#">HTRA2</a> —  <a href="#">XIAP</a> → <a href="#">AKT</a>            —  <a href="#">GSK3B</a> —  <a href="#">AURKA</a> → <a href="#">E2F1</a> </p>	<p> <a href="#">10837489</a> <a href="#">11035810</a>  <a href="#">11583623</a> <a href="#">11602612</a>  <a href="#">11606597</a> <a href="#">11803371</a>  <a href="#">12172554</a> <a href="#">14976264</a>  <a href="#">15077116</a> <a href="#">15574336</a>  <a href="#">15637055</a> <a href="#">15678105</a> </p>
	<p> <a href="#">STAT1</a> → <a href="#">FANCA</a> —  <a href="#">CAPN1_CAPNS1</a> → <a href="#">PTK2</a> → <a href="#">SRC</a> → <a href="#">AURKA</a>            → <a href="#">E2F1</a> </p>	<p> <a href="#">11927607</a> <a href="#">20300951</a>  <a href="#">20378826</a> <a href="#">20518497</a>  <a href="#">22271894</a> <a href="#">25501815</a> </p>
	<p> <a href="#">MMP10</a> → <a href="#">MMP7</a> → <a href="#">SPPI</a> → <a href="#">ITGA4_ITGB1</a> → <a href="#">SRC</a> → <a href="#">AURKA</a>            → <a href="#">E2F1</a> </p>	<p> <a href="#">11375993</a> <a href="#">20300951</a>  <a href="#">25501815</a> <a href="#">9578462</a> </p>
	<p> <a href="#">MS4A1</a> → <a href="#">FYN</a> → <a href="#">GRB2</a> → <a href="#">PAK1</a> → <a href="#">AURKA</a> → <a href="#">E2F1</a> </p>	<p> <a href="#">12522133</a> <a href="#">20300951</a>  <a href="#">7545683</a> <a href="#">8943564</a> </p>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
E2F1	<p>ZEB2 → CTBP1_ZEB2 → VIM → ITGA5_ITGB1 → PTK2 → SRC                      → AURKA → E2F1</p>	<p><a href="#">19889638</a> <a href="#">20300951</a>  <a href="#">20378826</a> <a href="#">25501815</a></p>
	<p>PRKCB → MS4A1 → FYN → GRB2 → PAK1 → AURKA → E2F1</p>	<p><a href="#">12522133</a> <a href="#">20300951</a>  <a href="#">7545683</a> <a href="#">8943564</a></p>
	<p>BIK → BAK1 → HTRA2 —  XIAP → AKT —  GSK3B —  AURKA                      → E2F1</p>	<p><a href="#">11035810</a> <a href="#">11583623</a>  <a href="#">11602612</a> <a href="#">11606597</a>  <a href="#">11803371</a> <a href="#">12172554</a>  <a href="#">15574336</a> <a href="#">15678105</a>  <a href="#">18469004</a> <a href="#">20300951</a>  <a href="#">22513362</a> <a href="#">23518498</a></p>
	<p>TP53BP1 → BRCA1 → FANCA —  CAPN1_CAPNS1 → PTK2 → SRC                      → AURKA → E2F1</p>	<p><a href="#">11927607</a> <a href="#">12364621</a>  <a href="#">20300951</a> <a href="#">20378826</a>  <a href="#">20518497</a> <a href="#">25501815</a></p>
	<p>EED → CPGMET —  BRCA1 → FANCA —  CAPN1_CAPNS1 → PTK2                      → SRC → AURKA → E2F1</p>	<p><a href="#">11927607</a> <a href="#">16357870</a>  <a href="#">20300951</a> <a href="#">20378826</a>  <a href="#">20518497</a> <a href="#">25501815</a></p>
E2F1	<p>PAK1 → AURKA → E2F1</p>	<p><a href="#">20300951</a></p>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

KINASE\*\*:

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
PRKCE	RCE1 → RHOA → PTK2 → PLCG1 → PRKCE	<a href="#">10430888</a> <a href="#">18854312</a> <a href="#">19805522</a>
	FBP1 ─ NPM1 → AURKA → PTK2 → PLCG1 → PRKCE	<a href="#">10430888</a> <a href="#">25501815</a>
	TP53 ─ PTK2 → PLCG1 → PRKCE	<a href="#">10430888</a> <a href="#">15157737</a> <a href="#">17725966</a>
	YAPI → SLC7A5 → ITGA5_ITGB1 → PTK2 → PLCG1 → PRKCE	<a href="#">10430888</a> <a href="#">19889638</a>
	LMO1 → LDB1_LMO1 → LYL1_TAL1 → EPOR → PIK3CA → SLC9A1 → PTK2 → PLCG1 → PRKCE	<a href="#">10087335</a> <a href="#">10430888</a>
PRKCE	CHEK2 → BRCA1 → FANCA ─ CAPN1_CAPNS1 → PTK2 → PLCG1 → PRKCE	<a href="#">10430888</a> <a href="#">14701743</a> <a href="#">20518497</a>
	ULK1 → FBP1 ─ NPM1 → AURKA → PTK2 → PLCG1 → PRKCE	<a href="#">10430888</a> <a href="#">25501815</a>
	ITGAM → ITGAM_ITGB2 → ILK → PTK2 → PLCG1 → PRKCE	<a href="#">10430888</a> <a href="#">19118217</a> <a href="#">8649427</a> <a href="#">9736715</a>
	ITGAL → ITGAL_ITGB2 → ILK → PTK2 → PLCG1 → PRKCE	<a href="#">10430888</a> <a href="#">19118217</a> <a href="#">8649427</a> <a href="#">9736715</a>
	IL4R → JAK3 → PIK3CA → SLC9A1 → PTK2 → PLCG1 → PRKCE	<a href="#">10430888</a> <a href="#">16129412</a> <a href="#">18281483</a> <a href="#">8266076</a> <a href="#">8962143</a>

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
PRKCE	ILK → PTK2 → PLCG1 → PRKCE	<a href="#">10430888</a> <a href="#">19118217</a>
	MMP7 → SPP1 → ITGAV_ITGB3 → PTK2B → PTK2 → PLCG1 → PRKCE	<a href="#">10430888</a> <a href="#">10835423</a> <a href="#">11375993</a> <a href="#">11683411</a> <a href="#">11927607</a> <a href="#">16760434</a> <a href="#">19889638</a> <a href="#">7592829</a> <a href="#">8649427</a>
	FANCA —  CAPN1_CAPNS1 → PTK2 → PLCG1 → PRKCE	<a href="#">10430888</a> <a href="#">20518497</a>
	FANCG → FANCA —  CAPN1_CAPNS1 → PTK2 → PLCG1 → PRKCE	<a href="#">10430888</a> <a href="#">15138265</a> <a href="#">20518497</a>
	PLK1 → VIM → ITGA5_ITGB1 → PTK2 → PLCG1 → PRKCE	<a href="#">10430888</a> <a href="#">19889638</a>
PRKCE	LMO2 → LDB1_LMO2 → LYL1_TAL1 → EPOR → PIK3CA → SLC9A1 → PTK2 → PLCG1 → PRKCE	<a href="#">10087335</a> <a href="#">10430888</a>
	ARHGEF12 → RHOA → PTK2 → PLCG1 → PRKCE	<a href="#">10430888</a> <a href="#">18854312</a> <a href="#">19805522</a>
	MMP2 → MMP9 → IGFBP2 → ITGA5_ITGB1 → PTK2 → PLCG1 → PRKCE	<a href="#">10430888</a> <a href="#">12879005</a> <a href="#">16569642</a> <a href="#">19889638</a> <a href="#">20514406</a>
	CCNK → CDK12 → BRCA1 → FANCA —  CAPN1_CAPNS1 → PTK2 → PLCG1 → PRKCE	<a href="#">10430888</a> <a href="#">20518497</a>
	IL21R → IL21_IL21R → PIK3CA → SLC9A1 → PTK2 → PLCG1 → PRKCE	<a href="#">10430888</a> <a href="#">11438544</a> <a href="#">18281483</a> <a href="#">19230867</a> <a href="#">8598449</a> <a href="#">9178903</a>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
PRKCE	GSK3B —  AURKA —> PTK2 —> PLCG1 —> PRKCE	<a href="#">10430888</a> <a href="#">22513362</a> <a href="#">25501815</a>
	ATRIP —> FANCA —  CAPN1_CAPNS1 —> PTK2 —> PLCG1 —> PRKCE	<a href="#">10430888</a> <a href="#">20518497</a>
	STAT1 —> FANCA —  CAPN1_CAPNS1 —> PTK2 —> PLCG1 —> PRKCE	<a href="#">10430888</a> <a href="#">20518497</a>
	MMP10 —> MMP7 —> SPPI —> ITGAV_ITGB3 —> PTK2B —> PTK2 —> PLCG1 —> PRKCE	<a href="#">10430888</a> <a href="#">10835423</a> <a href="#">11375993</a> <a href="#">11683411</a> <a href="#">11927607</a> <a href="#">16760434</a> <a href="#">19889638</a> <a href="#">7592829</a> <a href="#">8649427</a> <a href="#">9578462</a>
	MS4A1 —> LCK —> ITK —> PLCG1 —> PRKCE	<a href="#">10586033</a> <a href="#">23219468</a> <a href="#">9178760</a> <a href="#">9312162</a>
PRKCE	ZEB2 —> CTBP1_ZEB2 —> VIM —> ITGA5_ITGB1 —> PTK2 —> PLCG1 —> PRKCE	<a href="#">10430888</a> <a href="#">19889638</a>
	PRKCB —> CARD11 —> BCL10 —> MALTI —> PRKCE	<a href="#">15125833</a> <a href="#">16356855</a> <a href="#">19815501</a> <a href="#">20516126</a> <a href="#">23690623</a>
	TP53BP1 —> BRCA1 —> FANCA —  CAPN1_CAPNS1 —> PTK2 —> PLCG1 —> PRKCE	<a href="#">10430888</a> <a href="#">12364621</a> <a href="#">20518497</a>
	PAK1 —> ILK —> PTK2 —> PLCG1 —> PRKCE	<a href="#">10430888</a> <a href="#">19118217</a>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
ILK	<p>PPP2R2A —  VIM → ITGA5_ITGB1 → ILK</p>	<p><a href="#">8538749</a> <a href="#">9736715</a></p>
	<p>RCE1 → RAC1 → PAK1 → ILK</p>	
	<p>RASSF1 → SAV1 → STK4 → LATS2 —  WWTR1 → SLC7A5 → ITGA4_ITGB1 → ILK</p>	<p><a href="#">21489991</a> <a href="#">26898830</a> <a href="#">8538749</a> <a href="#">9736715</a></p>
	<p>PMAIP1 —  MCL1 —  BAK1 → HTRA2 —  XIAP → TGFBR1_TGFB2 → RHOA → PTK2 → GRB2 → PAK1 → ILK</p>	<p><a href="#">10806474</a> <a href="#">10837489</a> <a href="#">11356828</a> <a href="#">11583623</a> <a href="#">11602612</a> <a href="#">11606597</a> <a href="#">11803371</a> <a href="#">12522133</a> <a href="#">15077116</a> <a href="#">15574336</a> <a href="#">15637055</a> <a href="#">15694340</a></p>
	<p>TP53 —  PTK2 → GRB2 → PAK1 → ILK</p>	<p><a href="#">12522133</a> <a href="#">15157737</a> <a href="#">16298995</a> <a href="#">17725966</a></p>
ILK	<p>YAP1 → SLC7A5 → ITGA4_ITGB1 → ILK</p>	<p><a href="#">8538749</a> <a href="#">9736715</a></p>
	<p>LMO1 → LDB1_LMO1 → LYL1_TALI → EPOR → PIK3CA → SLC9A1 → PTK2 → GRB2 → PAK1 → ILK</p>	<p><a href="#">10806474</a> <a href="#">12522133</a> <a href="#">16298995</a></p>
	<p>CHEK2 → BRCA1 —  CDH3 → ITGA6_ITGB4 → SHC1 → GRB2 → PAK1 → ILK</p>	<p><a href="#">11044453</a> <a href="#">12522133</a> <a href="#">12660812</a> <a href="#">14701743</a> <a href="#">19882246</a> <a href="#">7556090</a> <a href="#">7650032</a> <a href="#">8112292</a> <a href="#">8262059</a> <a href="#">9126968</a> <a href="#">9171350</a> <a href="#">9852124</a></p>
	<p>TP63 —  ID2 → ITGB4 → ITGA6_ITGB4 → SHC1 → GRB2 → PAK1 → ILK</p>	<p><a href="#">11044453</a> <a href="#">12522133</a> <a href="#">12660812</a> <a href="#">7556090</a> <a href="#">7650032</a> <a href="#">8112292</a> <a href="#">8262059</a> <a href="#">9126968</a> <a href="#">9171350</a> <a href="#">9852124</a> <a href="#">9927207</a></p>
	<p>ITGAM → ITGAM_ITGB2 → ILK</p>	<p><a href="#">9736715</a></p>

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
ILK	ITGAL → ITGAL_ITGB2 → ILK	<a href="#">9736715</a>
	IL4R → JAK3 → PIK3CA → SLC9A1 → PTK2 → GRB2 → PAK1 → ILK	<a href="#">10806474</a> <a href="#">12522133</a> <a href="#">12660812</a> <a href="#">12923167</a> <a href="#">15143164</a> <a href="#">16129412</a> <a href="#">16298995</a> <a href="#">18281483</a> <a href="#">23318428</a> <a href="#">8266076</a> <a href="#">8962143</a> <a href="#">9824671</a>
	GSTP1 → GAPDH → AKT → GSK3B → AURKA → PTK2 → GRB2 → PAK1 → ILK	<a href="#">10806474</a> <a href="#">11035810</a> <a href="#">11604394</a> <a href="#">11809746</a> <a href="#">12172554</a> <a href="#">12522133</a> <a href="#">15143164</a> <a href="#">15678105</a> <a href="#">16298995</a> <a href="#">17012749</a> <a href="#">17483337</a> <a href="#">18854312</a>
	MAP4K2 → MAP3K1 → MAP2K3 → MAPK12 → PLK1 → VIM → ITGA5_ITGB1 → ILK	<a href="#">11062067</a> <a href="#">11784851</a> <a href="#">8538749</a> <a href="#">9736715</a>
	MMP7 → SPP1 → ITGA4_ITGB1 → ILK	<a href="#">11375993</a> <a href="#">8538749</a> <a href="#">9736715</a>
	FAS → DAXX → RASSF1 → SAV1 → STK4 → LATS2 → WWTR1 → SLC7A5 → ITGA4_ITGB1 → ILK	<a href="#">11003656</a> <a href="#">11483955</a> <a href="#">21199877</a> <a href="#">21489991</a> <a href="#">26898830</a> <a href="#">8538749</a> <a href="#">9736715</a>
ILK	PMS1 → CHEK1 → WEE1 → CCNB1_CDK1 → CDK1 → DNMT2 → RAC1 → PAK1 → ILK	<a href="#">8428596</a>
	DNMT3A → CDKN1A → CCNB1_CDK1 → CDK1 → DNMT2 → RAC1 → PAK1 → ILK	
	FANCA → CAPN1_CAPNS1 → PTK2 → GRB2 → PAK1 → ILK	<a href="#">12522133</a> <a href="#">16298995</a> <a href="#">20518497</a> <a href="#">8649427</a>
	SETD2 → CDKN1A → CCNB1_CDK1 → CDK1 → DNMT2 → RAC1 → PAK1 → ILK	<a href="#">18585004</a>

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
ILK	<p>MITF → HIF1A —  DNMT2 → RAC1 → PAK1 → ILK</p>	<p><a href="#">12086670</a> <a href="#">15983061</a></p>
	<p>MAP3K5 → MAP2K7 → MAPK9 → BCL2L1 —  BCL2L1 —  BAK1            → HTRA2 —  XIAP → TGFBRI_TGFB2 → RHOA → PTK2 →            GRB2 → PAK1 → ILK</p>	<p><a href="#">10806474</a> <a href="#">11062067</a>  <a href="#">11356828</a> <a href="#">11583623</a>  <a href="#">11602612</a> <a href="#">11606597</a>  <a href="#">11803371</a> <a href="#">12169272</a>  <a href="#">12522133</a> <a href="#">12566458</a>  <a href="#">12660812</a> <a href="#">12818176</a></p>
	<p>ETS1 → ITGA3 → ITGA3_ITGB1 → ILK</p>	<p><a href="#">8538749</a> <a href="#">9736715</a></p>
	<p>BID —  BCL2L1 —  BAK1 → HTRA2 —  XIAP → TGFBRI_TGFB2            → RHOA → PTK2 → GRB2 → PAK1 → ILK</p>	<p><a href="#">10806474</a> <a href="#">11356828</a>  <a href="#">11583623</a> <a href="#">11602612</a>  <a href="#">11606597</a> <a href="#">11803371</a>  <a href="#">12522133</a> <a href="#">15353804</a>  <a href="#">15574336</a> <a href="#">15694340</a>  <a href="#">15901672</a> <a href="#">16298995</a></p>
	<p>XRCC6 → XRCC5_XRCC6 → CHEK2 → BRCA1 —  CDH3 →            ITGA6_ITGB4 → SHC1 → GRB2 → PAK1 → ILK</p>	<p><a href="#">11044453</a> <a href="#">12522133</a>  <a href="#">12660812</a> <a href="#">14701743</a>  <a href="#">15668230</a> <a href="#">19882246</a>  <a href="#">7556090</a> <a href="#">7650032</a>  <a href="#">8112292</a> <a href="#">8262059</a>  <a href="#">9126968</a> <a href="#">9171350</a></p>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
ILK	<p>FANCG → FANCA —  CAPN1_CAPNS1 → PTK2 → GRB2 → PAK1                      → ILK</p>	<p><a href="#">12522133</a> <a href="#">15138265</a>  <a href="#">16298995</a> <a href="#">20518497</a>  <a href="#">8649427</a></p>
	<p>PLK1 → VIM → ITGA5_ITGB1 → ILK</p>	<p><a href="#">8538749</a> <a href="#">9736715</a></p>
	<p>LMO2 → LDB1_LMO2 → LYLI_TAL1 → EPOR → PIK3CA → SLC9A1                      → PTK2 → GRB2 → PAK1 → ILK</p>	<p><a href="#">10806474</a> <a href="#">12522133</a>  <a href="#">16298995</a></p>
	<p>ARHGEF12 → RHOA → PTK2 → GRB2 → PAK1 → ILK</p>	<p><a href="#">10806474</a> <a href="#">12522133</a>  <a href="#">16298995</a> <a href="#">18854312</a>  <a href="#">19118217</a></p>
	<p>RPS6KB2 → XIAP → TGFBRI_TGFBR2 → RHOA → PTK2 → GRB2                      → PAK1 → ILK</p>	<p><a href="#">10806474</a> <a href="#">11356828</a>  <a href="#">12522133</a> <a href="#">16298995</a>  <a href="#">18854312</a> <a href="#">19118217</a></p>

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
ILK	MMP2 → MMP3 → SPP1 → ITGA4_ITGB1 → ILK	<a href="#">11120741</a> <a href="#">11375993</a> <a href="#">8538749</a> <a href="#">8663255</a> <a href="#">9665471</a> <a href="#">9736715</a>
	CCNK → CDK12 → BRCA1 —  CDH3 → ITGA6_ITGB4 → SHCI → GRB2 → PAK1 → ILK	<a href="#">11044453</a> <a href="#">12522133</a> <a href="#">12660812</a> <a href="#">19882246</a> <a href="#">7556090</a> <a href="#">7650032</a> <a href="#">8112292</a> <a href="#">8262059</a> <a href="#">9126968</a> <a href="#">9171350</a> <a href="#">9852124</a> <a href="#">9927207</a>
	IL21R → IL21_IL21R → PIK3CA → SLC9A1 → PTK2 → GRB2 → PAK1 → ILK	<a href="#">10806474</a> <a href="#">11438544</a> <a href="#">12522133</a> <a href="#">16298995</a> <a href="#">18281483</a> <a href="#">19230867</a> <a href="#">9178903</a>
	GSK3B —  AURKA → PTK2 → GRB2 → PAK1 → ILK	<a href="#">10806474</a> <a href="#">12522133</a> <a href="#">16298995</a> <a href="#">22513362</a> <a href="#">25501815</a> <a href="#">9736715</a>
	BAP1 → BAP1_L3MBTL2 —  EZH2 —  CIITA —  MMP9 → IGFBP2 → ITGA5_ITGB1 → ILK	<a href="#">16569642</a> <a href="#">20514406</a> <a href="#">20634887</a> <a href="#">8538749</a> <a href="#">9736715</a>
ILK	ATRIP → FANCA —  CAPN1_CAPNS1 → PTK2 → GRB2 → PAK1 → ILK	<a href="#">12522133</a> <a href="#">16298995</a> <a href="#">20518497</a> <a href="#">8649427</a>
	STAT1 → FANCA —  CAPN1_CAPNS1 → PTK2 → GRB2 → PAK1 → ILK	<a href="#">11882364</a> <a href="#">12522133</a> <a href="#">16298995</a> <a href="#">20518497</a> <a href="#">8649427</a>
	MMP10 → MMP7 → SPP1 → ITGA4_ITGB1 → ILK	<a href="#">11375993</a> <a href="#">8538749</a> <a href="#">9578462</a> <a href="#">9736715</a>
	MS4A1 → FYN → GRB2 → PAK1 → ILK	<a href="#">12522133</a> <a href="#">7545683</a> <a href="#">8943564</a>
	ZEB2 → CTBP1_ZEB2 → VIM → ITGA5_ITGB1 → ILK	<a href="#">8538749</a> <a href="#">9736715</a>

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
ILK	PRKCB → ITGAD_ITGB2 → ILK	<a href="#">11700305</a> <a href="#">9736715</a>
	BIK → BAK1 → HTRA2 — XIAP → TGFBR1_TGFBR2 → RHOA → PTK2 → GRB2 → PAK1 → ILK	<a href="#">10806474</a> <a href="#">11356828</a> <a href="#">11583623</a> <a href="#">11602612</a> <a href="#">11606597</a> <a href="#">11803371</a> <a href="#">12522133</a> <a href="#">15574336</a> <a href="#">16298995</a> <a href="#">18469004</a> <a href="#">18854312</a> <a href="#">19118217</a>
	TP53BP1 → BRCA1 — CDH3 → ITGA6_ITGB4 → SHC1 → GRB2 → PAK1 → ILK	<a href="#">11044453</a> <a href="#">12364621</a> <a href="#">12522133</a> <a href="#">12660812</a> <a href="#">19882246</a> <a href="#">7556090</a> <a href="#">7650032</a> <a href="#">8112292</a> <a href="#">8262059</a> <a href="#">9126968</a> <a href="#">9171350</a> <a href="#">9852124</a>
	EED — CIITA — MMP9 → IGFBP2 → ITGA5_ITGB1 → ILK	<a href="#">16569642</a> <a href="#">20514406</a> <a href="#">8538749</a> <a href="#">9736715</a>
	PAK1 → ILK	



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
PAK1	<p>PPP2R2A —  SRC —&gt; DNM2 —&gt; RAC1 —&gt; PAK1</p>	<p><a href="#">12782622</a> <a href="#">17686471</a></p>
	<p>RCE1 —&gt; RAC1 —&gt; PAK1</p>	
	<p>PEBP1 —  IKKB —&gt; MAP3K8 —&gt; PIN1 —  GSK3B —  AURKA —&gt;</p> <p>PTK2 —&gt; GRB2 —&gt; PAK1</p>	<p><a href="#">10806474</a> <a href="#">11585904</a>  <a href="#">11809746</a> <a href="#">12522133</a>  <a href="#">16298995</a> <a href="#">22513362</a>  <a href="#">25501815</a></p>
	<p>TNFAIP3 —  MAP3K14 —&gt; IKKB —&gt; MAP3K8 —&gt; PIN1 —  GSK3B</p> <p>—  AURKA —&gt; PTK2 —&gt; GRB2 —&gt; PAK1</p>	<p><a href="#">10094049</a> <a href="#">10806474</a>  <a href="#">10887201</a> <a href="#">11784851</a>  <a href="#">11809746</a> <a href="#">12522133</a>  <a href="#">15024054</a> <a href="#">15208311</a>  <a href="#">16298995</a> <a href="#">22513362</a>  <a href="#">25501815</a> <a href="#">9275204</a></p>
	<p>CD81 —&gt; CD19 —&gt; PIK3CB —&gt; PRKCZ —  GSK3B —  AURKA —&gt;</p> <p>PTK2 —&gt; GRB2 —&gt; PAK1</p>	<p><a href="#">10806474</a> <a href="#">11481324</a>  <a href="#">11809746</a> <a href="#">12522133</a>  <a href="#">16298995</a> <a href="#">16510873</a>  <a href="#">17606986</a> <a href="#">22513362</a>  <a href="#">25501815</a></p>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
PAK1	<p> <a href="#">PMAIP1</a> —  <a href="#">MCL1</a> —  <a href="#">BAK1</a> —  <a href="#">HTRA2</a> —  <a href="#">XIAP</a> —  <a href="#">TGFBRI_TGFBR2</a>  <a href="#">RHOA</a> —  <a href="#">PTK2</a> —  <a href="#">GRB2</a> —  <a href="#">PAK1</a> </p>	<p> <a href="#">10806474</a> <a href="#">10837489</a>  <a href="#">11356828</a> <a href="#">11583623</a>  <a href="#">11602612</a> <a href="#">11606597</a>  <a href="#">11803371</a> <a href="#">12522133</a>  <a href="#">15077116</a> <a href="#">15574336</a>  <a href="#">15637055</a> <a href="#">15694340</a> </p>
	<p> <a href="#">EIF3C</a> —  <a href="#">EIF3E</a> —  <a href="#">EIF4E</a> —  <a href="#">VEGFA</a> —  <a href="#">FLT1</a> —  <a href="#">GRB2</a> —  <a href="#">PAK1</a> </p>	<p> <a href="#">12522133</a> <a href="#">14741347</a>  <a href="#">17560152</a> <a href="#">18079407</a>  <a href="#">18515749</a> <a href="#">9099677</a>  <a href="#">9751730</a> </p>
	<p> <a href="#">TP53</a> —  <a href="#">PTK2</a> —  <a href="#">GRB2</a> —  <a href="#">PAK1</a> </p>	<p> <a href="#">12522133</a> <a href="#">15157737</a>  <a href="#">16298995</a> <a href="#">17725966</a> </p>
	<p> <a href="#">YAP1</a> —  <a href="#">SLC7A5</a> —  <a href="#">ITGA1_ITGB1</a> —  <a href="#">FYN</a> —  <a href="#">GRB2</a> —  <a href="#">PAK1</a> </p>	<p> <a href="#">12522133</a> <a href="#">8943564</a> </p>
	<p> <a href="#">LMO1</a> —  <a href="#">LDB1_LMO1</a> —  <a href="#">LYL1_TAL1</a> —  <a href="#">EPOR</a> —  <a href="#">PIK3CA</a> —  <a href="#">SLC9A1</a>  <a href="#">PTK2</a> —  <a href="#">GRB2</a> —  <a href="#">PAK1</a> </p>	<p> <a href="#">10806474</a> <a href="#">12522133</a>  <a href="#">16298995</a> </p>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
PAK1	CHEK2 → BRCA1 — CDH3 → ITGA6_ITGB4 → SHC1 → GRB2 → PAK1	<a href="#">11044453</a> <a href="#">12522133</a> <a href="#">12660812</a> <a href="#">14701743</a> <a href="#">19882246</a> <a href="#">7556090</a> <a href="#">7650032</a> <a href="#">8112292</a> <a href="#">8262059</a> <a href="#">9126968</a> <a href="#">9171350</a> <a href="#">9852124</a>
	TP63 — ID2 → ITGB4 → ITGA6_ITGB4 → SHC1 → GRB2 → PAK1	<a href="#">11044453</a> <a href="#">12522133</a> <a href="#">12660812</a> <a href="#">7556090</a> <a href="#">7650032</a> <a href="#">8112292</a> <a href="#">8262059</a> <a href="#">9126968</a> <a href="#">9171350</a> <a href="#">9852124</a> <a href="#">9927207</a>
	ITGAM → ITGAM_ITGB2 → ILK → PTK2 → GRB2 → PAK1	<a href="#">12522133</a> <a href="#">16298995</a> <a href="#">19118217</a> <a href="#">8649427</a> <a href="#">9736715</a>
	ITGAL → ITGAL_ITGB2 → ILK → PTK2 → GRB2 → PAK1	<a href="#">12522133</a> <a href="#">16298995</a> <a href="#">19118217</a> <a href="#">8649427</a> <a href="#">9736715</a>
	IL4R → JAK3 → PIK3CA → SLC9A1 → PTK2 → GRB2 → PAK1	<a href="#">10806474</a> <a href="#">12522133</a> <a href="#">12660812</a> <a href="#">12923167</a> <a href="#">15143164</a> <a href="#">16129412</a> <a href="#">16298995</a> <a href="#">18281483</a> <a href="#">23318428</a> <a href="#">8266076</a> <a href="#">8962143</a> <a href="#">9824671</a>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
	<p>ILK → PTK2 → GRB2 → PAK1</p>	<p><a href="#">12522133</a> <a href="#">16298995</a> <a href="#">19118217</a> <a href="#">8649427</a></p>
	<p>GSTP1 → GAPDH → AKT → GSK3B → AURKA → PTK2 → GRB2 → PAK1</p>	<p><a href="#">10806474</a> <a href="#">11035810</a> <a href="#">11604394</a> <a href="#">11809746</a> <a href="#">12172554</a> <a href="#">12522133</a> <a href="#">15143164</a> <a href="#">15678105</a> <a href="#">16298995</a> <a href="#">17012749</a> <a href="#">18854312</a> <a href="#">19345670</a></p>
PAK1	<p>CD19 → PIK3CB → PRKCZ → GSK3B → AURKA → PTK2 → GRB2 → PAK1</p>	<p><a href="#">10806474</a> <a href="#">11481324</a> <a href="#">11809746</a> <a href="#">12522133</a> <a href="#">16298995</a> <a href="#">16510873</a> <a href="#">17606986</a> <a href="#">22513362</a> <a href="#">25501815</a></p>
	<p>MMP7 → SPP1 → ITGAV_ITGB3 → PTK2B → SHC1 → GRB2 → PAK1</p>	<p><a href="#">10835423</a> <a href="#">11375993</a> <a href="#">11683411</a> <a href="#">11882364</a> <a href="#">12522133</a> <a href="#">12660812</a> <a href="#">7592829</a> <a href="#">7650032</a> <a href="#">8112292</a> <a href="#">8262059</a> <a href="#">9126968</a> <a href="#">9852124</a></p>
	<p>PMS1 → CHEK1 → WEE1 → CCNB1_CDK1 → CDK1 → DNM2 → RAC1 → PAK1</p>	<p><a href="#">8428596</a></p>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
PAK1	<p>DNMT3A —  CDKN1A —  CCNB1_CDK1 —&gt; CDK1 —&gt; DNMT2 —&gt; RAC1                      —&gt; PAK1</p>	
	<p>FANCA —  CAPN1_CAPNS1 —&gt; PTK2 —&gt; GRB2 —&gt; PAK1</p>	<p><a href="#">12522133</a> <a href="#">16298995</a>  <a href="#">20518497</a> <a href="#">8649427</a></p>
	<p>SETD2 —&gt; CDKN1A —  CCNB1_CDK1 —&gt; CDK1 —&gt; DNMT2 —&gt; RAC1                      —&gt; PAK1</p>	<p><a href="#">18585004</a></p>
	<p>MITF —&gt; HIF1A —  DNMT2 —&gt; RAC1 —&gt; PAK1</p>	<p><a href="#">12086670</a> <a href="#">15983061</a></p>
	<p>MAP3K5 —&gt; MAP2K7 —&gt; MAPK9 —&gt; BCL2L1 —  BCL2L1 —  BAK1                      —&gt; HTRA2 —  XIAP —&gt; TGFBRI_TGFB2 —&gt; RHOA —&gt; PTK2 —&gt;                      GRB2 —&gt; PAK1</p>	<p><a href="#">10806474</a> <a href="#">11062067</a>  <a href="#">11356828</a> <a href="#">11583623</a>  <a href="#">11602612</a> <a href="#">11606597</a>  <a href="#">11803371</a> <a href="#">12169272</a>  <a href="#">12522133</a> <a href="#">12566458</a>  <a href="#">12660812</a> <a href="#">12818176</a></p>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
PAK1	<p><b>ETS1</b> → ITGB4 → ITGA6_ITGB4 → <b>SHC1</b> → GRB2 → <b>PAK1</b></p>	<p><a href="#">11044453</a> <a href="#">12522133</a>  <a href="#">12660812</a> <a href="#">7556090</a>  <a href="#">7650032</a> <a href="#">8112292</a>  <a href="#">8262059</a> <a href="#">9126968</a>  <a href="#">9171350</a> <a href="#">9852124</a>  <a href="#">9927207</a></p>
	<p><b>BID</b> —  <b>BCL2L1</b> —  <b>BAK1</b> → <b>HTRA2</b> —  <b>XIAP</b> → <b>TGFBRI_TGFBR2</b>  → <b>RHOA</b> → <b>PTK2</b> → <b>GRB2</b> → <b>PAK1</b></p>	<p><a href="#">10806474</a> <a href="#">11356828</a>  <a href="#">11583623</a> <a href="#">11602612</a>  <a href="#">11606597</a> <a href="#">11803371</a>  <a href="#">12522133</a> <a href="#">15353804</a>  <a href="#">15574336</a> <a href="#">15694340</a>  <a href="#">15901672</a> <a href="#">16298995</a></p>
	<p><b>XRCC6</b> → <b>XRCC5_XRCC6</b> → <b>CHEK2</b> → <b>BRCA1</b> —  <b>CDH3</b> →  <b>ITGA6_ITGB4</b> → <b>SHC1</b> → <b>GRB2</b> → <b>PAK1</b></p>	<p><a href="#">11044453</a> <a href="#">12522133</a>  <a href="#">12660812</a> <a href="#">14701743</a>  <a href="#">15668230</a> <a href="#">19882246</a>  <a href="#">7556090</a> <a href="#">7650032</a>  <a href="#">8112292</a> <a href="#">8262059</a>  <a href="#">9126968</a> <a href="#">9171350</a></p>
	<p><b>FANCG</b> → <b>FANCA</b> —  <b>CAPN1_CAPNS1</b> → <b>PTK2</b> → <b>GRB2</b> → <b>PAK1</b></p>	<p><a href="#">12522133</a> <a href="#">15138265</a>  <a href="#">16298995</a> <a href="#">20518497</a>  <a href="#">8649427</a></p>
	<p><b>LMO2</b> → <b>LDB1_LMO2</b> → <b>LYL1_TAL1</b> → <b>EPOR</b> → <b>PIK3CA</b> → <b>SLC9A1</b>  → <b>PTK2</b> → <b>GRB2</b> → <b>PAK1</b></p>	<p><a href="#">10806474</a> <a href="#">12522133</a>  <a href="#">16298995</a></p>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
PAK1	<p>ARHGEF2 → RHOA → PTK2 → GRB2 → PAK1</p>	<p><a href="#">10806474</a> <a href="#">12522133</a> <a href="#">16298995</a> <a href="#">18854312</a></p>
	<p>RPS6KB2 → XIAP → TGFBR1_TGFBR2 → RHOA → PTK2 → GRB2 → PAK1</p>	<p><a href="#">10806474</a> <a href="#">11356828</a> <a href="#">12522133</a> <a href="#">16298995</a> <a href="#">18854312</a></p>
	<p>MMP2 → MMP9 → IGFBP2 → ITGA5_ITGB1 → FYN → GRB2 → PAK1</p>	<p><a href="#">12522133</a> <a href="#">12879005</a> <a href="#">16569642</a> <a href="#">20514406</a> <a href="#">8943564</a></p>
	<p>CCNK → CDK12 → BRCA1 — CDH3 → ITGA6_ITGB4 → SHC1 → GRB2 → PAK1</p>	<p><a href="#">11044453</a> <a href="#">12522133</a> <a href="#">12660812</a> <a href="#">19882246</a> <a href="#">7556090</a> <a href="#">7650032</a> <a href="#">8112292</a> <a href="#">8262059</a> <a href="#">9126968</a> <a href="#">9171350</a> <a href="#">9852124</a> <a href="#">9927207</a></p>
	<p>IL21R → IL21_IL21R → PIK3CA → SLC9A1 → PTK2 → GRB2 → PAK1</p>	<p><a href="#">10806474</a> <a href="#">11438544</a> <a href="#">12522133</a> <a href="#">16298995</a> <a href="#">18281483</a> <a href="#">19230867</a> <a href="#">9178903</a></p>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
PAK1	GSK3B —  AURKA —> PTK2 —> GRB2 —> PAK1	<a href="#">10806474</a> <a href="#">12522133</a> <a href="#">16298995</a> <a href="#">22513362</a> <a href="#">25501815</a>
	BAP1 —> BAP1_L3MBTL2 —  EZH2 —> CPGMET —  BRCA1 —  CDH3 —> ITGA6_ITGB4 —> SHC1 —> GRB2 —> PAK1	<a href="#">11044453</a> <a href="#">12522133</a> <a href="#">12660812</a> <a href="#">16357870</a> <a href="#">19079346</a> <a href="#">19882246</a> <a href="#">22211105</a> <a href="#">7556090</a> <a href="#">7650032</a> <a href="#">8112292</a> <a href="#">8262059</a> <a href="#">9126968</a>
	ATRIP —> FANCA —  CAPN1_CAPNS1 —> PTK2 —> GRB2 —> PAK1	<a href="#">12522133</a> <a href="#">16298995</a> <a href="#">20518497</a> <a href="#">8649427</a>
	STAT1 —> FANCA —  CAPN1_CAPNS1 —> PTK2 —> GRB2 —> PAK1	<a href="#">11882364</a> <a href="#">12522133</a> <a href="#">16298995</a> <a href="#">20518497</a> <a href="#">8649427</a>
	MMP10 —> MMP7 —> SPPI —> ITGAV_ITGB3 —> PTK2B —> SHC1 —> GRB2 —> PAK1	<a href="#">10835423</a> <a href="#">11375993</a> <a href="#">11683411</a> <a href="#">11882364</a> <a href="#">12522133</a> <a href="#">12660812</a> <a href="#">7592829</a> <a href="#">7650032</a> <a href="#">8112292</a> <a href="#">8262059</a> <a href="#">9126968</a> <a href="#">9578462</a>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
PAK1	MS4A1 → FYN → GRB2 → PAK1	<a href="#">12522133</a> <a href="#">7545683</a> <a href="#">8943564</a>
	ZEB2 → CTBP1_ZEB2 → VIM → ITGA5_ITGB1 → FYN → GRB2 → PAK1	<a href="#">12522133</a> <a href="#">8943564</a>
	PRKCB → MS4A1 → FYN → GRB2 → PAK1	<a href="#">12522133</a> <a href="#">7545683</a> <a href="#">8943564</a>
	BIK → BAK1 → HTRA2 —  XIAP → TGFBR1_TGFBR2 → RHOA → PTK2 → GRB2 → PAK1	<a href="#">10806474</a> <a href="#">11356828</a> <a href="#">11583623</a> <a href="#">11602612</a> <a href="#">11606597</a> <a href="#">11803371</a> <a href="#">12522133</a> <a href="#">15574336</a> <a href="#">16298995</a> <a href="#">18469004</a> <a href="#">18854312</a>
	TP53BP1 → BRCA1 —  CDH3 → ITGA6_ITGB4 → SHC1 → GRB2 → PAK1	<a href="#">11044453</a> <a href="#">12364621</a> <a href="#">12522133</a> <a href="#">12660812</a> <a href="#">19882246</a> <a href="#">7556090</a> <a href="#">7650032</a> <a href="#">8112292</a> <a href="#">8262059</a> <a href="#">9126968</a> <a href="#">9171350</a> <a href="#">9852124</a>
PAK1	EED → CPGMET —  BRCA1 —  CDH3 → ITGA6_ITGB4 → SHC1 → GRB2 → PAK1	<a href="#">11044453</a> <a href="#">12522133</a> <a href="#">12660812</a> <a href="#">16357870</a> <a href="#">19882246</a> <a href="#">7556090</a> <a href="#">7650032</a> <a href="#">8112292</a> <a href="#">8262059</a> <a href="#">9126968</a> <a href="#">9171350</a> <a href="#">9852124</a>

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
MTOR	<p>PPP2R2A —  AKT —  AKT1S1 —  MTOR</p>	<p><a href="#">17510057</a> <a href="#">17517883</a> <a href="#">19276681</a> <a href="#">20138985</a></p>
	<p>RCE1 → RAC1 → MTOR</p>	
	<p>PEBP1 —  IKKBK → MAP3K8 → PIN1 → AKT —  AKT1S1 —  MTOR</p>	<p><a href="#">11585904</a> <a href="#">12138205</a> <a href="#">17510057</a> <a href="#">17517883</a> <a href="#">19276681</a> <a href="#">20138985</a></p>
	<p>TNFAIP3 —  MAP3K14 → IKKBK → MAP3K8 → PIN1 → AKT —  AKT1S1 —  MTOR</p>	<p><a href="#">10094049</a> <a href="#">10887201</a> <a href="#">11784851</a> <a href="#">12138205</a> <a href="#">15024054</a> <a href="#">15208311</a> <a href="#">17510057</a> <a href="#">17517883</a> <a href="#">19276681</a> <a href="#">20138985</a> <a href="#">9275204</a></p>
	<p>RASSF1 → SAV1 → STK4 → LATS2 —  WWTR1 → SLC7A5 →</p>	<p><a href="#">21489991</a> <a href="#">22424946</a> <a href="#">26898830</a></p>
MTOR	<p>CD81 → CD19 → PIK3CB → PDPK1 → AKT —  AKT1S1 —  MTOR</p>	<p><a href="#">10698680</a> <a href="#">17510057</a> <a href="#">17517883</a> <a href="#">19276681</a> <a href="#">20138985</a></p>
	<p>DDIT4 → TSC1_TSC2 —  RHEB → MTOR</p>	<p><a href="#">12869586</a></p>
	<p>PMAIP1 —  MCL1 —  BAK1 → HTRA2 —  XIAP → AKT —  AKT1S1 —  MTOR</p>	<p><a href="#">10837489</a> <a href="#">11583623</a> <a href="#">11602612</a> <a href="#">11606597</a> <a href="#">11803371</a> <a href="#">15077116</a> <a href="#">15574336</a> <a href="#">15637055</a> <a href="#">15694340</a> <a href="#">15721256</a> <a href="#">15901672</a> <a href="#">16697956</a></p>
	<p>TP53 → ULK1 —  MTOR</p>	<p><a href="#">21475306</a> <a href="#">23651856</a></p>
	<p>YAP1 → SLC7A5 → MTOR</p>	<p><a href="#">22424946</a></p>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
MTOR	<p>LMO1 → LDB1_LMO1 → LYLI_TALI → EPOR → PIK3CB → PDPKI                      → AKT → AKT1S1 → MTOR</p>	<p><a href="#">10698680</a> <a href="#">17510057</a>  <a href="#">17517883</a> <a href="#">19276681</a>  <a href="#">20138985</a></p>
	<p>CHEK2 → BRCA1 → CDKN1A → CCNBI_CDK1 → XIAP → AKT                      → AKT1S1 → MTOR</p>	<p><a href="#">10542266</a> <a href="#">14701743</a>  <a href="#">17510057</a> <a href="#">17517883</a>  <a href="#">19276681</a> <a href="#">20138985</a>  <a href="#">23640046</a> <a href="#">27927753</a></p>
	<p>TP63 → STK11 → PRKAA1 → ULK1 → MTOR</p>	<p><a href="#">14985505</a> <a href="#">15231735</a>  <a href="#">21159649</a> <a href="#">21460630</a></p>
	<p>ULK1 → MTOR</p>	
	<p>ITGAM → ITGAM_ITGB2 → ILK → AKT → AKT1S1 → MTOR</p>	<p><a href="#">17510057</a> <a href="#">17517883</a>  <a href="#">19276681</a> <a href="#">20138985</a>  <a href="#">9736715</a></p>
MTOR	<p>ITGAL → ITGAL_ITGB2 → ILK → AKT → AKT1S1 → MTOR</p>	<p><a href="#">17510057</a> <a href="#">17517883</a>  <a href="#">19276681</a> <a href="#">20138985</a>  <a href="#">9736715</a></p>
	<p>IL4R → JAK3 → PIK3CB → PDPKI → AKT → AKT1S1 → MTOR</p>	<p><a href="#">10698680</a> <a href="#">11035047</a>  <a href="#">15010462</a> <a href="#">16129412</a>  <a href="#">16873377</a> <a href="#">17510057</a>  <a href="#">17517883</a> <a href="#">19276681</a>  <a href="#">20138985</a> <a href="#">8266076</a></p>
	<p>ILK → AKT → AKT1S1 → MTOR</p>	<p><a href="#">17510057</a> <a href="#">17517883</a>  <a href="#">19276681</a> <a href="#">20138985</a>  <a href="#">9736715</a></p>
	<p>GSTPI → GAPDH → AKT → AKT1S1 → MTOR</p>	<p><a href="#">17510057</a> <a href="#">17517883</a>  <a href="#">19276681</a> <a href="#">20138985</a></p>
	<p>CD19 → PIK3CB → PDPKI → AKT → AKT1S1 → MTOR</p>	<p><a href="#">10698680</a> <a href="#">17510057</a>  <a href="#">17517883</a> <a href="#">19276681</a>  <a href="#">20138985</a></p>

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
MTOR	<p>MAP4K2 → MAP3K1 → MAP2K3 → MAPK14 → MAPKAP2 → AKT</p> <p>AKT1S1 ⊣ MTOR</p>	<p><a href="#">11784851</a> <a href="#">15273249</a></p> <p><a href="#">17510053</a> <a href="#">17510057</a></p> <p><a href="#">17517883</a> <a href="#">19276681</a></p> <p><a href="#">20138985</a> <a href="#">20978232</a></p> <p><a href="#">9430721</a></p>
	<p>MMP7 → SPP1 → ITGA4_ITGB1 → ILK → AKT</p> <p>AKT1S1 ⊣ AKT</p> <p>MTOR ⊣ AKT1S1</p>	<p><a href="#">11375993</a> <a href="#">17510057</a></p> <p><a href="#">17517883</a> <a href="#">19276681</a></p> <p><a href="#">20138985</a> <a href="#">8538749</a></p> <p><a href="#">9736715</a></p>
	<p>FAS → DAXX → RASSF1 → SAV1 → STK4 → LATS2</p> <p>SLC7A5 → MTOR</p> <p>LATS2 ⊣ WWTR1</p>	<p><a href="#">11003656</a> <a href="#">11483955</a></p> <p><a href="#">21199877</a> <a href="#">21489991</a></p> <p><a href="#">22424946</a> <a href="#">26898830</a></p>
	<p>TSC1 → TSC1_TSC2</p> <p>RHEB ⊣ TSC1_TSC2</p> <p>RHEB → MTOR</p>	<p><a href="#">12869586</a></p>
	<p>PMS1 → CHEK1 → WEE1</p> <p>AKT1S1 ⊣ MTOR</p> <p>WEE1 ⊣ CCNB1_CDK1</p> <p>CCNB1_CDK1 → XIAP → AKT</p> <p>AKT1S1 ⊣ AKT</p>	<p><a href="#">17510057</a> <a href="#">17517883</a></p> <p><a href="#">19276681</a> <a href="#">20138985</a></p> <p><a href="#">23640046</a> <a href="#">27927753</a></p> <p><a href="#">8428596</a></p>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
MTOR	<p><b>DNMT3A</b> —  CDKN1A —  CCNB1_CDK1 —&gt; XIAP —&gt; AKT —  AKT1S1 —  MTOR</p>	<p><a href="#">17510057</a> <a href="#">17517883</a> <a href="#">19276681</a> <a href="#">20138985</a> <a href="#">23640046</a> <a href="#">27927753</a></p>
	<p><b>FANCA</b> —  CAPN1_CAPNS1 —&gt; PTK2 —&gt; SRC —&gt; NEDD4 —&gt; AKT —  AKT1S1 —  MTOR</p>	<p><a href="#">11927607</a> <a href="#">17510057</a> <a href="#">17517883</a> <a href="#">19276681</a> <a href="#">20138985</a> <a href="#">20378826</a> <a href="#">20518497</a> <a href="#">23195959</a> <a href="#">25292214</a></p>
	<p><b>SETD2</b> —&gt; CDKN1A —  CCNB1_CDK1 —&gt; XIAP —&gt; AKT —  AKT1S1 —  MTOR</p>	<p><a href="#">17510057</a> <a href="#">17517883</a> <a href="#">18585004</a> <a href="#">19276681</a> <a href="#">20138985</a> <a href="#">23640046</a> <a href="#">27927753</a></p>
	<p><b>MITF</b> —&gt; HIF1A —  DNMT2 —&gt; RAC1 —&gt; PAK1 —&gt; AKT —  AKT1S1 —  MTOR</p>	<p><a href="#">12086670</a> <a href="#">15983061</a> <a href="#">17502379</a> <a href="#">17510057</a> <a href="#">17517883</a> <a href="#">19276681</a> <a href="#">20138985</a></p>
	<p><b>MAP3K5</b> —&gt; MAP2K7 —&gt; MAPK9 —&gt; BCL2L1 —  BCL2L1 —  BAK1 —&gt; HTRA2 —  XIAP —&gt; AKT —  AKT1S1 —  MTOR</p>	<p><a href="#">11062067</a> <a href="#">11583623</a> <a href="#">11602612</a> <a href="#">11606597</a> <a href="#">11803371</a> <a href="#">12169272</a> <a href="#">12566458</a> <a href="#">12818176</a> <a href="#">15574336</a> <a href="#">15694340</a> <a href="#">15901672</a> <a href="#">16478725</a></p>

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
MTOR	<p><b>ETS1</b> → <b>KIF4</b> → <b>AKT</b> — <b>AKT1S1</b> — <b>MTOR</b></p>	<p><a href="#">15718470</a> <a href="#">17510057</a>  <a href="#">17517883</a> <a href="#">19276681</a>  <a href="#">20138985</a></p>
	<p><b>BID</b> — <b>BCL2L1</b> — <b>BAK1</b> → <b>HTRA2</b> — <b>XIAP</b> → <b>AKT</b> — <b>AKT1S1</b>  — <b>MTOR</b></p>	<p><a href="#">11583623</a> <a href="#">11602612</a>  <a href="#">11606597</a> <a href="#">11803371</a>  <a href="#">15353804</a> <a href="#">15574336</a>  <a href="#">15694340</a> <a href="#">15901672</a>  <a href="#">17510057</a> <a href="#">17517883</a>  <a href="#">18469004</a> <a href="#">19276681</a></p>
	<p><b>LMO2</b> → <b>LDB1</b> <b>LMO2</b> → <b>LYL1_TAL1</b> → <b>EPOR</b> → <b>PIK3CB</b> → <b>PDPK1</b>  → <b>AKT</b> — <b>AKT1S1</b> — <b>MTOR</b></p>	<p><a href="#">10698680</a> <a href="#">17510057</a>  <a href="#">17517883</a> <a href="#">19276681</a>  <a href="#">20138985</a></p>
	<p><b>ARHGEF12</b> → <b>RHOA</b> → <b>PTK2</b> → <b>SRC</b> → <b>NEDD4</b> → <b>AKT</b> — <b>AKT1S1</b> — <b>MTOR</b></p>	<p><a href="#">17510057</a> <a href="#">17517883</a>  <a href="#">18854312</a> <a href="#">19276681</a>  <a href="#">20138985</a> <a href="#">20378826</a>  <a href="#">23195959</a> <a href="#">25292214</a></p>
	<p><b>RPS6KB2</b> → <b>XIAP</b> → <b>AKT</b> — <b>AKT1S1</b> — <b>MTOR</b></p>	<p><a href="#">17510057</a> <a href="#">17517883</a>  <a href="#">19276681</a> <a href="#">20138985</a>  <a href="#">23640046</a></p>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
MTOR	<p>MMP2 → MMP3 → SPP1 → ITGA4_ITGB1 → ILK → AKT</p> <p>AKTIS1 ⊣ MTOR</p>	<p><a href="#">11120741</a> <a href="#">11375993</a>  <a href="#">17510057</a> <a href="#">17517883</a>  <a href="#">19276681</a> <a href="#">20138985</a>  <a href="#">8538749</a> <a href="#">8663255</a>  <a href="#">9665471</a> <a href="#">9736715</a></p>
	<p>CCNK → CDK12 → BRCA1 → CDKN1A</p> <p>CCNB1_CDK1 ⊣ XIAP</p> <p>AKT ⊣ AKTIS1 ⊣ MTOR</p>	<p><a href="#">17510057</a> <a href="#">17517883</a>  <a href="#">19276681</a> <a href="#">20138985</a>  <a href="#">23640046</a> <a href="#">27927753</a></p>
	<p>IL21R → IL21_IL21R → PIK3CB → PDK1 → AKT</p> <p>AKTIS1 ⊣ MTOR</p>	<p><a href="#">10698680</a> <a href="#">17510057</a>  <a href="#">17517883</a> <a href="#">19276681</a>  <a href="#">20138985</a> <a href="#">9178903</a></p>
	<p>GSK3B ⊣ WWTR1 → SLC7A5 → MTOR</p>	<p><a href="#">22424946</a></p>
	<p>BAP1 → BAP1_L3MBTL2</p> <p>EZH2 ⊣ CPGMET ⊣ CDKN1A</p> <p>CCNB1_CDK1 → XIAP → AKT</p> <p>AKTIS1 ⊣ MTOR</p>	<p><a href="#">16357870</a> <a href="#">17510057</a>  <a href="#">17517883</a> <a href="#">19276681</a>  <a href="#">20138985</a> <a href="#">23640046</a>  <a href="#">27927753</a></p>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
	<p> <b>ATRIP</b> → <b>CHEK1</b> → <b>WEE1</b> —  <b>CCNB1_CDK1</b> → <b>XIAP</b> → <b>AKT</b> —   <b>AKTIS1</b> —  <b>MTOR</b> </p>	<p> <a href="#">17510057</a> <a href="#">17517883</a>  <a href="#">19276681</a> <a href="#">20138985</a>  <a href="#">23640046</a> <a href="#">27927753</a>  <a href="#">8428596</a> </p>
	<p> <b>FOXO3</b> → <b>BBC3</b> —  <b>MCL1</b> —  <b>BAK1</b> → <b>HTRA2</b> —  <b>XIAP</b> → <b>AKT</b>  —  <b>AKTIS1</b> —  <b>MTOR</b> </p>	<p> <a href="#">10837489</a> <a href="#">11583623</a>  <a href="#">11602612</a> <a href="#">11606597</a>  <a href="#">11803371</a> <a href="#">14976264</a>  <a href="#">15077116</a> <a href="#">15574336</a>  <a href="#">15637055</a> <a href="#">15694340</a>  <a href="#">15721256</a> <a href="#">15901672</a> </p>
MTOR	<p> <b>STAT1</b> → <b>CDKN1A</b> —  <b>CCNB1_CDK1</b> → <b>XIAP</b> → <b>AKT</b> —  <b>AKTIS1</b>  —  <b>MTOR</b> </p>	<p> <a href="#">17510057</a> <a href="#">17517883</a>  <a href="#">19276681</a> <a href="#">20138985</a>  <a href="#">22271894</a> <a href="#">23640046</a>  <a href="#">27927753</a> </p>
	<p> <b>MMP10</b> → <b>MMP7</b> → <b>SPPI</b> → <b>ITGA4_ITGB1</b> → <b>ILK</b> → <b>AKT</b> —   <b>AKTIS1</b> —  <b>MTOR</b> </p>	<p> <a href="#">11375993</a> <a href="#">17510057</a>  <a href="#">17517883</a> <a href="#">19276681</a>  <a href="#">20138985</a> <a href="#">8538749</a>  <a href="#">9578462</a> <a href="#">9736715</a> </p>
	<p> <b>MS4A1</b> → <b>FYN</b> → <b>NTRK2</b> → <b>TNK2</b> → <b>AKT</b> —  <b>AKTIS1</b> —  <b>MTOR</b> </p>	<p> <a href="#">14506255</a> <a href="#">17510057</a>  <a href="#">17517883</a> <a href="#">19276681</a>  <a href="#">20138985</a> <a href="#">23598414</a>  <a href="#">7545683</a> <a href="#">9648856</a> </p>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
MTOR	<p>ZEB2 → CTBP1_ZEB2 → VIM → ITGA5_ITGB1 → ILK → AKT</p> <p>AKT1S1 ⊣ MTOR</p>	<p><a href="#">17510057</a> <a href="#">17517883</a>  <a href="#">19276681</a> <a href="#">20138985</a>  <a href="#">8538749</a> <a href="#">9736715</a></p>
	<p>PRKCB → CARD11 → BCL10 → MALTI → MTOR</p>	<p><a href="#">16356855</a> <a href="#">19815501</a>  <a href="#">20516126</a> <a href="#">23690623</a></p>
	<p>BIK → BAK1 → HTRA2 ⊣ XIAP → AKT ⊣ AKT1S1 ⊣ MTOR</p>	<p><a href="#">11583623</a> <a href="#">11602612</a>  <a href="#">11606597</a> <a href="#">11803371</a>  <a href="#">15574336</a> <a href="#">17510057</a>  <a href="#">17517883</a> <a href="#">18469004</a>  <a href="#">19276681</a> <a href="#">20138985</a>  <a href="#">23640046</a></p>
	<p>TP53BP1 → BRCA1 → CDKN1A ⊣ CCNB1_CDK1 → XIAP → AKT</p> <p>AKT1S1 ⊣ MTOR</p>	<p><a href="#">10542266</a> <a href="#">12364621</a>  <a href="#">17510057</a> <a href="#">17517883</a>  <a href="#">19276681</a> <a href="#">20138985</a>  <a href="#">23640046</a> <a href="#">27927753</a></p>
	<p>EED → CPGMET ⊣ CDKN1A ⊣ CCNB1_CDK1 → XIAP → AKT</p> <p>AKT1S1 ⊣ MTOR</p>	<p><a href="#">16357870</a> <a href="#">17510057</a>  <a href="#">17517883</a> <a href="#">19276681</a>  <a href="#">20138985</a> <a href="#">23640046</a>  <a href="#">27927753</a></p>
MTOR	<p>PAKI → AKT ⊣ AKT1S1 ⊣ MTOR</p>	<p><a href="#">17510057</a> <a href="#">17517883</a>  <a href="#">19276681</a> <a href="#">20138985</a></p>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
HK2	PPP2R2A —  AKT → HK2	
	RCE1 → RAC1 → PAK1 → AKT → HK2	
	PEBP1 —  IKKKB → MAP3K8 → PIN1 → AKT → HK2	<a href="#">11585904</a> <a href="#">12138205</a>
	TNFAIP3 —  MAP3K14 → IKKKB → MAP3K8 → PIN1 → AKT → HK2 HK2	<a href="#">10094049</a> <a href="#">10887201</a> <a href="#">11784851</a> <a href="#">12138205</a> <a href="#">15024054</a> <a href="#">15208311</a> <a href="#">9275204</a>
	RASSF1 → SAV1 → STK4 → LATS2 —  IKKKB → MAP3K8 → PIN1 → AKT → HK2	<a href="#">12138205</a> <a href="#">21489991</a> <a href="#">25946971</a> <a href="#">26898830</a>
HK2	CD81 → CD19 → PIK3CB → PDPK1 → AKT → HK2	<a href="#">10698680</a>
	DDIT4 → TSC1_TSC2 —  RHEB → GRB10 → AKT → HK2	<a href="#">12869586</a> <a href="#">15718470</a> <a href="#">16221682</a> <a href="#">16226444</a> <a href="#">19995915</a> <a href="#">21659605</a>
	PMAIP1 —  MCL1 —  BAK1 → HTRA2 —  XIAP → AKT → HK2	<a href="#">10837489</a> <a href="#">11583623</a> <a href="#">11602612</a> <a href="#">11606597</a> <a href="#">11803371</a> <a href="#">15077116</a> <a href="#">15574336</a> <a href="#">15637055</a> <a href="#">15694340</a> <a href="#">15721256</a> <a href="#">15901672</a> <a href="#">16697956</a>
	EIF3C → EIF3E → EIF4E → XIAP → AKT → HK2	<a href="#">23640046</a>
	YAP1 → SLC7A5 → ITGA4_ITGB1 → ILK → AKT → HK2	<a href="#">8538749</a> <a href="#">9736715</a>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
HK2	<p><b>LMO1</b> → LDB1_LMO1 → LYL1_TAL1 → EPOR → <b>PIK3CB</b> → PDPK1                      → AKT → HK2</p>	<a href="#">10698680</a>
	<p><b>CHEK2</b> → BRCA1 → CDKN1A <b>⊣</b> CCNB1_CDK1 → XIAP → AKT                      → HK2</p>	<a href="#">10542266</a> <a href="#">14701743</a> <a href="#">23640046</a> <a href="#">27927753</a>
	<p><b>TP63</b> → CDKN1A <b>⊣</b> CCNB1_CDK1 → XIAP → AKT → HK2</p>	<a href="#">23640046</a> <a href="#">27927753</a>
	<p><b>ULK1</b> <b>⊣</b> GRB10 → AKT → HK2</p>	<a href="#">15718470</a> <a href="#">16221682</a> <a href="#">16226444</a> <a href="#">19995915</a> <a href="#">21659605</a>
	<p><b>ITGAM</b> → ITGAM_ITGB2 → <b>ILK</b> → AKT → HK2</p>	<a href="#">9736715</a>
HK2	<p><b>ITGAL</b> → ITGAL_ITGB2 → <b>ILK</b> → AKT → HK2</p>	<a href="#">9736715</a>
	<p><b>IL4R</b> → JAK3 → <b>PIK3CB</b> → PDPK1 → AKT → HK2</p>	<a href="#">10698680</a> <a href="#">11035047</a> <a href="#">15010462</a> <a href="#">16129412</a> <a href="#">16873377</a> <a href="#">8266076</a>
	<p><b>ILK</b> → AKT → HK2</p>	<a href="#">9736715</a>
	<p><b>GSTPI</b> → GAPDH → AKT → HK2</p>	
	<p><b>CD19</b> → <b>PIK3CB</b> → PDPK1 → AKT → HK2</p>	<a href="#">10698680</a>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
HK2	<p>MAP4K2 → MAP3K1 → MAP2K3 → MAPK14 → MAPKAPK2 → AKT → HK2</p>	<p><a href="#">11784851</a> <a href="#">15273249</a> <a href="#">17510053</a> <a href="#">20978232</a> <a href="#">9430721</a></p>
	<p>MMP7 → SPP1 → ITGA4_ITGB1 → ILK → AKT → HK2</p>	<p><a href="#">11375993</a> <a href="#">8538749</a> <a href="#">9736715</a></p>
	<p>FAS → DAXX → RASSF1 → SAV1 → STK4 → LATS2 → IKKBK → MAP3K8 → PIN1 → AKT → HK2</p>	<p><a href="#">11003656</a> <a href="#">11483955</a> <a href="#">12138205</a> <a href="#">19223555</a> <a href="#">21199877</a> <a href="#">21489991</a> <a href="#">25946971</a> <a href="#">26898830</a></p>
	<p>TSC1 → TSC1_TSC2 → RHEB → GRB10 → AKT → HK2</p>	<p><a href="#">12869586</a> <a href="#">15718470</a> <a href="#">16221682</a> <a href="#">16226444</a> <a href="#">19995915</a> <a href="#">21659605</a></p>
	<p>PMS1 → CHEK1 → WEE1 → CCNB1_CDK1 → XIAP → AKT → HK2</p>	<p><a href="#">23640046</a> <a href="#">27927753</a> <a href="#">8428596</a></p>
HK2	<p>DNMT3A → CDKN1A → CCNB1_CDK1 → XIAP → AKT → HK2</p>	<p><a href="#">23640046</a> <a href="#">27927753</a></p>
	<p>FANCA → CAPN1_CAPNS1 → PTK2 → SRC → NEDD4 → AKT → HK2</p>	<p><a href="#">11927607</a> <a href="#">20378826</a> <a href="#">20518497</a> <a href="#">23195959</a> <a href="#">25292214</a></p>
	<p>SETD2 → CDKN1A → CCNB1_CDK1 → XIAP → AKT → HK2</p>	<p><a href="#">18585004</a> <a href="#">23640046</a> <a href="#">27927753</a></p>
	<p>MITF → HIF1A → DNMT2 → RAC1 → PAK1 → AKT → HK2</p>	<p><a href="#">12086670</a> <a href="#">15983061</a></p>
	<p>MAP3K5 → MAP2K7 → MAPK9 → BCL2L1 → BCL2L1 → BAK1 → HTRA2 → XIAP → AKT → HK2</p>	<p><a href="#">11062067</a> <a href="#">11583623</a> <a href="#">11602612</a> <a href="#">11606597</a> <a href="#">11803371</a> <a href="#">12169272</a> <a href="#">12566458</a> <a href="#">12818176</a> <a href="#">15574336</a> <a href="#">15694340</a> <a href="#">15901672</a> <a href="#">16478725</a></p>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
HK2	<p><b>ETS1</b> → <b>KIF14</b> → <b>AKT</b> → <b>HK2</b></p>	
	<p><b>BID</b> —  <b>BCL2L1</b> —  <b>BAK1</b> → <b>HTRA2</b> —  <b>XIAP</b> → <b>AKT</b> → <b>HK2</b></p>	<p><a href="#">11583623</a> <a href="#">11602612</a>  <a href="#">11606597</a> <a href="#">11803371</a>  <a href="#">15353804</a> <a href="#">15574336</a>  <a href="#">15694340</a> <a href="#">15901672</a>  <a href="#">18469004</a> <a href="#">23640046</a></p>
	<p><b>LMO2</b> → <b>LDB1_LMO2</b> → <b>LYL1_TAL1</b> → <b>EPOR</b> → <b>PIK3CB</b> → <b>PDPK1</b>  → <b>AKT</b> → <b>HK2</b></p>	<p><a href="#">10698680</a></p>
	<p><b>ARHGEF12</b> → <b>RHOA</b> → <b>PTK2</b> → <b>SRC</b> → <b>NEDD4</b> → <b>AKT</b> → <b>HK2</b></p>	<p><a href="#">18854312</a> <a href="#">20378826</a>  <a href="#">23195959</a> <a href="#">25292214</a></p>
	<p><b>RPS6KB2</b> → <b>XIAP</b> → <b>AKT</b> → <b>HK2</b></p>	<p><a href="#">23640046</a></p>
HK2	<p><b>MMP2</b> → <b>MMP3</b> → <b>SPP1</b> → <b>ITGA4_ITGB1</b> → <b>ILK</b> → <b>AKT</b> → <b>HK2</b></p>	<p><a href="#">11120741</a> <a href="#">11375993</a>  <a href="#">8538749</a> <a href="#">8663255</a>  <a href="#">9665471</a> <a href="#">9736715</a></p>
	<p><b>CCNK</b> → <b>CDK12</b> → <b>BRCA1</b> → <b>CDKN1A</b> —  <b>CCNB1_CDK1</b> → <b>XIAP</b>  → <b>AKT</b> → <b>HK2</b></p>	<p><a href="#">23640046</a> <a href="#">27927753</a></p>
	<p><b>IL21R</b> → <b>IL21_IL21R</b> → <b>PIK3CB</b> → <b>PDPK1</b> → <b>AKT</b> → <b>HK2</b></p>	<p><a href="#">10698680</a> <a href="#">9178903</a></p>
	<p><b>GSK3B</b> —  <b>AURKA</b> → <b>SRC</b> → <b>NEDD4</b> → <b>AKT</b> → <b>HK2</b></p>	<p><a href="#">21785464</a> <a href="#">22513362</a>  <a href="#">23195959</a> <a href="#">25292214</a></p>
	<p><b>BAP1</b> → <b>BAP1_L3MBTL2</b> —  <b>EZH2</b> → <b>CPGMET</b> —  <b>CDKN1A</b> —   <b>CCNB1_CDK1</b> → <b>XIAP</b> → <b>AKT</b> → <b>HK2</b></p>	<p><a href="#">16357870</a> <a href="#">23640046</a>  <a href="#">27927753</a></p>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
HK2	<p><b>ATRP</b> → <b>CHEK1</b> → <b>WEE1</b> —  <b>CCNB1_CDK1</b> → <b>XIAP</b> → <b>AKT</b> →</p> <p>HK2</p>	<p><a href="#">23640046</a> <a href="#">27927753</a> <a href="#">8428596</a></p>
	<p><b>FOXO3</b> → <b>BBC3</b> —  <b>MCL1</b> —  <b>BAK1</b> → <b>HTRA2</b> —  <b>XIAP</b> → <b>AKT</b></p> <p>→ HK2</p>	<p><a href="#">10837489</a> <a href="#">11583623</a> <a href="#">11602612</a> <a href="#">11606597</a> <a href="#">11803371</a> <a href="#">14976264</a> <a href="#">15077116</a> <a href="#">15574336</a> <a href="#">15637055</a> <a href="#">15694340</a> <a href="#">15721256</a> <a href="#">15901672</a></p>
	<p><b>STAT1</b> → <b>CDKN1A</b> —  <b>CCNB1_CDK1</b> → <b>XIAP</b> → <b>AKT</b> → <b>HK2</b></p>	<p><a href="#">22271894</a> <a href="#">23640046</a> <a href="#">27927753</a></p>
	<p><b>MMP10</b> → <b>MMP7</b> → <b>SPP1</b> → <b>ITGA4_ITGB1</b> → <b>ILK</b> → <b>AKT</b> →</p> <p>HK2</p>	<p><a href="#">11375993</a> <a href="#">8538749</a> <a href="#">9578462</a> <a href="#">9736715</a></p>
	<p><b>MS4A1</b> → <b>FYN</b> → <b>NTRK2</b> → <b>TNK2</b> → <b>AKT</b> → <b>HK2</b></p>	<p><a href="#">14506255</a> <a href="#">23598414</a> <a href="#">7545683</a> <a href="#">9648856</a></p>
HK2	<p><b>ZEB2</b> → <b>CTBP1_ZEB2</b> → <b>VIM</b> → <b>ITGA5_ITGB1</b> → <b>ILK</b> → <b>AKT</b> →</p> <p>HK2</p>	<p><a href="#">8538749</a> <a href="#">9736715</a></p>
	<p><b>PRKCB</b> → <b>GSTP1</b> → <b>GAPDH</b> → <b>AKT</b> → <b>HK2</b></p>	
	<p><b>BIK</b> → <b>BAK1</b> → <b>HTRA2</b> —  <b>XIAP</b> → <b>AKT</b> → <b>HK2</b></p>	<p><a href="#">11583623</a> <a href="#">11602612</a> <a href="#">11606597</a> <a href="#">11803371</a> <a href="#">15574336</a> <a href="#">18469004</a> <a href="#">23640046</a></p>
	<p><b>TP53BP1</b> → <b>BRCA1</b> → <b>CDKN1A</b> —  <b>CCNB1_CDK1</b> → <b>XIAP</b> → <b>AKT</b></p> <p>→ HK2</p>	<p><a href="#">10542266</a> <a href="#">12364621</a> <a href="#">23640046</a> <a href="#">27927753</a></p>
	<p><b>EED</b> → <b>CPGMET</b> —  <b>CDKN1A</b> —  <b>CCNB1_CDK1</b> → <b>XIAP</b> → <b>AKT</b></p> <p>→ HK2</p>	<p><a href="#">16357870</a> <a href="#">23640046</a> <a href="#">27927753</a></p>
HK2	<p><b>PAK1</b> → <b>AKT</b> → <b>HK2</b></p>	

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
AURKA	PPP2R2A —  SRC —> AURKA	<a href="#">25501815</a>
	RCE1 —> RAC1 —> PAK1 —> AURKA	
	PEBP1 —  IKKB —> MAP3K8 —> PIN1 —  GSK3B —  AURKA	<a href="#">11585904</a> <a href="#">22513362</a>
	TNFAIP3 —  MAP3K14 —> IKKB —> MAP3K8 —> PIN1 —  GSK3B —  AURKA	<a href="#">10094049</a> <a href="#">10887201</a> <a href="#">11784851</a> <a href="#">15024054</a> <a href="#">15208311</a> <a href="#">22513362</a> <a href="#">9275204</a>
	RASSF1 —> SAV1 —> STK4 —> LATS2 —  IKKB —> MAP3K8 —> PIN1 —  GSK3B —  AURKA	<a href="#">21489991</a> <a href="#">22513362</a> <a href="#">25946971</a> <a href="#">26898830</a>
AURKA	CD81 —> CD19 —> PIK3CB —> PRKCZ —  GSK3B —  AURKA	<a href="#">11481324</a> <a href="#">16510873</a> <a href="#">17606986</a> <a href="#">22513362</a>
	DDIT4 —> TSC1_TSC2 —  RHEB —  ULK1 —> FBPI —  NPM1 —> AURKA	<a href="#">12869586</a> <a href="#">21258367</a>
	PMAIP1 —  MCL1 —  BAK1 —> HTRA2 —  XIAP —> AKT —  GSK3B —  AURKA	<a href="#">10837489</a> <a href="#">11035810</a> <a href="#">11583623</a> <a href="#">11602612</a> <a href="#">11606597</a> <a href="#">11803371</a> <a href="#">12172554</a> <a href="#">15077116</a> <a href="#">15574336</a> <a href="#">15637055</a> <a href="#">15678105</a> <a href="#">15694340</a>
	FBPI —  NPM1 —> AURKA	
	EIF3C —> EIF3E —> EIF4E —> XIAP —> AKT —  GSK3B —  AURKA	<a href="#">11035810</a> <a href="#">12172554</a> <a href="#">15678105</a> <a href="#">22513362</a> <a href="#">23640046</a>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
AURKA	TP53  PTK2  SRC  AURKA	<a href="#">15157737</a> <a href="#">17725966</a> <a href="#">20378826</a> <a href="#">25501815</a>
	YAP1  SLC7A5  ITGA4_ITGB1  SRC  AURKA	<a href="#">25501815</a>
	LMO1  LDB1_LMO1  LYL1_TALI  EPOR  PIK3CA  SLC9A1 PTK2  SRC  AURKA	<a href="#">20378826</a> <a href="#">25501815</a>
	CHEK2  BRCA1  FANCA  CAPN1_CAPNS1  PTK2  SRC AURKA	<a href="#">11927607</a> <a href="#">14701743</a> <a href="#">20378826</a> <a href="#">20518497</a> <a href="#">25501815</a>
	TP63  STK11  PRKAA1  ULK1  FBP1  NPM1  AURKA	<a href="#">14985505</a> <a href="#">15231735</a> <a href="#">21159649</a>
AURKA	ULK1  FBP1  NPM1  AURKA	
	ITGAM  ITGAM_ITGB2  ILK  GSK3B  AURKA	<a href="#">22513362</a> <a href="#">9736715</a>
	ITGAL  ITGAL_ITGB2  ILK  GSK3B  AURKA	<a href="#">22513362</a> <a href="#">9736715</a>
	IL4R  JAK3  PIK3CA  SLC9A1  PTK2  SRC  AURKA	<a href="#">16129412</a> <a href="#">16684964</a> <a href="#">18281483</a> <a href="#">20378826</a> <a href="#">20671117</a> <a href="#">25501815</a> <a href="#">8266076</a> <a href="#">8962143</a>
	ILK  GSK3B  AURKA	<a href="#">22513362</a> <a href="#">9736715</a>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
AURKA	GSTP1 → GAPDH → AKT —  GSK3B —  AURKA	<a href="#">11035810</a> <a href="#">12172554</a> <a href="#">15678105</a> <a href="#">22513362</a> <a href="#">27563096</a>
	CD19 → PIK3CB → PRKCZ —  GSK3B —  AURKA	<a href="#">11481324</a> <a href="#">16510873</a> <a href="#">17606986</a> <a href="#">22513362</a>
	MAP4K2 → MAP3K1 → MAP2K3 → MAPK12 → PLK1 → TPX2 → AURKA	<a href="#">11062067</a> <a href="#">11784851</a> <a href="#">14580337</a> <a href="#">15173575</a>
	MMP7 → SPP1 → ITGA4_ITGB1 → SRC → AURKA	<a href="#">11375993</a> <a href="#">25501815</a>
	FAS → DAXX → RASSF1 → SAV1 → STK4 → LATS2 —  IKKBK → MAP3K8 → PIN1 —  GSK3B —  AURKA	<a href="#">11003656</a> <a href="#">11483955</a> <a href="#">21199877</a> <a href="#">21489991</a> <a href="#">22513362</a> <a href="#">25946971</a> <a href="#">26898830</a>
AURKA	TSC1 → TSC1_TSC2 —  RHEB —  ULK1 → FBPI —  NPM1 → AURKA	<a href="#">12869586</a> <a href="#">21258367</a>
	PMS1 → CHEK1 → WEE1 —  CCNB1_CDK1 → MAPK12 → PLK1 → TPX2 → AURKA	<a href="#">14580337</a> <a href="#">15173575</a> <a href="#">8428596</a>
	DNMT3A —  CDKN1A —  CCNB1_CDK1 → MAPK12 → PLK1 → TPX2 → AURKA	<a href="#">14580337</a> <a href="#">15173575</a>
	FANCA —  CAPN1_CAPNS1 → PTK2 → SRC → AURKA	<a href="#">11927607</a> <a href="#">20378826</a> <a href="#">20518497</a> <a href="#">25501815</a>
	SETD2 → CDKN1A —  CCNB1_CDK1 → MAPK12 → PLK1 → TPX2 → AURKA	<a href="#">14580337</a> <a href="#">15173575</a> <a href="#">18585004</a>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
AURKA	<p>MITF → HIF1A — DNMT2 → RAC1 → PAK1 → AURKA</p>	<p><a href="#">12086670</a> <a href="#">15983061</a></p>
	<p>MAP3K5 → MAP2K7 → MAPK9 → BCL2L1 — BCL2L1 — BAK1                      → HTRA2 — XIAP → AKT — GSK3B — AURKA</p>	<p><a href="#">11035810</a> <a href="#">11062067</a>  <a href="#">11583623</a> <a href="#">11602612</a>  <a href="#">11606597</a> <a href="#">11803371</a>  <a href="#">12169272</a> <a href="#">12172554</a>  <a href="#">12566458</a> <a href="#">12818176</a>  <a href="#">15574336</a> <a href="#">15678105</a></p>
	<p>ETS1 → KIF4 → AKT — GSK3B — AURKA</p>	<p><a href="#">11035810</a> <a href="#">12172554</a>  <a href="#">15678105</a> <a href="#">22513362</a></p>
	<p>BID — BCL2L1 — BAK1 → HTRA2 — XIAP → AKT — GSK3B                      — AURKA</p>	<p><a href="#">11035810</a> <a href="#">11583623</a>  <a href="#">11602612</a> <a href="#">11606597</a>  <a href="#">11803371</a> <a href="#">12172554</a>  <a href="#">15353804</a> <a href="#">15574336</a>  <a href="#">15678105</a> <a href="#">15694340</a>  <a href="#">15901672</a> <a href="#">18469004</a></p>
	<p>FANCG → FANCA — CAPN1_CAPNS1 → PTK2 → SRC → AURKA</p>	<p><a href="#">11927607</a> <a href="#">15138265</a>  <a href="#">20378826</a> <a href="#">20518497</a>  <a href="#">25501815</a></p>
	AURKA	<p>PLK1 → TPX2 → AURKA</p>
<p>LMO2 → LDB1_LMO2 → LYLI_TAL1 → EPOR → PIK3CA → SLC9A1                      → PTK2 → SRC → AURKA</p>		<p><a href="#">20378826</a> <a href="#">25501815</a></p>
<p>ARHGEF2 → RHOA → PTK2 → SRC → AURKA</p>		<p><a href="#">18854312</a> <a href="#">20378826</a>  <a href="#">25501815</a></p>
<p>RPS6KB2 → XIAP → AKT — GSK3B — AURKA</p>		<p><a href="#">11035810</a> <a href="#">12172554</a>  <a href="#">15678105</a> <a href="#">22513362</a>  <a href="#">23640046</a></p>
<p>MMP2 → MMP3 → SPPI → ITGA4_ITGB1 → SRC → AURKA</p>		<p><a href="#">11120741</a> <a href="#">11375993</a>  <a href="#">25501815</a> <a href="#">8663255</a>  <a href="#">9665471</a></p>

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
AURKA	<p>CCNK → CDK12 → BRCA1 → FANCA —  CAPN1_CAPNS1 → PTK2                      → SRC → AURKA</p>	<p><a href="#">11927607</a> <a href="#">20378826</a>  <a href="#">20518497</a> <a href="#">25501815</a></p>
	<p>IL21R → IL21_IL21R → PIK3CA → SLC9A1 → PTK2 → SRC → AURKA</p>	<p><a href="#">11438544</a> <a href="#">18281483</a>  <a href="#">19230867</a> <a href="#">20378826</a>  <a href="#">25501815</a> <a href="#">9178903</a></p>
	<p>GSK3B —  AURKA</p>	<p><a href="#">22513362</a></p>
	<p>BAP1 → BAP1_L3MBTL2 —  EZH2 → CPGMET —  BRCA1 → FANCA                      —  CAPN1_CAPNS1 → PTK2 → SRC → AURKA</p>	<p><a href="#">11927607</a> <a href="#">16357870</a>  <a href="#">19079346</a> <a href="#">20378826</a>  <a href="#">20518497</a> <a href="#">22211105</a>  <a href="#">25501815</a></p>
	<p>ATRIP → FANCA —  CAPN1_CAPNS1 → PTK2 → SRC → AURKA</p>	<p><a href="#">11927607</a> <a href="#">20378826</a>  <a href="#">20518497</a> <a href="#">25501815</a></p>
AURKA	<p>FOXO3 → BBC3 —  MCL1 —  BAK1 → HTRA2 —  XIAP → AKT                      —  GSK3B —  AURKA</p>	<p><a href="#">10837489</a> <a href="#">11035810</a>  <a href="#">11583623</a> <a href="#">11602612</a>  <a href="#">11606597</a> <a href="#">11803371</a>  <a href="#">12172554</a> <a href="#">14976264</a>  <a href="#">15077116</a> <a href="#">15574336</a>  <a href="#">15637055</a> <a href="#">15678105</a></p>
	<p>STAT1 → FANCA —  CAPN1_CAPNS1 → PTK2 → SRC → AURKA</p>	<p><a href="#">11927607</a> <a href="#">20378826</a>  <a href="#">20518497</a> <a href="#">22271894</a>  <a href="#">25501815</a></p>
	<p>MMP10 → MMP7 → SPPI → ITGA4_ITGB1 → SRC → AURKA</p>	<p><a href="#">11375993</a> <a href="#">25501815</a>  <a href="#">9578462</a></p>
	<p>MS4A1 → FYN → GRB2 → PAK1 → AURKA</p>	<p><a href="#">12522133</a> <a href="#">7545683</a>  <a href="#">8943564</a></p>
	<p>ZEB2 → CTBP1_ZEB2 → VIM → ITGA5_ITGB1 → PTK2 → SRC → AURKA</p>	<p><a href="#">19889638</a> <a href="#">20378826</a>  <a href="#">25501815</a></p>



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

Master Regulators	Molecular Pathway Rationale for Master Regulators	Reference PMIDs
AURKA	<p>PRKCB → MS4A1 → FYN → GRB2 → PAK1 → AURKA</p>	<p><a href="#">12522133</a> <a href="#">7545683</a> <a href="#">8943564</a></p>
	<p>BIK → BAK1 → HTRA2 —  XIAP → AKT —  GSK3B —  AURKA</p>	<p><a href="#">11035810</a> <a href="#">11583623</a> <a href="#">11602612</a> <a href="#">11606597</a> <a href="#">11803371</a> <a href="#">12172554</a> <a href="#">15574336</a> <a href="#">15678105</a> <a href="#">18469004</a> <a href="#">22513362</a> <a href="#">23640046</a></p>
	<p>TP53BP1 → BRCA1 → FANCA —  CAPN1_CAPNS1 → PTK2 → SRC → AURKA</p>	<p><a href="#">11927607</a> <a href="#">12364621</a> <a href="#">20378826</a> <a href="#">20518497</a> <a href="#">25501815</a></p>
	<p>EED → CPGMET —  BRCA1 → FANCA —  CAPN1_CAPNS1 → PTK2 → SRC → AURKA</p>	<p><a href="#">11927607</a> <a href="#">16357870</a> <a href="#">20378826</a> <a href="#">20518497</a> <a href="#">25501815</a></p>
	<p>PAK1 → AURKA</p>	

\*\* Assayable key kinase biomarkers identified for this patient.



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

### 7. Singula™ Assessment sections: How to Read the Report

Cellworks Precision Medicine Reports equip oncologists with the knowledge of how an individual patient will respond to all standard care drugs (Singula™) and novel combination therapies (Ventura™) prior to treatment. The biosimulation analyzes mutational interactions of 4,000+ networked genes to predict and rank phenotype responses to millions of drug combinations.

Singula™ reports predict an individual patient's response to Standard Care therapies.

#### Please Note:

The current assessment assumes that the drugs are faithfully delivered to the site of action. Cellworks considers all molecular interactions once the therapy is delivered to the site of action (Pharmacodynamics of the drug compound). Cellworks does not account for absorption, distribution, metabolism & excretion (ADME) properties of the drug that determine how the drug is delivered to the site of action. Any toxicity in the delivery process, or pharmacokinetics, is not considered.

Cellworks does not provide recommendations on drug dosage. However, it is highly recommended to follow the dosage instructions in the drug FDA labels and standard guidelines.

#### 1. Drug Response Prediction

The 'Therapies of Interest' column lists the Standard Care drugs for a given indication. Cellworks digital drug models of these therapies are biosimulated on the patient disease model. The predicted outcome of treatment with each of these drugs is printed in the 'Patient Predicted Response' column. An entry of 'Responder' indicates that the patient is predicted to respond to the corresponding drug. This means the drug has impacted the master regulators and disease phenotypes to a significant extent; an entry of 'Non-Responder' indicates that the patient is predicted to not respond to the corresponding drug implying that the drug did not sufficiently impact the patient specific master regulators and disease phenotypes.

A detailed rationale explaining each predicted treatment outcome is provided in the 'Therapy Rationale' section (Section 5).

#### 2. Master Regulators

Cellworks multi-omics biosimulation determines master regulators in the patient's disease network. They are points of convergence of the pathways impacted by the aberrations in the patient's genomic profile. These master regulators are tumor promoter/suppressor genes that a drug needs to impact for the patient to respond to treatment.

Detailed illustrations showing molecular biochemical pathways from genomic aberrations in the patient profile to the master regulators are provided in the Genomic Aberration to Master Regulator Pathway Section (Section 6).

#### 2.1. Treatment Impact on Master Regulators

Cellworks multi-omics biosimulation classifies a patient as a responder or a non-responder to a drug based on the impact the drug has on the phenotype of the patient's cancer as well as the impact on the master regulators identified in the patient's disease network.

If the drug successfully impacts a master regulator to a significant extent, it is represented by a check symbol ('✓'). Absence of a check symbol



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

implies that the drug does not sufficiently impact the master regulator.

### 3. Phenotype Index Values

The drug efficacy score is an aggregation of the impact of a drug on the phenotypes of a disease model. To create a patient disease model, Cellworks evaluates the downstream impact on phenotypic endpoints. These endpoints are evaluated as index values showing the deviation from healthy cell values. The endpoints are correlated to the 10 Hallmarks of Cancer. As part of the biosimulation process, each drug model is evaluated on these same endpoints to determine to what extent the disease model deviation returns to a healthy cell value range.

### 4. Active Clinical Trials

All clinical trial details are provided by <https://clinicaltrials.gov/>. The inclusion criteria is matched to the patients genomic profile and exclusion details are evaluated when possible. The list is not meant to be exhaustive and is solely provided for information. Physicians and patients are encouraged to use this list as a starting point for evaluating potential clinical trials.

### 5.1 Summary of Patient Genomic Profile

This section provides a summary of the patient genomics used for therapy assessment. It shows the type of input received from the next generation sequencing data (NGS) with the number of genetic mutations, copy number variations (CNVs) and any epigenetic data that is reported. Some indications also require additional lab tests as input to the biosimulation process.

### 5.2 Aberrations by Chromosome Location

The plot contains the CNVs from the patient profile as determined by NGS, showing gain and loss values. The values are plotted in chromosomal order for ease of understanding. The genomic mutations are plotted at the bottom of the chart colored to illustrate gain of function (blue dot), loss of function (red dot), or switch of function (purple dot).

### 5.3 Detailed Information of Genomic Aberration(s) Modeled

Aberrations of oncogenic significance found in the patient's genomic profile are used to create the disease model of the patient and are listed in this section. Based on the type of mutation and original functionality of a gene, aberrations are categorized into 5 major groups -

- I. Gene Mutation(s) with Gain of Function
- II. Gene Mutation(s) with Loss of Function
- III. Gene Mutation(s) with Switch of Function
- IV. Gene(s) with Increase in Copy Number Variation [CNV]
- V. Gene(s) with Decrease in Copy Number Variation [CNV]

This information forms the patient-specific input on which a Cellworks assessment is based.

### 6. Therapy Rationales

Each therapy recommendation made in a Cellworks report is accompanied by a clear rationale explaining the reason behind the



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

---

recommendation.

A therapy rationale illustrates the role of key aberrations in causing sensitivity or resistance to drugs. A drug will have a therapy rationale for every aberration that contributes significantly to its sensitivity or resistance.

The first illustration in the rationale defines the mechanism of action of the drug.

The second illustration articulates the signaling or metabolic pathway by which the aberration of interest contributes to drug sensitivity or resistance including the point of intersection with the drug's mechanism of action.

The pathway can be read as a dependent relationship (represented by an arrow) where an increase in one gene increases the next, or a block or inverse relationship (represented by a line with a bar) where an increase in one gene decreases the next. The description is accompanied by relevant PMID references that support the drug mechanism of action and rationale for drug sensitivity or resistance.

### 7. Genomic Aberration to Key Biomarker Pathways

This section illustrates molecular biochemical pathways from a genomic aberration in the patient profile to critical master regulators identified by Cellworks' multi-omics biosimulation. These illustrations explain why the master regulators listed in Section 2 are important to the patient's disease network. The illustration is accompanied by relevant PMID references that were used to determine the interaction.



## Non-Small Cell Lung Cancer (NSCLC) - NOS

Clinical ID: **ABC123**

Cellworks ID: **123456**

Physician: **Dr. Smith**

### 8. Terms of Use:

#### Cellworks Therapeutic Solutions

The Cellworks proprietary workflow solution used to generate this test report from patient's medical records (Test Report), has not been approved by any regulatory or medical authority. Cellworks generated information is adjunctive information to physicians and molecular tumor boards. CELLWORKS DOES NOT ASSURE OR GUARANTEE THE SUCCESS OF ANY THERAPEUTIC OPTION IDENTIFIED IN THIS TEST REPORT. Cellworks reports have not been validated or specifically developed for pregnant women or nursing mothers. The therapeutic options provided in the Test Report are not ranked in order of efficacy, safety or cost-effectiveness and are sorted based on our model's analysis of the input data. All individual drugs included in therapy options identified in the Test Report have been cleared and approved by the United States Food and Drug Administration (FDA) for other indications. At the specific request of the patient or treating physician, the Test Report may identify drugs or therapy options that are also in an advanced stage of clinical trials and yet to be approved. This will provide adjunctive information to the physicians for selecting a clinical trial for the patient.

Therapeutic agents associated with potential benefit or lack of benefit, as indicated in the Test Report are based on biomarker results provided in the report and on published evidence with PMID references. This evidence in some cases may have been obtained from studies performed in the cancer type present in the tested patient's sample.

#### No Guarantee of Clinical Benefit

The finding of a biomarker expression does not necessarily indicate pharmacologic effectiveness or lack thereof. The agents identified may or may not be suitable for use with a particular patient and the Test Report does not guarantee or suggest that any particular agent will be effective with the treatment of any particular condition. The user of this Test Report remains responsible for the conduct of patient care and for evaluating the clinical relevance of information provided by the prediction software.

#### Intended Use

Cellworks is not an entity licensed to practice medicine or clinical activity and the Test Report generated by Cellworks does not amount to, or substitute, qualified professional medical advice. THIS REPORT IS PREPARED AS ADJUNCTIVE INFORMATION TO ASSIST HEALTH CARE PROVIDERS TO EVALUATE THEIR PATIENTS. CELLWORKS IS NOT RESPONSIBLE FOR ANY USE OF THIS TEST REPORT OR DATA BY ANY UNQUALIFIED PERSON. Decisions on patient care and treatment, including safety and security of treatments based on this Test Report must be based on the independent medical judgment of the treating physician, taking into consideration all applicable information concerning the patient's condition and the treatment should not solely be based on this Test Report. Cellworks provides no guarantee of the accuracy, relevance, exhaustiveness or appropriateness of any of the medical information referenced through this Test Report.

CELLWORKS DISCLAIMS ALL WARRANTIES, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTIES OF TITLE, NON- INFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, IN RELATION TO INTERFACE, ITS SERVICES AND THE TEST REPORT. CELLWORKS PROVIDES NO ASSURANCE OR GUARANTEE THAT A HEALTHCARE PROVIDER, INSURER OR ANY OTHER THIRD PARTY PAYOR, WHETHER GOVERNMENTAL OR PRIVATE, WILL REIMBURSE A PATIENT FOR THE COST OF GENERATING TEST REPORT.

This is an automatically generated report. No signature is required.  
--END OF THE REPORT--

January 01, 2021

support@cellworksgroup.zendesk.com

Report Version: US-V-18.1.1